The amyloid cascade hypothesis for Alzheimer's disease of therapeutics

Nature Reviews Drug Discovery

10, 698-712

DOI: 10.1038/nrd3505

Citation Report

#	Article	IF	Citations
1	Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nature Reviews Drug Discovery, 2011, 10, 853-867.	21.5	70
3	Target of Î³-secretase modulators, presenilin marks the spot. EMBO Journal, 2011, 30, 4696-4698.	3.5	9
4	Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimerâ€™s Disease. Frontiers in Physiology, 2012, 3, 229.	1.3	93
5	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. Biochemical Journal, 2012, 446, 165-177.	1.7	89
6	Computational Methods in the Discovery and Design of BACE-1 Inhibitors. Current Medicinal Chemistry, 2012, 19, 6095-6111.	1.2	2
7	L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases Î²-amyloid peptide production in HEK293-APPswe cells. Acta Pharmacologica Sinica, 2012, 33, 1459-1468.	2.8	6
8	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging in Medicine, 2012, 4, 343-357.	0.0	12
9	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	7.1	65
10	Regional dynamics of amyloid-Î² deposition in healthy elderly, mild cognitive impairment and Alzheimerâ€™s disease: a voxelwise PiBâ€“PET longitudinal study. Brain, 2012, 135, 2126-2139.	3.7	222
11	Cerebrospinal Fluid Amyloid-Î² (AÎ²) as an Effect Biomarker for Brain AÎ² Lowering Verified by Quantitative Preclinical Analyses. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 366-375.	1.3	34
12	PSEN1 Mutation Carriers Present Lower Cerebrospinal Fluid Amyoid-Î²42 Levels than Sporadic Early-Onset Alzheimer's Disease Patients but no Differences in Neuronal Injury Biomarkers. Journal of Alzheimer's Disease, 2012, 30, 605-616.	1.2	6
13	Presenilins, Deranged Calcium Homeostasis, Synaptic Loss and Dysfunction in Alzheimer's Disease. Messenger (Los Angeles, Calif: Print), 2012, 1, 53-62.	0.3	19
14	Neurological disorders and therapeutics targeted to surmount the blood–brain barrier. International Journal of Nanomedicine, 2012, 7, 3259.	3.3	84
15	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
16	Protein quality control in Alzheimerâ€™s disease: the contentious role of ubiquilin-1. Future Neurology, 2012, 7, 5-8.	0.9	2
17	Dietary polyphenol-derived protection against neurotoxic Î²-amyloid protein: from molecular to clinical. Food and Function, 2012, 3, 1242.	2.1	52
18	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	21.5	239
19	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery, 2012, 7, 281-297.	2.5	42

#	Article	IF	Citations
20	Synthesis of a potent photoreactive acidic Î³-secretase modulator for target identification in cells. Bioorganic and Medicinal Chemistry, 2012, 20, 6523-6532.	1.4	11
21	Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome. Archives of Medical Research, 2012, 43, 645-654.	1.5	54
22	A breach in the bloodâ€“brain barrier. Nature, 2012, 485, 451-452.	13.7	25
23	Alzheimer's Disease: Presenilin 2-Sparing Î³-Secretase Inhibition Is a Tolerable AÎ² Peptide-Lowering Strategy. Journal of Neuroscience, 2012, 32, 17297-17305.	1.7	43
24	Optimization of a Natural Product-Based Class of Î³-Secretase Modulators. Journal of Medicinal Chemistry, 2012, 55, 9270-9282.	2.9	44
25	Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea racemosa. ACS Chemical Neuroscience, 2012, 3, 941-951.	1.7	58
26	MicroRNA-153 Physiologically Inhibits Expression of Amyloid-Î² Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients. Journal of Biological Chemistry, 2012, 287, 31298-31310.	1.6	175
27	Use of proteomic methods in the analysis of human body fluids in <scp>A</scp>lzheimer research. Electrophoresis, 2012, 33, 3617-3630.	1.3	35
28	Combining conformational sampling and selection to identify the binding mode of zinc-bound amyloid peptides with bifunctional molecules. Journal of Computer-Aided Molecular Design, 2012, 26, 963-976.	1.3	11
29	Amyloid beta (AÎ²) peptide modulators and other current treatment strategies for Alzheimerâ€™s disease (AD). Expert Opinion on Emerging Drugs, 2012, 17, 43-60.	1.0	55
30	Evaluation of [¹¹C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. ACS Medicinal Chemistry Letters, 2012, 3, 936-941.	1.3	52
31	â€œIt Ainâ€™t Over â€™til Itâ€™s Overâ€^aâ€”The Search for Treatments and Cures for Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2012, 3, 862-866.	1.3	13
32	Therapeutic approaches to modulating Notch signaling: Current challenges and future prospects. Seminars in Cell and Developmental Biology, 2012, 23, 465-472.	2.3	107
33	Initial Optimization of a New Series of Î³-Secretase Modulators Derived from a Triterpene Glycoside. ACS Medicinal Chemistry Letters, 2012, 3, 908-913.	1.3	23
34	Design and Synthesis of Î²-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of Î²-Amyloid Peptides. Journal of Medicinal Chemistry, 2012, 55, 9346-9361.	2.9	82
35	Relationship between genetic risk factors and markers for Alzheimerâ€™s disease pathology. Biomarkers in Medicine, 2012, 6, 477-495.	0.6	25
36	The Effect of Curcumin on the Stability of AÎ² Dimers. Journal of Physical Chemistry B, 2012, 116, 7428-7435.	1.2	92
37	Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent Î³-Secretase Modulators. Journal of Medicinal Chemistry, 2012, 55, 9089-9106.	2.9	59

#	Article	IF	Citations
38	Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid Î² (AÎ²) production in the trans -Golgi network. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2077-82.	3.3	195
39	The toxic AÎ² oligomer and Alzheimer's disease: an emperor in need of clothes. Nature Neuroscience, 2012, 15, 349-357.	7.1	1,690
40	Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. RSC Advances, 2012, 2, 5008.	1.7	48
41	Alzheimer's Disease 2012. American Journal of Pathology, 2012, 180, 1762-1767.	1.9	30
42	Label-free electrochemical detection of Amyloid beta aggregation in the presence of iron, copper and zinc. Journal of Electroanalytical Chemistry, 2012, 681, 89-95.	1.9	49
43	Tianma modulates proteins with various neuro-regenerative modalities in differentiated human neuronal SH-SY5Y cells. Neurochemistry International, 2012, 60, 827-836.	1.9	23
44	Diagnostic imaging of Alzheimer's disease with copper and technetium complexes. Coordination Chemistry Reviews, 2012, 256, 2367-2380.	9.5	62
45	Metal compounds as inhibitors of Î²-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease. Coordination Chemistry Reviews, 2012, 256, 2357-2366.	9.5	65
46	Alzheimer Mechanisms and Therapeutic Strategies. Cell, 2012, 148, 1204-1222.	13.5	1,548
47	Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microbial Cell Factories, 2012, 11, 55.	1.9	33
48	Current advances in the treatment of Alzheimer's disease: focused on considerations targeting AÎ² and tau. Translational Neurodegeneration, 2012, 1, 21.	3.6	74
49	Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease. Annual Reports in Medicinal Chemistry, 2012, , 55-69.	0.5	6
50	Current status of vaccination therapies in Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 647-651.	2.1	14
51	A protective mutation. Nature, 2012, 488, 38-39.	13.7	20
52	MicroRNA 146a (miR-146a) Is Over-Expressed during Prion Disease and Modulates the Innate Immune Response and the Microglial Activation State. PLoS ONE, 2012, 7, e30832.	1.1	143
53	The epidemiological neuropathology of dementia and the implications for drug development. Neurodegenerative Disease Management, 2012, 2, 471-482.	1.2	7
54	The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or AÎ²1â€“42-induced cognitive dysfunction in mice. Journal of Ethnopharmacology, 2012, 143, 611-620.	2.0	56
55	Good gene, bad gene: New APP variant may be both. Progress in Neurobiology, 2012, 99, 281-292.	2.8	31

#	Article	IF	Citations
56	Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease. Molecular Neurobiology, 2012, 46, 605-613.	1.9	36
57	Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived Î²-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 9025-9044.	2.9	43
58	Engineered Polymer Nanoparticles Containing Hydrophobic Dipeptide for Inhibition of Amyloid-Î² Fibrillation. Biomacromolecules, 2012, 13, 2662-2670.	2.6	91
59	scyllo-Inositol, Preclinical, and Clinical Data for Alzheimerâ€™s Disease. Advances in Pharmacology, 2012, 64, 177-212.	1.2	61
60	The Imbalance of Vascular Molecules in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 699-709.	1.2	33
61	Modulation of Î³-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Molecular Neurodegeneration, 2012, 7, 61.	4.4	62
62	Cell Line Specific Modulation of Extracellular AÎ²42 by Hsp40. PLoS ONE, 2012, 7, e37755.	1.1	7
63	Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased AÎ² Plaque Accumulation in a Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e53275.	1.1	171
64	Loss of RBPj in Postnatal Excitatory Neurons Does Not Cause Neurodegeneration or Memory Impairments in Aged Mice. PLoS ONE, 2012, 7, e48180.	1.1	22
65	Metal Chaperones: A Holistic Approach to the Treatment of Alzheimerâ€™s Disease. Frontiers in Psychiatry, 2012, 3, 15.	1.3	20
66	-Secretase Modulators: Can We Combine Potency with Safety?. International Journal of Alzheimer's Disease, 2012, 2012, 1-10.	1.1	27
67	The Alzheimer's Amyloid-Degrading Peptidase, Neprilysin: Can We Control It?. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	1.1	57
68	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	67
69	Neuroregenerative Mechanisms of Allopregnanolone in Alzheimerâ€™s Disease. Frontiers in Endocrinology, 2011, 2, 117.	1.5	38
70	A Clinical Approach to Early-Onset Inheritable Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 154-161.	0.9	16
71	Bioinorganic Chemistry of Alzheimerâ€™s Disease. Chemical Reviews, 2012, 112, 5193-5239.	23.0	581
72	Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS AÎ² Reduction. ACS Medicinal Chemistry Letters, 2012, 3, 897-902.	1.3	97
73	Tailoring of Membrane Proteins by Alternative Splicing of Pre-mRNA. Biochemistry, 2012, 51, 5541-5556.	1.2	28

#	Article	IF	Citations
74	Neuroscience-based Tests for Assessing Cognitive Changes in Normal Aging and in the Prodromal Phase of Alzheimerâ€™s Disease. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 1-10.	0.7	0
75	Amyloid-Binding Aptamer Conjugated Curcuminâ€“PLGA Nanoparticle for Potential Use in Alzheimerâ€™s Disease. BioNanoScience, 2012, 2, 83-93.	1.5	24
76	Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cellular Signalling, 2012, 24, 402-409.	1.7	71
77	A review on coumarins as acetylcholinesterase inhibitors for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2012, 20, 1175-1180.	1.4	434
78	A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aî²42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiology of Disease, 2012, 46, 701-709.	2.1	32
79	Synaptic Protein Alterations in Parkinsonâ€™s Disease. Molecular Neurobiology, 2012, 45, 126-143.	1.9	27
80	ESI-MS identification of the minimal zinc-binding center in natural isoforms of Î²-amyloid domain 1â€“16. Molecular Biology, 2013, 47, 440-445.	0.4	12
81	Characterization of the internal dynamics and conformational space of zinc-bound amyloid Î² peptides by replica-exchange molecular dynamics simulations. European Biophysics Journal, 2013, 42, 575-586.	1.2	9
82	Retrospective molecular docking study of WY-25105 ligand to Î²-secretase and bias of the three-dimensional structure flexibility. Journal of Molecular Modeling, 2013, 19, 2971-2979.	0.8	6
83	Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?. Expert Opinion on Investigational Drugs, 2013, 22, 941-943.	1.9	8
84	Molecular links between Alzheimerâ€™s disease and diabetes mellitus. Neuroscience, 2013, 250, 140-150.	1.1	173
85	Discovering putative prion sequences in complete proteomes using probabilistic representations of Q/N-rich domains. BMC Genomics, 2013, 14, 316.	1.2	73
86	Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neuroscience, 2013, 14, 44.	0.8	58
87	Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. Current Opinion in Chemical Biology, 2013, 17, 320-328.	2.8	56
88	The Innate Immune System in Alzheimer's Disease. Else-KrÃ¶ner-Fresenius-Symposia, 2013, , 86-90.	0.1	1
89	BACE1 as a Therapeutic Target in Alzheimerâ€™s Disease: Rationale and Current Status. Drugs and Aging, 2013, 30, 755-764.	1.3	46
90	Transgenic models of Alzheimer's disease: Better utilization of existing models through viral transgenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1437-1448.	1.8	27
91	Acetylcholinesterase inhibitors: Modeling potential candidates. International Journal of Quantum Chemistry, 2013, 113, 1461-1466.	1.0	6

#	Article	IF	Citations
92	Non-phosgene route to unsymmetrical ureas from N-Cbz-Î±-amino acid amides. Tetrahedron Letters, 2013, 54, 5467-5469.	0.7	3
93	A novel method for the preparation of a neurotoxic complex. Analytical Biochemistry, 2013, 435, 137-139.	1.1	1
94	Hydroxyethylamine-based inhibitors of BACE1: P1â€“P3 macrocyclization can improve potency, selectivity, and cell activity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4459-4464.	1.0	17
95	Fibrillar seeds alleviate amyloid-Î² cytotoxicity by omitting formation of higher-molecular-weight oligomers. Biochemical and Biophysical Research Communications, 2013, 439, 321-326.	1.0	13
96	Amyloid Î² precursor protein as a molecular target for amyloid Î²â€“induced neuronal degeneration in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2525-2537.	1.5	40
97	Activation of the endoplasmic reticulum stress response by the amyloid-beta 1â€“40 peptide in brain endothelial cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2191-2203.	1.8	103
98	Soluble amyloid precursor protein 770 is a novel biomarker candidate for acute coronary syndrome. Proteomics - Clinical Applications, 2013, 7, 657-663.	0.8	5
99	Alzheimer disease therapyâ€”moving from amyloid-Î² to tau. Nature Reviews Neurology, 2013, 9, 677-686.	4.9	421
100	Models of Alzheimerâ€™s Disease. , 2013, , 595-632.		0
101	Pathogenesis, modulation, and therapy of Alzheimerâ€™s disease: A perspective on roles of liver-X receptors. Translational Neuroscience, 2013, 4, .	0.7	3
102	Oxidative Stress in Aging-Matters of the Heart and Mind. International Journal of Molecular Sciences, 2013, 14, 17897-17925.	1.8	98
103	Gene Expression Profile and Functional Analysis of Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 693-701.	0.9	16
104	Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimerâ€™s disease. BMC Genomics, 2013, 14, 831.	1.2	39
105	Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against Î²-secretase-1 (BACE-1). Tetrahedron Letters, 2013, 54, 5802-5807.	0.7	5
106	Sorting receptor SORLA â€“ a trafficking path to avoid Alzheimer disease. Journal of Cell Science, 2013, 126, 2751-60.	1.2	97
107	Amyloid-Î² oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO Journal, 2013, 32, 2920-2937.	3.5	222
108	Modification of a Small Î²â€Barrel Protein, To Give Pseudoâ€Amyloid Structures, Inhibits Amyloid Î²â€Peptide Aggregation. Chemistry - A European Journal, 2013, 19, 4525-4531.	1.7	6
109	Elevated amyloid-Î² plaque deposition in dietary selenium-deficient Tg2576 transgenic mice. Metallomics, 2013, 5, 479.	1.0	26

#	Article	IF	Citations
110	Voxel-based morphometry analyses in Alzheimer's disease. , 2013, , .		4
111	Diagnostic Imaging Agents for Alzheimerâ€™s Disease: Copper Radiopharmaceuticals that Target AÎ² Plaques. Journal of the American Chemical Society, 2013, 135, 16120-16132.	6.6	86
112	Investigating the binding interactions of galantamine with Î²-amyloid peptide. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 239-243.	1.0	20
113	Î²-arrestin 2 regulates AÎ² generation and Î³-secretase activity in Alzheimer's disease. Nature Medicine, 2013, 19, 43-49.	15.2	158
114	Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. Neurobiology of Aging, 2013, 34, 1632-1643.	1.5	20
116	APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based Î³-Secretase Modulation. Stem Cell Reports, 2013, 1, 491-498.	2.3	58
117	Stimulate or Degenerate: Deep Brain Stimulation of the Nucleus Basalis Meynert in Alzheimer Dementia. World Neurosurgery, 2013, 80, S27.e35-S27.e43.	0.7	31
118	Muscle-Directed Anti-AÎ² Single-Chain Antibody Delivery via AAV1 Reduces Cerebral AÎ² Load in an Alzheimerâ€™s Disease Mouse Model. Journal of Molecular Neuroscience, 2013, 49, 277-288.	1.1	20
119	Metallostasis in Alzheimer's disease. Free Radical Biology and Medicine, 2013, 62, 76-89.	1.3	297
120	Amyloid Î² deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	4.9	1,738
121	Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease. Journal of Medicinal Chemistry, 2013, 56, 4135-4155.	2.9	105
122	Triazolopyrimidinones as Î³-secretase modulators: structureâ€“activity relationship, modulator profile, and in vivo profiling. MedChemComm, 2013, 4, 422.	3.5	10
123	SAR investigations on a novel class of gamma-secretase modulators based on a unique scaffold. MedChemComm, 2013, 4, 569.	3.5	10
124	Materiomics: An â€omics Approach to Biomaterials Research. Advanced Materials, 2013, 25, 802-824.	11.1	134
125	Inhibition of Glycogen Synthase Kinase-3 Ameliorates Î²-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model. Journal of Biological Chemistry, 2013, 288, 1295-1306.	1.6	193
126	AÎ²42-Binding Peptoids as Amyloid Aggregation Inhibitors and Detection Ligands. ACS Chemical Neuroscience, 2013, 4, 952-962.	1.7	44
127	The missing link in the amyloid cascade of Alzheimerâ€™s disease â€“ Metal ions. Neurochemistry International, 2013, 62, 367-378.	1.9	72
128	The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Research Reviews, 2013, 12, 757-763.	5.0	130

#	Article	IF	Citations
129	The Supramolecular Chemistry of Î²-Sheets. Journal of the American Chemical Society, 2013, 135, 5477-5492.	6.6	160
130	Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 2013, 125, 157-171.	2.1	79
131	Dissecting Î³â€secretase function. Journal of Neurochemistry, 2013, 125, 1-3.	2.1	2
132	Spirocyclic Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid Î² in a Higher Species. Journal of Medicinal Chemistry, 2013, 56, 3379-3403.	2.9	50
133	Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimerâ€™s brains. Acta Neuropathologica, 2013, 125, 861-878.	3.9	107
134	Developing Therapeutic Antibodies for Neurodegenerative Disease. Neurotherapeutics, 2013, 10, 459-472.	2.1	166
135	Metal binding ability of curcumin derivatives: a theoretical vs. experimental approach. Dalton Transactions, 2013, 42, 5304.	1.6	36
136	The unfolded protein response in Alzheimerâ€™s disease. Seminars in Immunopathology, 2013, 35, 277-292.	2.8	102
137	Studying micro RNA Function and Dysfunction in Alzheimerâ€™s Disease. Frontiers in Genetics, 2012, 3, 327.	1.1	65
138	<scp>A</scp>lzheimer's Disease Biomarkers: More Than Molecular Diagnostics. Drug Development Research, 2013, 74, 92-111.	1.4	6
139	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesisâ€"but what lies beyond?. Biochemical Pharmacology, 2013, 85, 289-305.	2.0	181
140	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-Î² changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathologica, 2013, 126, 631-641.	3.9	125
141	Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain Research Bulletin, 2013, 96, 28-38.	1.4	24
142	Single Point Mutation Alters the Microstate Dynamics of Amyloid Î²-Protein AÎ²42 as Revealed by Dihedral Dynamics Analyses. Journal of Physical Chemistry B, 2013, 117, 6206-6216.	1.2	24
143	Effects of membrane interaction and aggregation of amyloid Î²-peptide on lipid mobility and membrane domain structure. Physical Chemistry Chemical Physics, 2013, 15, 8929.	1.3	73
144	Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders. Neuron, 2013, 78, 957-969.	3.8	54
145	The effect of oxysterols on the interaction of Alzheimer's amyloid beta with model membranes. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 2487-2495.	1.4	42
146	Process Development and Scale-up of a Î²-Secretase Inhibitor via a Stereospecific Jocic Reaction. Organic Process Research and Development, 2013, 17, 985-990.	1.3	12

#	Article	IF	Citations
147	Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain Î²-amyloid through PPARÎ³ activation. Acta Pharmacologica Sinica, 2013, 34, 455-463.	2.8	65
148	Peroxisome Proliferator-activated Receptors and Alzheimer's Disease: Hitting the Bloodâ€“Brain Barrier. Molecular Neurobiology, 2013, 48, 438-451.	1.9	36
149	Alzheimer's disease: which type of amyloid-preventing drug agents to employ?. Physical Chemistry Chemical Physics, 2013, 15, 8868.	1.3	50
150	The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease. , 2013, 54, 871.		176
151	Has inhibition of AÎ² production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of Î³-secretase inhibitor data. European Journal of Clinical Pharmacology, 2013, 69, 1247-1260.	0.8	31
152	Rational heterodoxy: Cholesterol reformation of the amyloid doctrine. Ageing Research Reviews, 2013, 12, 282-288.	5.0	33
153	Amyloid Precursor Proteins Interact with the Heterotrimeric G Protein Go in the Control of Neuronal Migration. Journal of Neuroscience, 2013, 33, 10165-10181.	1.7	34
154	Characterization of the polymorphic states of copper(II)-bound AÎ²(1-16) peptides by computational simulations. Journal of Computational Chemistry, 2013, 34, 2524-2536.	1.5	19
155	Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e99-e104.	0.5	2
156	Modeling of ageâ€dependent amyloid accumulation and Î³â€secretase inhibition of soluble and insoluble AÎ² in a transgenic mouse model of amyloid deposition. Pharmacology Research and Perspectives, 2013, 1, e00012.	1.1	4
157	Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 227-244.	1.2	46
159	Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimerâ€™s disease. Journal of Neural Transmission, 2013, 120, 103-111.	1.4	47
160	The Drosophila Homologue of the Amyloid Precursor Protein Is a Conserved Modulator of Wnt PCP Signaling. PLoS Biology, 2013, 11, e1001562.	2.6	71
161	SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in AÎ²PP/PS-1 Transgenic Mouse Brain. Journal of Alzheimer's Disease, 2013, 34, 349-365.	1.2	86
162	In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies, 2013, 2, 193-208.	1.2	90
163	Amyloid Pathology in Spinal Cord of the Transgenic Alzheimer's Disease Mice is Correlated to the Corticospinal Tract Pathway. Journal of Alzheimer's Disease, 2013, 35, 675-685.	1.2	20
164	Presenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo. Human Molecular Genetics, 2013, 22, 3828-3843.	1.4	68
165	Mechanism of amyloid Î²â^'protein dimerization determined using singleâ^'molecule AFM force spectroscopy. Scientific Reports, 2013, 3, 2880.	1.6	66

#	Article	IF	Citations
166	ApoE influences amyloid-Î² (AÎ²) clearance despite minimal apoE/AÎ² association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1807-16.	3.3	428
167	Alzheimerâ€™s Disease Diagnosis by Detecting Exogenous Fluorescent Signal of Ligand Bound to Beta Amyloid in the Lens of Human Eye: An Exploratory Study. Frontiers in Neurology, 2013, 4, 62.	1.1	36
168	Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimerâ€™s Disease. Pharmaceuticals, 2013, 6, 1304-1321.	1.7	35
169	A Semiâ€Physiological Model of Amyloidâ€Î² Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development. Journal of Clinical Pharmacology, 2013, 53, 691-698.	1.0	1
170	Modulation of Lipid Kinase PI4KIIÎ± Activity and Lipid Raft Association of Presenilin 1 Underlies Î³-Secretase Inhibition by Ginsenoside (20S)-Rg3. Journal of Biological Chemistry, 2013, 288, 20868-20882.	1.6	34
171	Novel Î³-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012. Expert Opinion on Therapeutic Patents, 2013, 23, 1349-1366.	2.4	47
172	Î³-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin. Journal of Biological Chemistry, 2013, 288, 9710-9720.	1.6	93
173	Aftins Increase Amyloid-Î²42, Lower Amyloid-Î²38, and Do Not Alter Amyloid-Î²40 Extracellular Production in vitro: Toward a Chemical Model of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 35, 107-120.	1.2	18
174	Increased Glutaminyl Cyclase Expression in Peripheral Blood of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 34, 263-271.	1.2	23
175	The Case for Tailoring Patent Awards Based on the Time-to-Market of Inventions. SSRN Electronic Journal, 2013, , .	0.4	0
176	Comparison of Two Different Methods for Measurement of Amyloid-Î² Peptides in Cerebrospinal Fluid after BACE1 Inhibition in a Dog Model. Journal of Alzheimer's Disease, 2013, 38, 39-48.	1.2	16
177	Modulators of Î³-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease. PLoS ONE, 2013, 8, e50759.	1.1	31
178	A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1Î”E9 Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e54769.	1.1	76
179	GPR3 Stimulates AÎ² Production via Interactions with APP and Î²-Arrestin2. PLoS ONE, 2013, 8, e74680.	1.1	32
180	Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes. CNS and Neurological Disorders - Drug Targets, 2013, 999, 19-20.	0.8	9
181	A tale of two drug targets: the evolutionary history of BACE1 and BACE2. Frontiers in Genetics, 2013, 4, 293.	1.1	17
182	Immunolocalization of Kisspeptin Associated with Amyloid-Î² Deposits in the Pons of an Alzheimerâ€™s Disease Patient. Journal of Neurodegenerative Diseases, 2013, 2013, 1-11.	1.1	9
183	Alzheimer's Disease and Prion Protein. Intractable and Rare Diseases Research, 2013, 2, 35-44.	0.3	15

#	Article	IF	Citations
184	Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors. PLoS ONE, 2014, 9, e84547.	1.1	148
185	Identification and Preclinical Pharmacology of the<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î³</mml:mi></mml:mrow></mml:math>-Secretase Modulator BMS-869780. International Journal of Alzheimer's Disease, 2014, 2014, 1-22.	1.1	12
186	Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science, 2014, 29, 893.	1.1	21
187	AlzheimerÃ¢â‚¬â„¢s disease: relevant molecular and physiopathological events affecting amyloid-ÃŽÂ² brain balance and the putative role of PPARs. Frontiers in Aging Neuroscience, 2014, 6, 176.	1.7	46
188	ÃŽÂ²-amyloid in biological samples: not all AÃŽÂ² detection methods are created equal. Frontiers in Aging Neuroscience, 2014, 6, 203.	1.7	3
189	Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of AlzheimerÃ¢â‚¬â„¢s disease: evidence for a pro-amyloidogenic role of MT1-MMP. Frontiers in Aging Neuroscience, 2014, 6, 247.	1.7	60
190	Incoordination between spikes and LFPs in AÃŽÂ²1Ã¢Ë†â€™42-mediated memory deficits in rats. Frontiers in Behavioral Neuroscience, 2014, 8, 411.	1.0	6
191	Polymorphism of the OLR1 3'UTR potential microRNA binding site and risk of Alzheimerâ€™s disease: a meta-analysis. Genetics and Molecular Research, 2014, 13, 10162-10172.	0.3	9
192	TL-2 attenuates Î²-amyloid induced neuronal apoptosis through the AKT/GSK-3Î²/Î²-catenin pathway. International Journal of Neuropsychopharmacology, 2014, 17, 1511-1519.	1.0	30
193	Ligand-Based and Structure-Based Investigation for Alzheimerâ€™s Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-16.	0.5	34
194	Intrinsically Disordered Proteins: Where Computation Meets Experiment. Polymers, 2014, 6, 2684-2719.	2.0	50
195	Promise and Challenge: The Lens Model as a Biomarker for Early Diagnosis of Alzheimer's Disease. Disease Markers, 2014, 2014, 1-5.	0.6	18
196	An effective treatment for Alzheimer's disease must consider both amyloid and tau. Bioscience Horizons, 2014, 7, hzu002-hzu002.	0.6	28
197	Towards Small Molecules as Therapies for Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. , 2014, , 199-290.		2
198	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Computational Biology, 2014, 10, e1003956.	1.5	151
199	Protective effect of pranlukast on AÎ² 1â€“42-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1. International Journal of Neuropsychopharmacology, 2014, 17, 581-592.	1.0	38
200	Intra-Hippocampal Transplantation of Neural Precursor Cells with Transgenic Over-Expression of IL-1 Receptor Antagonist Rescues Memory and Neurogenesis Impairments in an Alzheimerâ€™s Disease Model. Neuropsychopharmacology, 2014, 39, 401-414.	2.8	51
201	Alzheimerâ€™s disease from researcher to caregiver: a personal journey and call to action. Expert Review of Neurotherapeutics, 2014, 14, 465-467.	1.4	3

#	Article	IF	Citations
202	Sustained peripheral depletion of amyloid-Î² with a novel form of neprilysin does not affect central levels of amyloid-Î². Brain, 2014, 137, 553-564.	3.7	70
203	Cholesterol Drives AÎ²(1â€“42) Interaction with Lipid Rafts in Model Membranes. Langmuir, 2014, 30, 13934-13941.	1.6	29
204	Asymptotic solutions of the Oosawa model for the length distribution of biofilaments. Journal of Chemical Physics, 2014, 140, 194906.	1.2	28
205	Electroanalytical Sensors and Methods for Assays and Studies of Neurological Biomarkers. Electroanalysis, 2014, 26, 1236-1248.	1.5	8
206	Anilinotriazoles as potent gamma secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5805-5813.	1.0	17
207	Alzheimer's disease research and development: a call for a new research roadmap. Annals of the New York Academy of Sciences, 2014, 1313, 1-16.	1.8	31
208	In vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease. Lasers in Surgery and Medicine, 2014, 46, 27-33.	1.1	20
209	Effect of the AÎ² Aggregation Modulator MRZ-99030 on Retinal Damage in an Animal Model of Glaucoma. Neurotoxicity Research, 2014, 26, 440-446.	1.3	24
210	Apolipoprotein E receptor pathways in Alzheimer disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 255-270.	6.6	9
211	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Human Molecular Genetics, 2014, 23, 648-656.	1.4	126
212	Failure analysis of clinical trials to test the amyloid hypothesis. Annals of Neurology, 2014, 76, 159-161.	2.8	14
213	Intracellular AÎ² pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Communications, 2014, 2, 61.	2.4	84
214	Neurodegeneration and Neuroglia: Emphasis on Astroglia in Alzheimerâ€™s Disease. , 2014, , 265-291.		0
215	Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 1.	0.7	7
216	mNos2Deletion and HumanNOS2Replacement in Alzheimer Disease Models. Journal of Neuropathology and Experimental Neurology, 2014, 73, 752-769.	0.9	30
217	Allopregnanolone as regenerative therapeutic for Alzheimer's disease: Translational development and clinical promise. Progress in Neurobiology, 2014, 113, 40-55.	2.8	86
218	New developments in redox chemical delivery systems by means of 1,4-dihydroquinoline-based targetor: Application to galantamine delivery to the brain. European Journal of Medicinal Chemistry, 2014, 81, 218-226.	2.6	11
219	n-3 LCPUFA improves cognition: The young, the old and the sick. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 91, 1-20.	1.0	97

#	Article	IF	Citations
220	The end of Alzheimer's diseaseâ€"From biochemical pharmacology to ecopsychosociology: A personal perspective. Biochemical Pharmacology, 2014, 88, 677-681.	2.0	26
221	Structural Bioinformaticsâ€Based Identification of <scp>EGFR</scp> Inhibitor Gefitinib as a Putative Lead Compound for <scp>BACE</scp>. Chemical Biology and Drug Design, 2014, 83, 81-88.	1.5	13
222	Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in AÎ² Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig. Pharmaceutical Research, 2014, 31, 670-683.	1.7	9
223	Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death and Differentiation, 2014, 21, 696-706.	5.0	45
224	Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neuroscience Letters, 2014, 562, 63-68.	1.0	33
225	Transthyretin-Derived Peptides as Î²-Amyloid Inhibitors. ACS Chemical Neuroscience, 2014, 5, 542-551.	1.7	39
226	Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease â€“ a merging of hypotheses. Cell Calcium, 2014, 55, 175-181.	1.1	19
227	Tau acts as a mediator for <scp>A</scp>lzheimer's diseaseâ€related synaptic deficits. European Journal of Neuroscience, 2014, 39, 1202-1213.	1.2	43
228	The amyloid state and its association with protein misfolding diseases. Nature Reviews Molecular Cell Biology, 2014, 15, 384-396.	16.1	1,894
229	Amyloid Fibril Nucleation: Effect of Amino Acid Hydrophobicity. Journal of Physical Chemistry B, 2014, 118, 5289-5299.	1.2	13
230	Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2477-2480.	1.0	12
231	The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2033-2045.	1.0	138
232	11C-Labeling of a potent hydroxyethylamine BACE-1 inhibitor and evaluation in vitro and in vivo. Nuclear Medicine and Biology, 2014, 41, 536-543.	0.3	17
233	Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione Î³-Secretase Modulators. Journal of Medicinal Chemistry, 2014, 57, 1046-1062.	2.9	25
234	Antioxidant gene therapy against neuronal cell death. , 2014, 142, 206-230.		120
235	Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures. European Journal of Pharmacology, 2014, 739, 83-95.	1.7	72
236	Metabolism and functions of copper in brain. Progress in Neurobiology, 2014, 116, 33-57.	2.8	351
237	On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Ageing Research Reviews, 2014, 13, 10-12.	5.0	72

#	Article	IF	Citations
238	Emerging Therapeutics for Alzheimer's Disease. Annual Review of Pharmacology and Toxicology, 2014, 54, 381-405.	4.2	76
239	Lessons from a Failed Î³-Secretase Alzheimer Trial. Cell, 2014, 159, 721-726.	13.5	255
240	Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer's disease. Journal of the Neurological Sciences, 2014, 346, 6-10.	0.3	10
241	Estimation of phosphorylation level of amyloid-beta isolated from human blood plasma: Ultrahigh-resolution mass spectrometry. Molecular Biology, 2014, 48, 607-614.	0.4	8
242	MicroRNA-339-5p Down-regulates Protein Expression of Î²-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects. Journal of Biological Chemistry, 2014, 289, 5184-5198.	1.6	163
243	The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-Î² (AÎ²) Aggregation. Journal of Biological Chemistry, 2014, 289, 30977-30989.	1.6	132
244	Electrochemical Immunosensors for Effective Evaluation of Amyloid-Beta Modulators on Oligomeric and Fibrillar Aggregation Processes. Analytical Chemistry, 2014, 86, 4901-4909.	3.2	67
245	Z-Selective Olefin Metathesis on Peptides: Investigation of Side-Chain Influence, Preorganization, and Guidelines in Substrate Selection. Journal of the American Chemical Society, 2014, 136, 12469-12478.	6.6	78
246	The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. International Psychogeriatrics, 2014, 26, 9-18.	0.6	158
247	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease. Pathologie Et Biologie, 2014, 62, 333-336.	2.2	54
248	Cardiolipin Profile Changes are Associated to the Early Synaptic Mitochondrial Dysfunction in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1375-1392.	1.2	90
249	The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease. Journal of Controlled Release, 2014, 192, 317-324.	4.8	79
250	Amyloid-Î² Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease. Journal of Biological Chemistry, 2014, 289, 27080-27089.	1.6	17
251	Antiamyloid Therapy for Alzheimer's Disease â€" Are We on the Right Road?. New England Journal of Medicine, 2014, 370, 377-378.	13.9	106
252	Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. Journal of Neuroinflammation, 2014, 11, 98.	3.1	1,285
253	Interpreting Alzheimerâ€™s disease clinical trials in light of the effects on amyloid-Î². Alzheimer's Research and Therapy, 2014, 6, 14.	3.0	30
254	Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimerâ€™s disease immunotherapeutics. Alzheimer's Research and Therapy, 2014, 6, 42.	3.0	140
255	Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 76.	2.4	69

#	Article	IF	Citations
256	Conformation-specific antibodies to target amyloid Î² oligomers and their application to immunotherapy for Alzheimerâ€™s disease. Bioscience, Biotechnology and Biochemistry, 2014, 78, 1293-1305.	0.6	37
257	Transient dynamics of AÎ² contribute to toxicity in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2014, 71, 3507-3521.	2.4	76
258	The screening of Alzheimerâ€™s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	1.8	11
259	Simulated Interactions between Endothelin Converting Enzyme and AÎ² Peptide: Insights into Subsite Recognition and Cleavage Mechanism. International Journal of Peptide Research and Therapeutics, 2014, 20, 409-420.	0.9	15
260	Retro-inversal of Intracellular Selected Î²-Amyloid-Interacting Peptides: Implications for a Novel Alzheimerâ€™s Disease Treatment. Biochemistry, 2014, 53, 2101-2111.	1.2	17
261	Mildronate improves cognition and reduces amyloidâ€Î² pathology in transgenic Alzheimer's disease mice. Journal of Neuroscience Research, 2014, 92, 338-346.	1.3	8
262	Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2014, 29, 22-31.	1.3	29
263	Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimerâ€™s disease. Nature Communications, 2014, 5, 3443.	5.8	108
264	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimerâ€™s disease. Brain, 2014, 137, 1533-1549.	3.7	100
265	Altered Cerebrospinal Fluid Levels of Amyloid Î² and Amyloid Precursor-Like Protein 1 Peptides in Downâ€™s Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
266	Abundance of AÎ²5-xlike immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 13.	4.4	19
267	Chronic Aluminum Intake Causes Alzheimer's Disease: Applying Sir Austin Bradford Hill's Causality Criteria. Journal of Alzheimer's Disease, 2014, 40, 765-838.	1.2	97
268	Latest treatment options for Alzheimerâ€™s disease, Parkinsonâ€™s disease dementia and dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2014, 15, 1797-1810.	0.9	50
269	⁶⁸Ga based probe for Alzheimer's disease: synthesis and preclinical evaluation of homodimeric chalcone in Î²-amyloid imaging. Organic and Biomolecular Chemistry, 2014, 12, 7328.	1.5	32
270	Activated protein C inhibits amyloid Î² production via promoting expression of ADAM-10. Brain Research, 2014, 1545, 35-44.	1.1	15
271	Beyond pathology: APP, brain development and Alzheimer's disease. Current Opinion in Neurobiology, 2014, 27, 61-67.	2.0	41
272	Differential effects of angiotensin II receptor blockers on AÎ² generation. Neuroscience Letters, 2014, 567, 51-56.	1.0	13
273	A Bacteriophage Capsid Protein Provides a General Amyloid Interaction Motif (GAIM) That Binds and Remodels Misfolded Protein Assemblies. Journal of Molecular Biology, 2014, 426, 2500-2519.	2.0	54

#	Article	IF	Citations
274	Investigating Î³-secretase protein interactions in live cells using active site-directed clickable dual-photoaffinity probes. MedChemComm, 2014, 5, 321-327.	3.5	7
275	A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Annals of Neurology, 2014, 76, 185-205.	2.8	232
276	A Cell Model for the Initial Phase of Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 395-411.	1.2	33
277	Dysfunctional Wnt/Î²-catenin signaling contributes to bloodâ€“brain barrier breakdown in Alzheimerâ€™s disease. Neurochemistry International, 2014, 75, 19-25.	1.9	74
278	Montelukast rescues primary neurons against AÎ²1â€“42-induced toxicity through inhibiting CysLT1R-mediated NF-ÎºB signaling. Neurochemistry International, 2014, 75, 26-31.	1.9	44
279	APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular Psychiatry, 2014, 19, 351-357.	4.1	181
280	Telmisartan Treatment Ameliorates Memory Deficits in Streptozotocin-Induced Diabetic Mice via Attenuating Cerebral Amyloidosis. Journal of Pharmacological Sciences, 2014, 124, 418-426.	1.1	17
281	Camptothecin and its Analogs Reduce Amyloid-Î² Production and Amyloid-Î²42-Induced IL-1Î² Production. Journal of Alzheimer's Disease, 2014, 43, 465-477.	1.2	11
282	Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Frontiers in Genetics, 2014, 5, 88.	1.1	562
283	A critical analysis of the â€˜amyloid cascade hypothesisâ€™. Folia Neuropathologica, 2014, 3, 211-225.	0.5	87
286	Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-Î² plaque formation in organotypic hippocampal slice cultures. Scientific Reports, 2015, 5, 14624.	1.6	82
287	Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimerâ€™s disease. Scientific Reports, 2015, 5, 16127.	1.6	41
288	Transcriptomic Analysis of Drosophila Mushroom Body Neurons Lacking Amyloid-Î² Precursor-Like Protein Activity. Journal of Alzheimer's Disease, 2015, 46, 913-928.	1.2	2
289	Magnetite-Amyloid-Î² deteriorates activity and functional organization in an in vitro model for Alzheimerâ€™s disease. Scientific Reports, 2015, 5, 17261.	1.6	44
290	Modeling the Aggregation Propensity and Toxicity of Amyloid-Î² Variants. Journal of Alzheimer's Disease, 2015, 47, 215-229.	1.2	23
291	Biomarkers in Sporadic and Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317.	1.2	75
292	Peripherally Applied Synthetic Tetrapeptides HAEE and RADD Slow Down the Development of Cerebral Î²-Amyloidosis in AÎ²PP/PS1 Transgenic Mice. Journal of Alzheimer's Disease, 2015, 46, 849-853.	1.2	14
293	Targeting the Î³-/Î²-secretase interaction reduces Î²-amyloid generation and ameliorates Alzheimerâ€™s disease-related pathogenesis. Cell Discovery, 2015, 1, 15021.	3.1	31

#	Article	IF	Citations
294	The role of proteotoxic stress in vascular dysfunction in the pathogenesis of Alzheimerâ€™s disease. Endoplasmic Reticulum Stress in Diseases, 2015, 2, .	0.2	1
295	Active immunization against complement factor C5a: a new therapeutic approach for Alzheimerâ€™s disease. Journal of Neuroinflammation, 2015, 12, 150.	3.1	38
296	The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimerâ€™s disease. Molecular Brain, 2015, 8, 82.	1.3	44
297	Cu(II) enhances the effect of Alzheimerâ€™s amyloid-Î² peptide on microglial activation. Journal of Neuroinflammation, 2015, 12, 122.	3.1	31
298	An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. Journal of Neuroinflammation, 2015, 12, 153.	3.1	29
299	Modulation of AÎ²42 in vivo by Î³-secretase modulator in primates and humans. Alzheimer's Research and Therapy, 2015, 7, 55.	3.0	9
300	Lipids under stress â€“ a lipidomic approach for the study of mood disorders. BioEssays, 2015, 37, 1226-1235.	1.2	17
301	A Versatile Approach to CF₃â€Containing 2â€Pyrrolidones by Tandem Michael Additionâ€“Cyclization: Exemplification in the Synthesis of Amidine Class BACE1 Inhibitors. Chemistry - A European Journal, 2015, 21, 11719-11726.	1.7	16
302	Seven-Tesla MRI and neuroimaging biomarkers for Alzheimerâ€™s disease. Neurosurgical Focus, 2015, 39, E4.	1.0	12
303	Targeted Magnetic Nanoparticles for Remote Magnetothermal Disruption of Amyloidâ€Î²2 Aggregates. Advanced Healthcare Materials, 2015, 4, 2100-2109.	3.9	23
304	The Dependence of Amyloidâ€Î²2 Dynamics on Protein Force Fields and Water Models. ChemPhysChem, 2015, 16, 3278-3289.	1.0	103
305	Alzheimer's in 3D culture: Challenges and perspectives. BioEssays, 2015, 37, 1139-1148.	1.2	83
306	Thermodynamics of AÎ²_{16â€“21} dissociation from a fibril: Enthalpy, entropy, and volumetric properties. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1963-1972.	1.5	6
307	Computational analysis of candidate prion-like proteins in bacteria and their role. Frontiers in Microbiology, 2015, 6, 1123.	1.5	37
308	Can insulin signaling pathways be targeted to transport AÃŽÂ² out of the brain?. Frontiers in Aging Neuroscience, 2015, 7, 114.	1.7	27
309	Menopause, obesity and inflammation: interactive risk factors for Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 2015, 7, 130.	1.7	81
310	Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimerâ€™s Disease Pathogenesis. Frontiers in Aging Neuroscience, 2015, 7, 234.	1.7	37
311	Acute intracerebral treatment with amyloid-beta (1Ã¢â‚¬â€œ42) alters the profile of neuronal oscillations that accompany LTP induction and results in impaired LTP in freely behaving rats. Frontiers in Behavioral Neuroscience, 2015, 9, 103.	1.0	27

#	Article	IF	Citations
312	Fragile X mental retardation protein: from autism to neurodegenerative disease. Frontiers in Cellular Neuroscience, 2015, 9, 43.	1.8	20
313	Fluid Biomarkers in Clinical Trials of Alzheimerâ€™s Disease Therapeutics. Frontiers in Neurology, 2015, 6, 186.	1.1	22
314	Amylin at the interface between metabolic and neurodegenerative disorders. Frontiers in Neuroscience, 2015, 9, 216.	1.4	71
315	7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimerâ€™s Disease Treatment. Molecules, 2015, 20, 22084-22101.	1.7	35
316	First Administration of the Fc-Attenuated Anti-Î² Amyloid Antibody GSK933776 to Patients with Mild Alzheimerâ€™s Disease: A Randomized, Placebo-Controlled Study. PLoS ONE, 2015, 10, e0098153.	1.1	27
317	DBA/2J Genetic Background Exacerbates Spontaneous Lethal Seizures but Lessens Amyloid Deposition in a Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0125897.	1.1	27
318	A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice. PLoS ONE, 2015, 10, e0127686.	1.1	10
319	The Amyloid Precursor Protein Controls PIKfyve Function. PLoS ONE, 2015, 10, e0130485.	1.1	21
320	Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimerâ€™s Disease Pathogenesis. PLoS ONE, 2015, 10, e0139574.	1.1	67
321	Systematic AÎ² Analysis in Drosophila Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues. PLoS ONE, 2015, 10, e0133272.	1.1	30
322	Î²-Amyloid: the key peptide in the pathogenesis of Alzheimerâ€™s disease. Frontiers in Pharmacology, 2015, 6, 221.	1.6	216
323	Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimerâ€™s Disease. Current Alzheimer Research, 2015, 12, 32-46.	0.7	255
324	Icariin Prevents Amyloid Beta-Induced Apoptosis via the PI3K/Akt Pathway in PC-12 Cells. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	0.5	26
325	Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimerâ€™s Disease. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-17.	0.5	9
326	Vitamin D and Alzheimerâ€™s Disease: Neurocognition to Therapeutics. International Journal of Alzheimer's Disease, 2015, 2015, 1-11.	1.1	63
327	A Comparative Evaluation of a Novel Vaccine in APP/PS1 Mouse Models of Alzheimerâ€™s Disease. BioMed Research International, 2015, 2015, 1-16.	0.9	13
328	2-Phenylbenzothiazole conjugated with cyclopentadienyl tricarbonyl [CpM(CO)₃] (M =) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Transactions, 2015, 44, 6406-6415.	1.6	34
329	Prion-Protein-interacting Amyloid-Î² Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. Journal of Biological Chemistry, 2015, 290, 17415-17438.	1.6	104

#	Article	IF	Citations
330	Ca2+ dysregulation in the endoplasmic reticulum related to Alzheimerâ€™s disease: A review on experimental progress and computational modeling. BioSystems, 2015, 134, 1-15.	0.9	25
331	Clec4g (LSECtin) interacts with BACE1 and suppresses AÎ² generation. FEBS Letters, 2015, 589, 1418-1422.	1.3	12
332	Miniature microscopes for large-scale imaging of neuronal activity in freely behaving rodents. Current Opinion in Neurobiology, 2015, 32, 141-147.	2.0	70
333	Adapting simultaneous analysis phylogenomic techniques to study complex disease gene relationships. Journal of Biomedical Informatics, 2015, 54, 10-38.	2.5	3
334	Microcirculation of the brain: morphological assessment in degenerative diseases and restoration processes. Reviews in the Neurosciences, 2015, 26, 75-93.	1.4	20
335	Temperature and toxic Tau in Alzheimer's disease: new insights. Temperature, 2015, 2, 491-498.	1.7	29
336	EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-Î² oligomers and plaques. Nature Communications, 2015, 6, 8997.	5.8	96
337	Arginase 1+ microglia reduce AÎ² plaque deposition during IL-1Î²-dependent neuroinflammation. Journal of Neuroinflammation, 2015, 12, 203.	3.1	111
338	Natural Î²-Dihydroagarofuran-Type Sesquiterpenoids as Cognition-Enhancing and Neuroprotective Agents from Medicinal Plants of the Genus Celastrus. Journal of Natural Products, 2015, 78, 2175-2186.	1.5	42
339	Effect of Low-Intensity Ultrasound on Mortality of PC12 Induced by Amyloid Î²25â€“35. Journal of Medical and Biological Engineering, 2015, 35, 323-330.	1.0	0
340	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. Molecular Neurodegeneration, 2015, 10, 68.	4.4	69
341	What Theories Are Tested in Clinical Trials?. Philosophy of Science, 2015, 82, 1318-1329.	0.5	5
342	Targeting the Prodromal Stage of Alzheimer's Disease: Bioenergetic and Mitochondrial Opportunities. Neurotherapeutics, 2015, 12, 66-80.	2.1	59
343	Learning by Failing: Ideas and Concepts to Tackle Î³-Secretases in Alzheimer's Disease and Beyond. Annual Review of Pharmacology and Toxicology, 2015, 55, 419-437.	4.2	117
344	A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth. Neuropharmacology, 2015, 92, 146-157.	2.0	13
345	Î²-Amyloid peptides display protective activity against the human Alzheimerâ€™s disease-associated herpes simplex virus-1. Biogerontology, 2015, 16, 85-98.	2.0	170
346	Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions. Journal of NeuroImmune Pharmacology, 2015, 10, 402-424.	2.1	40
347	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. Journal of Medicinal Chemistry, 2015, 58, 4365-4382.	2.9	88

#	Article	IF	Citations
348	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. ACS Chemical Neuroscience, 2015, 6, 559-569.	1.7	35
349	Telencephalic neurocircuitry and synaptic plasticity in rodent spatial learning and memory. Brain Research, 2015, 1621, 294-308.	1.1	14
350	Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious Î²-secretase inhibitors for the potential treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 767-774.	1.0	30
351	Metabolic Profiling of CHO-AÎ²PP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-Î² Pathology and Potential Therapeutic Effects of Both PPARÎ³ and PPARÎ± Agonisms for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 215-231.	1.2	25
352	The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof. Chemical Communications, 2015, 51, 5556-5571.	2.2	104
353	Amyloid-Î² Immunotherapy Reduces Amyloid Plaques and Astroglial Reaction in Aged Domestic Dogs. Neurodegenerative Diseases, 2015, 15, 24-37.	0.8	17
354	Structural analysis of membrane-bound hECE-1 dimer using molecular modeling techniques: insights into conformational changes and AÎ²1â€“42 peptide binding. Amino Acids, 2015, 47, 543-559.	1.2	24
355	Clearing the way for tau immunotherapy in Alzheimer's disease. Journal of Neurochemistry, 2015, 132, 1-4.	2.1	16
356	ER stress signaling and neurodegeneration: At the intersection between Alzheimer's disease and Prion-related disorders. Virus Research, 2015, 207, 69-75.	1.1	28
357	An aberrant sugar modification of <scp>BACE</scp>1 blocks its lysosomal targeting in <scp>A</scp>lzheimer's disease. EMBO Molecular Medicine, 2015, 7, 175-189.	3.3	147
358	A multiâ€pathway perspective on protein aggregation: Implications for control of the rate and extent of amyloid formation. FEBS Letters, 2015, 589, 672-679.	1.3	38
359	N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders. European Journal of Medicinal Chemistry, 2015, 97, 719-731.	2.6	18
360	A Cyclic Peptide Mimic of the Î²-Amyloid Binding Domain on Transthyretin. ACS Chemical Neuroscience, 2015, 6, 778-789.	1.7	23
361	Localization and Trafficking of Amyloid-Î² Protein Precursor and Secretases: Impact on Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 329-347.	1.2	64
362	Drosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives. Journal of Alzheimer's Disease, 2015, 45, 1015-1038.	1.2	55
363	Tricyclic phenothiazine and phenoselenazine derivatives as potential multi-targeting agents to treat Alzheimer's disease. MedChemComm, 2015, 6, 1930-1941.	3.5	35
364	Nascent Î² -Hairpin Formation of a Natively Unfolded Peptide Reveals the Role of Hydrophobic Contacts. Biophysical Journal, 2015, 109, 630-638.	0.2	6
365	Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimerâ€™s disease amyloid plaques. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3699-708.	3.3	313

#	Article	IF	Citations
366	Alzheimerâ€™s Disease, Drosophila melanogaster and Polyphenols. Advances in Experimental Medicine and Biology, 2015, 863, 21-53.	0.8	6
367	Successive Stages of Amyloid-Î² Self-Assembly Characterized by Solid-State Nuclear Magnetic Resonance with Dynamic Nuclear Polarization. Journal of the American Chemical Society, 2015, 137, 8294-8307.	6.6	103
368	Lipids in Amyloid-Î² Processing, Aggregation, and Toxicity. Advances in Experimental Medicine and Biology, 2015, 855, 67-94.	0.8	56
369	Alzheimerâ€™s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs, 2015, 29, 487-502.	2.7	26
370	Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome. Neuron, 2015, 87, 382-398.	3.8	59
371	6-Phenoxy-2-phenylbenzoxazoles, novel inhibitors of receptor for advanced glycation end products (RAGE). Bioorganic and Medicinal Chemistry, 2015, 23, 4919-4935.	1.4	11
372	Development of alkoxy styrylchromone derivatives for imaging of cerebral amyloid-Î² plaques with SPECT. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3363-3367.	1.0	12
373	Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease. Hormones and Behavior, 2015, 76, 48-56.	1.0	26
374	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	4.5	94
375	Neuronal hyperactivity â€“ A key defect in Alzheimer's disease?. BioEssays, 2015, 37, 624-632.	1.2	182
376	Exogenous Î²-amyloid peptide interferes with GLUT4 localization in neurons. Brain Research, 2015, 1615, 42-50.	1.1	12
377	Design of Pyridopyrazine-1,6-dione Î³-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability. ACS Medicinal Chemistry Letters, 2015, 6, 596-601.	1.3	30
378	X-ray Crystallographic Structures of Oligomers of Peptides Derived from Î²₂-Microglobulin. Journal of the American Chemical Society, 2015, 137, 6304-6311.	6.6	36
379	Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 225-235.	1.4	7
380	The influence of cholesterol on membrane protein structure, function, and dynamics studied by molecular dynamics simulations. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 1783-1795.	1.4	144
381	Collaboration of geldanamycin-activated P70S6K and Hsp70 against beta-amyloid-induced hippocampal apoptosis: an approach to long-term memory and learning. Cell Stress and Chaperones, 2015, 20, 309-319.	1.2	15
382	Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Molecular Neurodegeneration, 2015, 10, 16.	4.4	95
383	Carbohydrates and Glycomimetics in Alzheimer's Disease Therapeutics and Diagnosis. RSC Drug Discovery Series, 2015, , 180-208.	0.2	3

#	Article	IF	Citations
384	Is interaction of amyloid Î²-peptides with metals involved in cognitive activity?. Metallomics, 2015, 7, 1205-1212.	1.0	18
385	Predicting Reduction of Cerebrospinal Fluid Î²-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	4.5	42
386	Uptake of raft components into amyloid Î²-peptide aggregates and membrane damage. Analytical Biochemistry, 2015, 481, 18-26.	1.1	8
387	Dantrolene, A Treatment for Alzheimer Disease?. Alzheimer Disease and Associated Disorders, 2015, 29, 1-5.	0.6	33
388	Autoregulated paracellular clearance of amyloid-Î² across the blood-brain barrier. Science Advances, 2015, 1, e1500472.	4.7	113
389	Amyloid-PET predicts inhibition of de novo plaque formation upon chronic Î³-secretase modulator treatment. Molecular Psychiatry, 2015, 20, 1179-1187.	4.1	46
390	Electrochemical quantification of the Alzheimerâ€™s disease amyloid-Î² (1â€“40) using amyloid-Î² fibrillization promoting peptide. Sensing and Bio-Sensing Research, 2015, 6, 7-12.	2.2	7
391	Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathologica Communications, 2015, 3, 25.	2.4	102
392	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. Archives of Biochemistry and Biophysics, 2015, 588, 1-14.	1.4	20
393	Accumulation of amyloid-Î² in the cerebellar cortex of essential tremor patients. Neurobiology of Disease, 2015, 82, 397-408.	2.1	16
394	The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimerâ€™s disease in vitro and in vivo. Neuroscience, 2015, 305, 26-35.	1.1	28
395	Improvement of Ageâ€Related Memory Impairment with Infusion of Young Plasma: A Role for the Peripheral Amyloid Sink?. Journal of the American Geriatrics Society, 2015, 63, 419-420.	1.3	2
396	Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease. Chemical Communications, 2015, 51, 13434-13450.	2.2	191
397	Dynamics of protein aggregation and oligomer formation governed by secondary nucleation. Journal of Chemical Physics, 2015, 143, 054901.	1.2	41
398	Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic AÎ² Variants. ACS Chemical Neuroscience, 2015, 6, 1990-1996.	1.7	16
399	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's and Dementia, 2015, 11, 1050-1068.	0.4	98
400	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	3.7	117
401	1,4-Oxazine Î²-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. Journal of Medicinal Chemistry, 2015, 58, 8216-8235.	2.9	67

#	Article	IF	Citations
402	PET Radioligands for Imaging of Tau Pathology: Current Status. Nuclear Medicine and Molecular Imaging, 2015, 49, 251-257.	0.6	9
403	Decreased amyloid-Î² and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Nature Neuroscience, 2015, 18, 1725-1727.	7.1	121
404	Discovery of indole-derived pyridopyrazine-1,6-dione Î³-secretase modulators that target presenilin. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 908-913.	1.0	20
405	Rhenium and technetium complexes that bind to amyloid-Î² plaques. Dalton Transactions, 2015, 44, 4933-4944.	1.6	20
406	Introduction of a Fluorescent Probe to Amyloidâ€Î² to Reveal Kinetic Insights into Its Interactions with Copper(II). Angewandte Chemie - International Edition, 2015, 54, 1227-1230.	7.2	47
407	Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss. Hippocampus, 2015, 25, 813-826.	0.9	169
408	Molecular Mechanism of the Inhibition and Remodeling of Human Islet Amyloid Polypeptide (hIAPP_{1â€“37}) Oligomer by Resveratrol from Molecular Dynamics Simulation. Journal of Physical Chemistry B, 2015, 119, 15-24.	1.2	51
409	Orientin alleviates cognitive deficits and oxidative stress in AÎ²1â€“42-induced mouse model of Alzheimer's disease. Life Sciences, 2015, 121, 104-109.	2.0	90
410	Microglial AÎ² Receptors in Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2015, 35, 71-83.	1.7	189
411	Pharmacotherapy of Alzheimerâ€™s disease: current and future trends. Expert Review of Neurotherapeutics, 2015, 15, 3-5.	1.4	55
412	Pathogenic properties of Alzheimer's Î²-amyloid identified from structureâ€“property patient-phenotype correlations. Dalton Transactions, 2015, 44, 2747-2754.	1.6	12
413	Carboxy Terminus Heat Shock Protein 70 Interacting Protein Reduces Tau-Associated Degenerative Changes. Journal of Alzheimer's Disease, 2015, 44, 937-947.	1.2	29
414	Amyloid-Beta Disrupts Calcium and Redox Homeostasis in Brain Endothelial Cells. Molecular Neurobiology, 2015, 51, 610-622.	1.9	46
415	The Role of Cholesterol Metabolism in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 51, 947-965.	1.9	62
416	Dysregulation of TrkB Receptors and BDNF Function by Amyloid-Î² Peptide is Mediated by Calpain. Cerebral Cortex, 2015, 25, 3107-3121.	1.6	84
417	Detection of Amyloid Î² Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 738-745.	0.9	38
418	Role of PrPC Expression in Tau Protein Levels and Phosphorylation in Alzheimerâ€™s Disease Evolution. Molecular Neurobiology, 2015, 51, 1206-1220.	1.9	25
419	Biometals and Their Therapeutic Implications in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 109-120.	2.1	109

#	Article	IF	Citations
420	Chelation-induced diradical formation as an approach to modulation of the amyloid-Î² aggregation pathway. Chemical Science, 2015, 6, 1018-1026.	3.7	15
421	Glial Asthenia and Functional Paralysis. Neuroscientist, 2015, 21, 552-568.	2.6	87
422	S-Nitrosylation in Alzheimer's disease. Molecular Neurobiology, 2015, 51, 268-280.	1.9	51
423	A century of confusion in researching Alzheimerâ€™s disease. International Journal of Healthcare, 2016, 2, .	0.2	4
424	Interaction between Amyloid Beta Toxicity and the PI3K Pathway in Alzheimerâ€™s Disease. , 2016, 6, .		8
425	Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 307-316.	0.7	15
426	Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates. Aging, 2016, 8, 1718-1734.	1.4	48
427	Generation of Cholinergic and Dopaminergic Interneurons from Human Pluripotent Stem Cells as a Relevant Tool for In Vitro Modeling of Neurological Disorders Pathology and Therapy. Stem Cells International, 2016, 2016, 1-16.	1.2	10
428	Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. Neural Plasticity, 2016, 2016, 1-15.	1.0	186
429	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	0.7	50
430	The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration. Frontiers in Cell and Developmental Biology, 2015, 3, 80.	1.8	125
431	Amyloid Plaques in Retina for Diagnosis in Alzheimerâ€™s Patients: a Meta-Analysis. Frontiers in Aging Neuroscience, 2016, 8, 267.	1.7	28
432	Cognitive Intervention As an Early Non-pharmacological Strategy in Alzheimer's Disease: A Translational Perspective. Frontiers in Aging Neuroscience, 2016, 8, 280.	1.7	5
433	Î²-Secretase 1â€™s Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice. Frontiers in Cellular Neuroscience, 2015, 9, 498.	1.8	19
434	One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. Frontiers in Neuroscience, 2016, 10, 177.	1.4	75
435	Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Frontiers in Neuroscience, 2016, 10, 541.	1.4	46
436	Structureâ€“activity relationship studies of benzylâ€, phenethylâ€, and pyridylâ€substituted tetrahydroacridinâ€9â€amines as multitargeting agents to treat Alzheimer's disease. Chemical Biology and Drug Design, 2016, 88, 710-723.	1.5	7
437	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. Journal of Neurochemistry, 2016, 139, 224-236.	2.1	17

#	Article	IF	Citations
438	The amyloid cascade hypothesis: are we poised for success or failure?. Journal of Neurochemistry, 2016, 139, 237-252.	2.1	308
439	Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease. Journal of Neurochemistry, 2016, 137, 101-111.	2.1	47
440	Natureâ€Inspired Multifunctional Ligands: Focusing on Amyloidâ€Based Molecular Mechanisms of Alzheimer's Disease. ChemMedChem, 2016, 11, 1309-1317.	1.6	31
442	Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, 166, 40-55.		127
443	MicroRNA-26b is upregulated in a double transgenic mouse model of Alzheimer's disease and promotes the expression of amyloid-Î² by targeting insulin-like growth factor 1. Molecular Medicine Reports, 2016, 13, 2809-2814.	1.1	28
444	Ten Challenges of the Amyloid Hypothesis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 447-457.	1.2	71
445	Protective Effect of Amyloid-Î² Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model. Journal of Alzheimer's Disease, 2016, 50, 1227-1241.	1.2	120
446	Evidence For and Against a Pathogenic Role of Reduced Î³-Secretase Activity in Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 781-799.	1.2	44
447	Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. Scientific Reports, 2016, 6, 33047.	1.6	102
448	Hyperexpression of STIM2 protein lowers the amount of Abeta plaques in the brain of Alzheimer's disease mouse model. St Petersburg Polytechnical University Journal Physics and Mathematics, 2016, 2, 329-336.	0.3	1
449	Anti-Viral Properties of Amyloid-Î² Peptides. Journal of Alzheimer's Disease, 2016, 54, 859-878.	1.2	70
450	AÎ²-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Reviews in Molecular Medicine, 2016, 18, e13.	1.6	34
451	Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Scientific Reports, 2016, 5, 18286.	1.6	37
452	3D culture models of Alzheimerâ€™s disease: a road map to a â€œcure-in-a-dishâ€• Molecular Neurodegeneration, 2016, 11, 75.	4.4	109
453	Monitoring Blood-Brain Barrier Integrity Following Amyloid-Î² Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model. Journal of Alzheimer's Disease, 2016, 54, 723-735.	1.2	17
454	Abnormal Population Responses in the Somatosensory Cortex of Alzheimerâ€™s Disease Model Mice. Scientific Reports, 2016, 6, 24560.	1.6	24
455	Two Phase 2 Multiple Ascendingâ€“Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 1131-1143.	1.2	78
456	Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AÎ²PP/PS1 Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 1157-1173.	1.2	18

#	Article	IF	Citations
457	Scaling and dimensionality in the chemical kinetics of protein filament formation. International Reviews in Physical Chemistry, 2016, 35, 679-703.	0.9	10
458	Curing bacterial infections with protein aggregates. Molecular Microbiology, 2016, 99, 827-830.	1.2	5
459	A theranostic agent for inÂvivo near-infrared imaging of Î²-amyloid species and inhibition of Î²-amyloid aggregation. Biomaterials, 2016, 94, 84-92.	5.7	79
460	Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension. American Journal of Obstetrics and Gynecology, 2016, 215, 464.e1-464.e7.	0.7	34
461	Design and synthesis of 5-cyclopropyl substituted cyclic acylguanidine compounds as BACE1 inhibitors. Chinese Chemical Letters, 2016, 27, 1626-1629.	4.8	0
462	Why Are Humans Vulnerable to Alzheimerâ€™s Disease?. , 2016, , 329-345.		1
463	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annual Review of Neuroscience, 2016, 39, 57-79.	5.0	97
464	Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry. European Journal of Medicinal Chemistry, 2016, 113, 258-272.	2.6	146
465	Effects of novel acylhydrazones derived from 4-quinolone on the acetylcholinesterase activity and AÎ²42 peptide fibrils formation. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1464-1470.	2.5	10
466	AÎ²1-42-induced dysfunction in synchronized gamma oscillation during working memory. Behavioural Brain Research, 2016, 307, 112-119.	1.2	13
467	Alzheimer's disease: a mathematical model for onset and progression. Mathematical Medicine and Biology, 2017, 34, 193-214.	0.8	45
468	Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. Future Medicinal Chemistry, 2016, 8, 697-711.	1.1	68
469	Heat shock proteins as potential targets for protective strategies in neurodegeneration. Lancet Neurology, The, 2016, 15, 748-759.	4.9	124
470	Familial Alzheimerâ€™s Disease Mutations in Presenilin Generate Amyloidogenic AÎ² Peptide Seeds. Neuron, 2016, 90, 410-416.	3.8	86
471	Part 1: Notch-sparing Î³-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2129-2132.	1.0	2
472	Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. Alzheimer's and Dementia, 2016, 12, 977-986.	0.4	27
473	NewN,N-dimethylcarbamate inhibitors of acetylcholinesterase: design synthesis and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 106-113.	2.5	11
474	Profiling the dynamics of CSF and plasma AÎ² reduction after treatment with JNJâ€54861911, a potent oral BACE inhibitor. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 202-212.	1.8	50

#	Article	IF	Citations
475	Luminescent Ru(II) Phenanthroline Complexes as a Probe for Real-Time Imaging of AÎ² Self-Aggregation and Therapeutic Applications in Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 9215-9227.	2.9	35
476	Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics, 2016, 16, 3042-3053.	1.3	69
477	Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide. Neuroscience, 2016, 331, 72-77.	1.1	19
478	Dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 138, 123-151.	1.0	35
479	Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3928-3937.	1.0	16
480	Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of <scp>d</scp>-Enantiomeric Peptides Designed to Eliminate Cytotoxic AÎ² Species. ACS Chemical Neuroscience, 2016, 7, 1088-1096.	1.7	24
481	Amyloid-Î² containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease. Mendeleev Communications, 2016, 26, 269-275.	0.6	33
482	Application of Free Energy Perturbation for the Design of BACE1 Inhibitors. Journal of Chemical Information and Modeling, 2016, 56, 1856-1871.	2.5	92
483	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer's and Dementia, 2016, 12, 1132-1148.	0.4	75
484	Cerebrospinal fluid neurogranin and <scp>YKL</scp> â€40 as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20.	1.7	137
485	Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. Journal of Neurochemistry, 2016, 136, 222-233.	2.1	53
487	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522.	2.2	15
488	Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability. Biomaterials, 2016, 106, 98-110.	5.7	123
489	Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Molecular Medicine Reports, 2016, 14, 2614-2624.	1.1	39
490	A New Use for an Old Treatment: Radiation Therapy and Alzheimer's Disease. Radiation Research, 2016, 185, 443-448.	0.7	16
491	Cellular model of neuronal atrophy induced by DYNC1I1 deficiency reveals protective roles of RAS-RAF-MEK signaling. Protein and Cell, 2016, 7, 638-650.	4.8	13
493	AZD3293: Pharmacokinetic andÂPharmacodynamic Effects inÂHealthyÂSubjects and Patients withÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1039-1053.	1.2	68
494	Risk factor SORL1: from genetic association to functional validation in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 653-665.	3.9	73

#	Article	IF	Citations
495	Photodynamic micelles for amyloid Î² degradation and aggregation inhibition. Chemical Communications, 2016, 52, 12044-12047.	2.2	25
496	SIRT1 as a therapeutic target for Alzheimerâ€™s disease. Reviews in the Neurosciences, 2016, 27, 813-825.	1.4	41
497	WY14643 Attenuates the Scopolamine-Induced Memory Impairments in Mice. Neurochemical Research, 2016, 41, 2868-2879.	1.6	12
498	Ratiometric Detection of Î²â€Amyloid and Discrimination from Lectins by a Supramolecular AIE Glyconanoparticle. Small, 2016, 12, 6562-6567.	5.2	44
499	Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of Î²-secretase inhibitors. Nature Communications, 2016, 7, 13042.	5.8	66
500	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)â€“A Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 10435-10450.	2.9	126
501	Vitamin k3 inhibits protein aggregation: Implication in the treatment of amyloid diseases. Scientific Reports, 2016, 6, 26759.	1.6	152
502	Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience, 2016, 17, 777-792.	4.9	685
503	From ARB to ARNI in Cardiovascular Control. Current Hypertension Reports, 2016, 18, 86.	1.5	12
504	2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927. Expert Opinion on Therapeutic Patents, 2016, 26, 1371-1376.	2.4	3
505	Mechanism of Nucleation and Growth of AÎ²40 Fibrils from All-Atom and Coarse-Grained Simulations. Journal of Physical Chemistry B, 2016, 120, 12088-12097.	1.2	25
506	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	4.5	84
507	Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke. Journal of Visualized Experiments, 2016, , .	0.2	2
508	AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. Journal of Alzheimer's Disease, 2016, 50, 1109-1123.	1.2	100
509	Characterization of FRM-36143 as a new Î³-secretase modulator for the potential treatment of familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 34.	3.0	15
510	Amyloid-Î² 1â€“24 C-terminal truncated fragment promotes amyloid-Î² 1â€“42 aggregate formation in the healthy brain. Acta Neuropathologica Communications, 2016, 4, 110.	2.4	27
511	Die â€œanderenâ€•Inositole und ihre Phosphate: Synthese, Biologie und Medizin (sowie jÃ¼ngste) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	3
512	Atomic Details of the Interactions of Glycosaminoglycans with Amyloid-Î² Fibrils. Journal of the American Chemical Society, 2016, 138, 8328-8331.	6.6	48

#	Article	IF	Citations
513	Tackling Alzheimerâ€™s Disease by Targeting Oxidative Stress and Mitochondria. , 2016, , 477-502.		1
514	Irreversible destruction of amyloid fibril plaques by conjugated polymer based fluorogenic nanogrenades. Journal of Materials Chemistry B, 2016, 4, 4502-4506.	2.9	11
515	Robust Translation of Â-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 125-137.	1.3	22
516	Microtubule-Tau Interaction as a Therapeutic Target for Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2016, 58, 145-152.	1.1	10
517	Cerebrospinal fluid ratios with AÎ²₄₂ predict preclinical brain Î²â€amyloid accumulation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 27-38.	1.2	44
518	Computational identification and analysis of neurodegenerative disease associated protein kinases in hominid genomes. Genes and Diseases, 2016, 3, 228-237.	1.5	12
519	Alzheimerâ€™s disease due to loss of function: A new synthesis of the available data. Progress in Neurobiology, 2016, 143, 36-60.	2.8	111
520	The â€œOtherâ€•Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in) Tj ETQq1 1 0.784314 rgBT	7.2	141
521	Computational study on donorâ€“acceptor optical markers for Alzheimer's disease: a game of charge transfer and electron delocalization. Physical Chemistry Chemical Physics, 2016, 18, 11634-11643.	1.3	9
522	The lipidome associated with the Î³-secretase complex is required for its integrity and activity. Biochemical Journal, 2016, 473, 321-334.	1.7	12
523	Alzheimerâ€™s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Molecular Neurodegeneration, 2016, 11, 5.	4.4	37
524	Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?. American Journal of Geriatric Psychiatry, 2016, 24, 239-247.	0.6	61
525	Nuclear magnetic resonance evidence for the dimer formation of beta amyloid peptide 1â€“42 in 1,1,1,3,3,3-hexafluoro-2-propanol. Analytical Biochemistry, 2016, 498, 59-67.	1.1	15
526	Intracellular FRET-based Screen for Redesigning the Specificity of Secreted Proteases. ACS Chemical Biology, 2016, 11, 961-970.	1.6	28
527	Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. Progress in Neurobiology, 2016, 144, 121-141.	2.8	238
528	The new Î² amyloid-derived peptide AÎ²1â€“6A2V-TAT(D) prevents AÎ² oligomer formation and protects transgenic C. elegans from AÎ² toxicity. Neurobiology of Disease, 2016, 88, 75-84.	2.1	17
529	EGb761 protects against AÎ²1-42 oligomer-induced cell damage via endoplasmic reticulum stress activation andHsp70 protein expression increase in SH-SY5Y cells. Experimental Gerontology, 2016, 75, 56-63.	1.2	18
530	Study of a Bifunctional AÎ² Aggregation Inhibitor with the Abilities of Antiamyloid-Î² and Copper Chelation. Biomacromolecules, 2016, 17, 661-668.	2.6	37

#	Article	IF	Citations
531	Amino Acid Metaclusters: Implications of Growth Trends on Peptide Self-Assembly and Structure. Analytical Chemistry, 2016, 88, 868-876.	3.2	40
532	P7C3 Attenuates the Scopolamine-Induced Memory Impairments in C57BL/6J Mice. Neurochemical Research, 2016, 41, 1010-1019.	1.6	20
533	Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. Biomaterials, 2016, 80, 33-45.	5.7	142
534	The interaction with gold suppresses fiber-like conformations of the amyloid Î² (16â€“22) peptide. Nanoscale, 2016, 8, 8737-8748.	2.8	55
535	Animal models of source memory. Journal of the Experimental Analysis of Behavior, 2016, 105, 56-67.	0.8	22
536	Gamma Secretase Modulators: New Alzheimerâ€™s Drugs on the Horizon?. Journal of Medicinal Chemistry, 2016, 59, 7389-7409.	2.9	118
537	The Cellular Phase of Alzheimerâ€™s Disease. Cell, 2016, 164, 603-615.	13.5	1,346
538	The cell-permeable AÎ²1-6A2VTAT(D) peptide reverts synaptopathy induced by AÎ²1-42wt. Neurobiology of Disease, 2016, 89, 101-111.	2.1	19
539	Characterization of Recognition Events between Proteins on a Single Molecule Level with Atomic Force Microscopy. Industrial & Engineering Chemistry Research, 2016, 55, 1469-1476.	1.8	6
540	Î²-Amyloid induces nuclear protease-mediated lamin fragmentation independent of caspase activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1189-1199.	1.9	10
541	Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions. Biochemical Journal, 2016, 473, 21-30.	1.7	65
542	The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access. Neurobiology of Disease, 2016, 89, 147-156.	2.1	52
543	Identification of 2-subsituted benzothiazole derivatives as triple-functional agents with potential for AD therapy. RSC Advances, 2016, 6, 17318-17327.	1.7	14
544	Amyloid-Î²-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimerâ€™s Disease. Analytical Chemistry, 2016, 88, 2755-2762.	3.2	97
545	Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-Î² Deposition in the Brain. Molecular Imaging and Biology, 2016, 18, 598-605.	1.3	23
546	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	6.3	2,430
547	Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimerâ€™s disease via SIRT1/NF-ÎºB pathway. Metabolic Brain Disease, 2016, 31, 771-778.	1.4	107
548	From a Microscopic to a Macroscopic Model for Alzheimer Disease: Two-Scale Homogenization of the Smoluchowski Equation in Perforated Domains. Journal of Nonlinear Science, 2016, 26, 717-753.	1.0	19

#	Article	IF	Citations
549	Opposing Effects of Cucurbit[7]uril and 1,2,3,4,6-Penta-O-galloyl-Î²-<scp>d</scp>-glucopyranose on Amyloid Î²_{25â€“35} Assembly. ACS Chemical Neuroscience, 2016, 7, 218-226.	1.7	27
550	Withanolide A offers neuroprotection, ameliorates stress resistance and prolongs the life expectancy of Caenorhabditis elegans. Experimental Gerontology, 2016, 78, 47-56.	1.2	57
551	Structure-Based Design of an Iminoheterocyclic Î²-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. Journal of Medicinal Chemistry, 2016, 59, 3231-3248.	2.9	36
552	Melanopsin retinal ganglion cell loss and circadian dysfunction in Alzheimer's disease (Review). Molecular Medicine Reports, 2016, 13, 3397-3400.	1.1	28
553	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
554	The Lipoxygenases: Their Regulation and Implication in Alzheimerâ€™s Disease. Neurochemical Research, 2016, 41, 243-257.	1.6	90
555	Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimerâ€™s. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 747-750.	1.0	28
556	Alzheimer's disease: The amyloid hypothesis on trial. British Journal of Psychiatry, 2016, 208, 1-3.	1.7	112
557	Sex Dimorphism Profile of Alzheimerâ€™s Disease-Type Pathologies in an APP/PS1 Mouse Model. Neurotoxicity Research, 2016, 29, 256-266.	1.3	89
558	Beneficial Effect of Astragaloside on Alzheimerâ€™s Disease Condition Using Cultured Primary Cortical Cells Under Î²-amyloid Exposure. Molecular Neurobiology, 2016, 53, 7329-7340.	1.9	34
559	Î²â€Amyloid pathogenesis: Chemical properties versus cellular levels. Alzheimer's and Dementia, 2016, 12, 184-194.	0.4	28
560	Tau imaging in neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1139-1150.	3.3	104
561	Network Approaches to the Understanding of Alzheimerâ€™s Disease: From Model Organisms to Humans. Methods in Molecular Biology, 2016, 1303, 447-458.	0.4	3
562	Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 442-451.	1.8	238
563	Why therapies for Alzheimerâ€™s disease do not work: Do we have consensus over the path to follow?. Ageing Research Reviews, 2016, 25, 70-84.	5.0	23
564	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Biosystems and Biorobotics, 2016, , 293-325.	0.2	2
565	Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimerâ€™s disease. Biogerontology, 2016, 17, 281-296.	2.0	149
566	Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimerâ€™s disease using multiple e-pharmacophore modeling and molecular dynamics. Journal of Biomolecular Structure and Dynamics, 2017, 35, 883-896.	2.0	5

#	Article	IF	Citations
567	Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery. Molecular Neurobiology, 2017, 54, 1046-1077.	1.9	241
568	Associations Between Hepatic Functions and Plasma Amyloid-Beta Levelsâ€"Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance. Molecular Neurobiology, 2017, 54, 2338-2344.	1.9	76
569	Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Progress in Neurobiology, 2017, 157, 273-291.	2.8	52
570	Assessment of GAPDH expression by quantitative real time PCR in blood of Moroccan AD cases. Journal of Clinical Neuroscience, 2017, 40, 24-26.	0.8	2
571	Interaction of Vascular Damage and Alzheimer Dementia: Focal Damage and Disconnection. Radiology, 2017, 282, 311-313.	3.6	10
572	Ketogenic diets and Alzheimerâ€™s disease. Food Science and Human Wellness, 2017, 6, 1-9.	2.2	39
575	Cyclodextrin Nanoparticles Bearing 8â€Hydroxyquinoline Ligands as Multifunctional Biomaterials. Chemistry - A European Journal, 2017, 23, 4442-4449.	1.7	23
576	Targeting Î²-amyloid plaques and oligomers: development of near-IR fluorescence imaging probes. Future Medicinal Chemistry, 2017, 9, 179-198.	1.1	23
577	Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. Medicinal Research Reviews, 2017, 37, 1186-1225.	5.0	248
578	Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening. RSC Advances, 2017, 7, 3429-3438.	1.7	55
579	Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. Advances in Biological Regulation, 2017, 64, 33-38.	1.4	30
580	Protein aggregation, misfolding and consequential human neurodegenerative diseases. International Journal of Neuroscience, 2017, 127, 1047-1057.	0.8	44
581	Protective effects of linalool against amyloid beta-induced cognitive deficits and damages in mice. Life Sciences, 2017, 174, 21-27.	2.0	59
582	BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats. Scientific Reports, 2017, 7, 44249.	1.6	12
583	Lack of association between MTHFR A1298C variant and Alzheimerâ€™s disease: evidence from a systematic review and cumulative meta-analysis. Neurological Research, 2017, 39, 426-434.	0.6	9
584	Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases. Journal of Alzheimer's Disease, 2017, 57, 395-409.	1.2	33
585	Insights into the Inhibitory Mechanism of Dicyanovinylâ€Substituted J147 Derivative against Aβ₄₂ Aggregation and Protofibril Destabilization: A Molecular Dynamics Simulation Study. ChemistrySelect, 2017, 2, 1645-1657.	0.7	25
586	Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction. Journal of Molecular Modeling, 2017, 23, 67.	0.8	24

#	Article	IF	Citations
587	Suspected non-Alzheimer's pathology â€“ Is it non-Alzheimer's or non-amyloid?. Ageing Research Reviews, 2017, 36, 20-31.	5.0	34
588	Physical principles of filamentous protein self-assembly kinetics. Journal of Physics Condensed Matter, 2017, 29, 153002.	0.7	21
589	TREM2, Microglia, and Neurodegenerative Diseases. Trends in Molecular Medicine, 2017, 23, 512-533.	3.5	327
590	Multitarget trehalose-carnosine conjugates inhibit AÎ² aggregation, tune copper(II) activity and decrease acrolein toxicity. European Journal of Medicinal Chemistry, 2017, 135, 447-457.	2.6	32
591	Fragment Binding to Î²-Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches. ACS Omega, 2017, 2, 685-697.	1.6	14
592	Multiscale simulations for understanding the evolution and mechanism of hierarchical peptide self-assembly. Physical Chemistry Chemical Physics, 2017, 19, 23614-23631.	1.3	48
593	Autophagy Activation Alleviates Amyloid-Î²-Induced Oxidative Stress, Apoptosis and Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells. Neurotoxicity Research, 2017, 32, 351-361.	1.3	44
594	A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. Scientific Reports, 2017, 7, 45592.	1.6	44
595	Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice. Neuroscience, 2017, 355, 200-211.	1.1	24
596	N -glycan and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2447-2454.	1.1	94
597	The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. Journal of Neuroscience Research, 2017, 95, 2217-2235.	1.3	149
598	Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. Nanoscale, 2017, 9, 10619-10632.	2.8	86
599	Development of 2-aminooxazoline 3-azaxanthene Î²-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D. MedChemComm, 2017, 8, 1196-1206.	3.5	16
600	BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid AÎ² Peptides. Journal of Clinical Pharmacology, 2017, 57, 1460-1471.	1.0	44
601	Immune and myodegenerative pathomechanisms in inclusion body myositis. Annals of Clinical and Translational Neurology, 2017, 4, 422-445.	1.7	41
602	Modulating 5-HT₄ and 5-HT₆ receptors in Alzheimerâ€™s disease treatment. Future Medicinal Chemistry, 2017, 9, 781-795.	1.1	46
603	Alzheimerâ€™s disease: How metal ions define Î²-amyloid function. Coordination Chemistry Reviews, 2017, 351, 127-159.	9.5	120
604	Alzheimerâ€™s Disease and ncRNAs. Advances in Experimental Medicine and Biology, 2017, 978, 337-361.	0.8	64

#	Article	IF	Citations
605	Intestinal microbial dysbiosis aggravates the progression of Alzheimerâ€™s disease in Drosophila. Nature Communications, 2017, 8, 24.	5.8	181
606	Î³-Secretase Modulators as AÎ²42-Lowering Pharmacological Agents to Treat Alzheimerâ€™s Disease. Topics in Medicinal Chemistry, 2017, , 87-118.	0.4	6
607	Potential anti-cholinesterase and Î²-site amyloid precursor protein cleaving enzyme 1 inhibitory activities of cornuside and gallotannins from Cornus officinalis fruits. Archives of Pharmacal Research, 2017, 40, 836-853.	2.7	32
608	Insights on the Interaction between Transthyretin and AÎ² in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal. Journal of Medicinal Chemistry, 2017, 60, 5749-5758.	2.9	24
609	Alzheimerâ€™s disease: where next for anti-amyloid therapies?. Brain, 2017, 140, 853-855.	3.7	57
610	Solid-State-NMR-Structure-Based Inhibitor Design to Achieve Selective Inhibition of the Parallel-in-Register Î²-Sheet versus Antiparallel Iowa Mutant Î²-Amyloid Fibrils. Journal of Physical Chemistry B, 2017, 121, 5544-5552.	1.2	6
611	Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists. Tetrahedron Letters, 2017, 58, 2629-2635.	0.7	18
612	Supercritical angle fluorescence as a tool to study the interaction between lipid bilayer and peptides. Proceedings of SPIE, 2017, , .	0.8	0
613	The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-Î² concentrations and clearance in the cynomolgus monkey. Toxicology and Applied Pharmacology, 2017, 323, 53-65.	1.3	29
614	Novel 2-Arylbenzimidazole derivatives as multi-targeting agents to treat Alzheimerâ€™s disease. Medicinal Chemistry Research, 2017, 26, 1506-1515.	1.1	9
615	Protective Roles of Monsonia angustifolia and Its Active Compounds in Experimental Models of Alzheimerâ€™s Disease. Journal of Agricultural and Food Chemistry, 2017, 65, 3133-3140.	2.4	13
616	Association between tau deposition and antecedent amyloid-Î² accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	3.7	93
617	Biochemically-defined pools of amyloid-Î² in sporadic Alzheimerâ€™s disease: correlation with amyloid PET. Brain, 2017, 140, 1486-1498.	3.7	123
618	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimer's and Dementia, 2017, 13, 1117-1124.	0.4	31
619	ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3129-E3138.	3.3	57
620	The circular <scp>RNA</scp> ci<scp>RS</scp>â€7 promotes <scp>APP</scp> and <scp>BACE</scp>1 degradation in an <scp>NF</scp>â€ÎºBâ€dependent manner. FEBS Journal, 2017, 284, 1096-1109.	2.2	120
621	Mouse Models of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 1171-1183.	1.2	201
622	A disease with a sweet tooth: exploring the Warburg effect in Alzheimerâ€™s disease. Biogerontology, 2017, 18, 301-319.	2.0	56

#	Article	IF	Citations
623	Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimerâ€™s disease: An integrative review. Progress in Neurobiology, 2017, 156, 1-68.	2.8	112
624	Systematic development of small molecules to inhibit specific microscopic steps of AÎ²42 aggregation in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	3.3	180
625	Safety and Efficacy of Anti-Amyloid-Î² Immunotherapy in Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of NeuroImmune Pharmacology, 2017, 12, 194-203.	2.1	53
626	Generation of Amyloidâ€Î² Peptides by Î³â€Secretase. Israel Journal of Chemistry, 2017, 57, 574-585.	1.0	1
627	Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023705.	2.3	51
628	Tau Positron Emission Tomography Imaging. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023721.	2.3	24
629	Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-Î² (AÎ²) Aggregation: Potential Therapeutics of Alzheimerâ€™s Disease. ACS Combinatorial Science, 2017, 19, 55-80.	3.8	168
630	Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimerâ€™s Disease Neuroimaging Initiative (J-ADNI) multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 850-857.	3.3	90
631	Cyanidin-3-O-glucoside attenuates amyloid-beta (1â€“40)-induced oxidative stress and apoptosis in SH-SY5Y cells through a Nrf2 mechanism. Journal of Functional Foods, 2017, 38, 474-485.	1.6	24
632	Alzheimerâ€™s disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71.	3.0	424
633	Biophysical Aspects of Alzheimerâ€™s Disease: Implications for Pharmaceutical Sciences. Pharmaceutical Research, 2017, 34, 2628-2636.	1.7	1
634	Flavonoids and their derivatives with Î²-amyloid aggregation inhibitory activity from the leaves and twigs of Pithecellobium clypearia Benth. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4823-4827.	1.0	13
635	Inhibiting Aggregation of Î²-Amyloid by Folded and Unfolded Forms of Fimbrial Protein of Gram-Negative Bacteria. ChemistrySelect, 2017, 2, 9058-9062.	0.7	0
636	Current evidence on the effect of dietary polyphenols intake on chronic diseases. Food and Chemical Toxicology, 2017, 110, 286-299.	1.8	200
637	Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. Current Psychiatry Reports, 2017, 19, 89.	2.1	22
638	Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension. European Heart Journal, 2017, 38, 3318-3320.	1.0	11
639	Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimerâ€™s Disease: Synthesis, Pharmacology, and Molecular Modeling Studies. ACS Chemical Neuroscience, 2017, 8, 2667-2675.	1.7	26
640	Molecular insights into AÎ²₄₂ protofibril destabilization with a fluorinated compound D744: A molecular dynamics simulation study. Journal of Molecular Recognition, 2017, 30, e2656.	1.1	24

#	Article	IF	Citations
641	Not All Î²-Sheets Are the Same: Amyloid Infrared Spectra, Transition Dipole Strengths, and Couplings Investigated by 2D IR Spectroscopy. Journal of Physical Chemistry B, 2017, 121, 8935-8945.	1.2	60
642	Effect of the herbal formulation Shen-Zhi-Ling on an APP/PS1 mouse model of Alzheimer's disease by modulating the biliverdin reductase/heme oxygenase 1 system. Experimental and Therapeutic Medicine, 2017, 14, 1961-1966.	0.8	9
643	New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation. European Journal of Medicinal Chemistry, 2017, 141, 197-210.	2.6	32
644	Dual/multitargeted xanthone derivatives for Alzheimer's disease: where do we stand?. Future Medicinal Chemistry, 2017, 9, 1611-1630.	1.1	25
645	Enjeux de professionnalisation et de formation des conceptions des troubles mentaux et psychosociaux dans la littÃ©rature spÃ©cialisÃ©e destinÃ©e aux travailleurs sociauxÂ: le cas de la maladie dâ€™Alzheimer. Phronesis, 0, 6, 64-81.	0.1	1
646	Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 676-685.	1.3	11
647	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimerâ€™s disease. Journal of Neural Transmission, 2017, 124, 1621-1625.	1.4	27
648	Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers. Clinical Drug Investigation, 2017, 37, 1025-1034.	1.1	28
649	Carbon Nanodotâ€Sensitized Modulation of Alzheimer's Î²â€Amyloid Selfâ€Assembly, Disassembly, and Toxicity. Small, 2017, 13, 1700983.	5.2	66
650	Design, synthesis, in vitro and in vivo evaluation of tacrineâ€“cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease. RSC Advances, 2017, 7, 33851-33867.	1.7	35
651	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 139, 378-389.	2.6	21
652	Synergistic inhibition of AÎ² production by combinations of Î³-secretase modulators. European Journal of Pharmacology, 2017, 812, 104-112.	1.7	3
653	Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease. European Journal of Neurology, 2017, 24, 1173-1182.	1.7	47
654	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 7434.	1.6	20
655	Melatonin as a mitochondrial protector in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2017, 74, 3999-4014.	2.4	57
656	Microscopic and macroscopic models for the onset and progression of Alzheimer's disease. Journal of Physics A: Mathematical and Theoretical, 2017, 50, 414003.	0.7	13
657	NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?. Free Radical Biology and Medicine, 2017, 112, 387-396.	1.3	88
658	Nutritional Strategies in the Management of Alzheimer Disease: Systematic Review With Network Meta-Analysis. Journal of the American Medical Directors Association, 2017, 18, 897.e13-897.e30.	1.2	23

#	Article	IF	Citations
659	Proposed biochemistry of Parkinsonâ€™s and Alzheimerâ€™s diseases. Medical Hypotheses, 2017, 109, 131-138.	0.8	11
660	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound AÎ² oligomers. Molecular Biology of the Cell, 2017, 28, 2623-2636.	0.9	88
661	Atomic-resolution map of the interactions between an amyloid inhibitor protein and amyloid Î² (AÎ²) peptides in the monomer and protofibril states. Journal of Biological Chemistry, 2017, 292, 17158-17168.	1.6	48
662	Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to Î² sheet in tau protein linked to Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 945-953.	2.5	63
663	Four Decades of Research in Alzheimerâ€™s Disease (1975â€“2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	1.2	33
664	Dissociation of haemolytic and oligomer-preventing activities of gramicidin S derivatives targeting the amyloid-Î² N-terminus. Chemical Communications, 2017, 53, 13340-13343.	2.2	7
665	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	3.3	170
666	Spiropiperidine Sultam and Lactam Templates: Diastereoselective Overman Rearrangement and Metathesis followed by NH Arylation. Journal of Organic Chemistry, 2017, 82, 12246-12256.	1.7	10
667	Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles. American Journal of Pathology, 2017, 187, 1828-1847.	1.9	16
668	Stabilizing amyloid-Î² peptide by the N-terminus capture is capable of preventing and eliminating amyloid-Î² oligomers. Chemical Communications, 2017, 53, 7673-7676.	2.2	10
669	Animal Models of Alzheimerâ€™s Disease. , 2017, , 1031-1085.		9
670	Alzheimerâ€™s disease: as it was in the beginning. Reviews in the Neurosciences, 2017, 28, 825-843.	1.4	62
671	Advances in Alzheimerâ€™s Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology, 2017, 35, 937-953.	4.9	121
672	Iminodiacetic acid-conjugated nanoparticles as a bifunctional modulator against Zn2+-mediated amyloid Î²-protein aggregation and cytotoxicity. Journal of Colloid and Interface Science, 2017, 505, 973-982.	5.0	33
673	A vaccine with AÎ² oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 41.	3.0	9
674	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2017, 58, 747-762.	1.2	9
675	Kinetic Analysis Reveals the Identity of AÎ²-Metal Complex Responsible for the Initial Aggregation of AÎ² in the Synapse. ACS Chemical Neuroscience, 2017, 8, 1970-1979.	1.7	22
676	Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione Î³-secretase modulators with robust central efficacy. MedChemComm, 2017, 8, 730-743.	3.5	16

#	Article	IF	Citations
677	Synthesis and Biological Evaluation of Novel Multi-target-Directed Benzazepines Against Excitotoxicity. Molecular Neurobiology, 2017, 54, 6697-6722.	1.9	3
678	Visual system manifestations of Alzheimer's disease. Acta Ophthalmologica, 2017, 95, e668-e676.	0.6	48
679	AÎ²-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	2.5	96
680	Vibration-Induced-Emission (VIE) for imaging amyloid Î² fibrils. Faraday Discussions, 2017, 196, 395-402.	1.6	26
681	D-A-D fluorogenic probe for the rapid imaging of amyloid Î² plaques inÂvivo. Dyes and Pigments, 2017, 136, 224-228.	2.0	19
682	Guanosine Prevents Anhedonic-Like Behavior and Impairment in Hippocampal Glutamate Transport Following Amyloid-Î²1â€“40 Administration in Mice. Molecular Neurobiology, 2017, 54, 5482-5496.	1.9	39
683	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
684	1,2,3,4,6-penta-O-galloyl-Î²-d-glucopyranose binds to the N-terminal metal binding region to inhibit amyloid Î²-protein oligomer and fibril formation. International Journal of Mass Spectrometry, 2017, 420, 24-34.	0.7	24
685	Epigallocatechin Gallate Attenuates Î²-Amyloid Generation and Oxidative Stress Involvement of PPARÎ³ in N2a/APP695 Cells. Neurochemical Research, 2017, 42, 468-480.	1.6	50
686	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-Î²42 in Alzheimerâ€™s disease. Brain, 2017, 140, 3301-3316.	3.7	14
687	Î²-Amyloid and the Pathomechanisms of Alzheimerâ€™s Disease: A Comprehensive View. Molecules, 2017, 22, 1692.	1.7	82
689	Acteoside and Isoacteoside Protect Amyloid Î² Peptide Induced Cytotoxicity, Cognitive Deficit and Neurochemical Disturbances In Vitro and In Vivo. International Journal of Molecular Sciences, 2017, 18, 895.	1.8	40
690	Wnt/TLR Dialog in Neuroinflammation, Relevance in Alzheimerâ€™s Disease. Frontiers in Immunology, 2017, 8, 187.	2.2	39
691	A Novel Genetic Screen Identifies Modifiers of Age-Dependent Amyloid Î² Toxicity in the Drosophila Brain. Frontiers in Aging Neuroscience, 2017, 9, 61.	1.7	12
692	Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. Frontiers in Aging Neuroscience, 2017, 9, 356.	1.7	49
693	Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2017, 10, 276.	1.4	87
694	Modifications and Trafficking of APP in the Pathogenesis of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2017, 10, 294.	1.4	120
695	Biomarkers for Alzheimerâ€™s Disease. , 2017, , 247-277.		0

#	Article	IF	Citations
696	Seeking a New Paradigm for Alzheimerâ€™s Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease. International Journal of Alzheimer's Disease, 2017, 2017, 1-6.	1.1	4
697	Novel derivative of Paeonol, Paeononlsilatie sodium, alleviates behavioral damage and hippocampal dendritic injury in Alzheimer's disease concurrent with cofilin1/phosphorylated-cofilin1 and RAC1/CDC42 alterations in rats. PLoS ONE, 2017, 12, e0185102.	1.1	21
698	CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimerâ€™s disease. PLoS ONE, 2017, 12, e0185541.	1.1	56
699	Neurochemical Aspects of Î²-Amyloid Cascade Hypothesis for Alzheimerâ€™s Disease. , 2017, , 1-46.		0
700	Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 82.	4.4	100
701	Young to Middle-Aged Dogs with High Amyloid-Î² Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests. Journal of Alzheimer's Disease, 2017, 56, 763-774.	1.2	23
702	Aging and Alzheimer's Disease. , 2017, , 311-340.		0
703	Editorial: Multi-target Drug Discovery - Part I. Current Topics in Medicinal Chemistry, 2017, 17, 2997-2999.	1.0	0
704	From Imaging Agents to Theranostic Drugs in Alzheimerâ€™s Disease. , 2017, , 74-106.		1
705	HERBAL MEDICINES AS NEUROPROTECTIVE AGENT: A MECHANISTIC APPROACH. International Journal of Pharmacy and Pharmaceutical Sciences, 2017, 9, 1.	0.3	72
706	Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1. Neurodegenerative Diseases, 2018, 18, 57-68.	0.8	5
708	Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. Neurobiology of Disease, 2018, 114, 1-16.	2.1	34
709	Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. Journal of Alzheimer's Disease, 2018, 62, 399-408.	1.2	11
710	An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study. Computational and Structural Biotechnology Journal, 2018, 16, 77-87.	1.9	56
711	Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease. Future Medicinal Chemistry, 2018, 10, 1037-1053.	1.1	10
712	Computational insights into Î²-site amyloid precursor protein enzyme 1 (BACE1) inhibition by tanshinones and salvianolic acids from Salvia miltiorrhiza via molecular docking simulations. Computational Biology and Chemistry, 2018, 74, 273-285.	1.1	14
713	Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications. Biochemical and Biophysical Research Communications, 2018, 504, 602-607.	1.0	9
714	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	1.2	67

#	Article	IF	Citations
715	1,2,4â€trihydroxynaphthaleneâ€2â€Oâ€Î²â€Dâ€glucopyranoside delays amyloidâ€Î²₄₂ aggregation and reduces amyloid cytotoxicity. BioFactors, 2018, 44, 272-280.	2.6	2
716	AÎ²-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-AÎ² single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neurosciences, 2018, 89, 49-59.	1.0	21
717	Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study. Scientific Reports, 2018, 8, 5557.	1.6	26
718	Sulforaphane Inhibits the Generation of Amyloid-Î² Oligomer and Promotes Spatial Learning and Memory in Alzheimerâ€™s Disease (PS1V97L) Transgenic Mice. Journal of Alzheimer's Disease, 2018, 62, 1803-1813.	1.2	48
719	Bifunctionality of Iminodiacetic Acid-Modified Lysozyme on Inhibiting Zn²⁺-Mediated Amyloid Î²-Protein Aggregation. Langmuir, 2018, 34, 5106-5115.	1.6	17
720	Effect of Fluvoxamine on Amyloid-Î² Peptide Generation and Memory. Journal of Alzheimer's Disease, 2018, 62, 1777-1787.	1.2	12
721	Controlled delivery of rivastigmine using transdermal patch for effective management of alzheimer's disease. Journal of Drug Delivery Science and Technology, 2018, 45, 408-414.	1.4	21
722	Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport. Neurobiology of Aging, 2018, 68, 68-75.	1.5	17
723	Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.3	40
724	Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau. Journal of Alzheimer's Disease, 2018, 61, 1201-1219.	1.2	4
725	Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine Î²-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1111-1115.	1.0	18
726	Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metabolism Reviews, 2018, 50, 74-93.	1.5	39
727	Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks AÎ²â€“Fibrinogen Interaction and AÎ²-Induced Contact System Activation. Biochemistry, 2018, 57, 1399-1409.	1.2	12
728	Amyloid Î²-targeted metal complexes for potential applications in Alzheimer's disease. Future Medicinal Chemistry, 2018, 10, 679-701.	1.1	45
729	Imaging tau and amyloid-Î² proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236.	4.9	321
730	How the formation of amyloid plaques and neurofibrillary tangles may be related: a mathematical modelling study. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2018, 474, 20170777.	1.0	18
731	Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms. Journal of Visualized Experiments, 2018, , .	0.2	1
732	Hypothesis: apoâ€lactoferrinâ€“Galantamine Proteoâ€alkaloid Conjugate for Alzheimer's disease Intervention. Journal of Cellular and Molecular Medicine, 2018, 22, 1957-1963.	1.6	6

#	Article	IF	Citations
733	Core Binding Site of a Thioflavin-T-Derived Imaging Probe on Amyloid Î² Fibrils Predicted by Computational Methods. ACS Chemical Neuroscience, 2018, 9, 957-966.	1.7	14
734	Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells. Molecular Neurobiology, 2018, 55, 7107-7117.	1.9	56
735	DNA methylation level of the neprilysin promoter in Alzheimer's disease brains. Neuroscience Letters, 2018, 670, 8-13.	1.0	10
736	Cromolyn Reduces Levels of the Alzheimerâ€™s Disease-Associated Amyloid Î²-Protein by Promoting Microglial Phagocytosis. Scientific Reports, 2018, 8, 1144.	1.6	68
737	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 351-355.	1.0	10
738	Beneficial effects of white wine polyphenols-enriched diet on Alzheimerâ€™s disease-like pathology. Journal of Nutritional Biochemistry, 2018, 55, 165-177.	1.9	36
739	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. Journal of Neural Transmission, 2018, 125, 673-679.	1.4	31
740	Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimerâ€™s disease. Nuclear Medicine Communications, 2018, 39, 186-192.	0.5	6
741	Synchrotron-Based Fourier Transform Infrared Microspectroscopy (Î¼FTIR) Study on the Effect of Alzheimerâ€™s AÎ² Amorphous and Fibrillar Aggregates on PC12 Cells. Analytical Chemistry, 2018, 90, 2772-2779.	3.2	18
742	Ameliorating effect of Alpinia oxyphyllaâ€"Schisandra chinensis herb pair on cognitive impairment in a mouse model of Alzheimerâ€™s disease. Biomedicine and Pharmacotherapy, 2018, 97, 128-135.	2.5	24
743	Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 290-302.	2.5	31
744	Long-term RF exposure on behavior and cerebral glucose metabolism in 5xFAD mice. Neuroscience Letters, 2018, 666, 64-69.	1.0	38
745	Inhibition of Î²-Amyloid Aggregation through a Designed Î²-Hairpin Peptide. Langmuir, 2018, 34, 1591-1600.	1.6	38
746	Long-term treadmill exercise attenuates AÎ² burdens and astrocyte activation in APP/PS1 mouse model of Alzheimerâ€™s disease. Neuroscience Letters, 2018, 666, 70-77.	1.0	74
747	Nanoparticle. Series in Bioengineering, 2018, , 1-36.	0.3	3
748	Loss of kallikreinâ€related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Molecular Medicine, 2018, 10, .	3.3	39
749	Regucalcin confers resistance to amyloidâ€Î²2 toxicity in neuronally differentiated <scp>PC</scp>12 cells. FEBS Open Bio, 2018, 8, 349-360.	1.0	4
750	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering, 2018, 19, 59-67.	3.8	8

#	Article	IF	Citations
751	Alzheimerâ€™s Disease: From Firing Instability to Homeostasis Network Collapse. Neuron, 2018, 97, 32-58.	3.8	188
752	ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression-and anxiety-related symptoms in a rat model of Alzheimer's disease. Brain Research Bulletin, 2018, 137, 265-276.	1.4	58
753	Thermoregulatory profile of neurodegenerationâ€induced dementia of the Alzheimer's type using intracerebroventricular streptozotocin in rats. Acta Physiologica, 2018, 224, e13084.	1.8	8
754	Well-Posedness of a Mathematical Model for Alzheimer's Disease. SIAM Journal on Mathematical Analysis, 2018, 50, 2362-2388.	0.9	9
755	Surface Enhanced Raman Spectroscopy for Medical Diagnostics. , 2018, , 1-66.		6
756	The short-term improvements of enriched environment in behaviors and pathological changes of APP/PS1 mice via regulating cytokines. Human Vaccines and Immunotherapeutics, 2018, 14, 2003-2011.	1.4	8
757	TRPC1 Null Exacerbates Memory Deficit and Apoptosis Induced by Amyloid-Î². Journal of Alzheimer's Disease, 2018, 63, 761-772.	1.2	12
758	NBD-BPEA regulates Zn2+- or Cu2+-induced AÎ²40 aggregation and cytotoxicity. Food and Chemical Toxicology, 2018, 119, 260-267.	1.8	4
759	The on-fibrillation-pathway membrane content leakage and off-fibrillation-pathway lipid mixing induced by 40-residue Î²-amyloid peptides in biologically relevant model liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1670-1680.	1.4	15
760	VDAC1, mitochondrial dysfunction, and Alzheimer's disease. Pharmacological Research, 2018, 131, 87-101.	3.1	153
761	Role of Mitochondria in Neurodegenerative Diseases: The Dark Side of the â€œEnergy Factoryâ€• , 2018, , 213-239.		6
762	Hybrid Multifunctional Modulators Inhibit Multifaceted AÎ² Toxicity and Prevent Mitochondrial Damage. ACS Chemical Neuroscience, 2018, 9, 1432-1440.	1.7	53
763	Extending a Systems Model of the APP Pathway: Separation of Î²- and Î³-Secretase Sequential Cleavage Steps of APP. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 507-518.	1.3	10
764	Metal-involved theranostics: An emerging strategy for fighting Alzheimerâ€™s disease. Coordination Chemistry Reviews, 2018, 362, 72-84.	9.5	53
765	An acute functional screen identifies an effective antibody targeting amyloid-Î² oligomers based on calcium imaging. Scientific Reports, 2018, 8, 4634.	1.6	15
766	Trace amounts of pyroglutaminated AÎ²-(3â€“42) enhance aggregation of AÎ²-(1â€“42) on neuronal membranes at physiological concentrations: FCS analysis of cell surface. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1603-1608.	1.4	5
767	PatologÃa vascular: Â¿causa o efecto en la enfermedad de Alzheimer?. NeurologÃa, 2018, 33, 112-120.	0.3	49
768	Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. Medicinal Research Reviews, 2018, 38, 261-324.	5.0	55

#	Article	IF	Citations
769	The role of regulatory T cells in nervous system pathologies. Journal of Neuroscience Research, 2018, 96, 951-968.	1.3	64
770	Vascular pathology: Cause or effect in Alzheimer disease?. NeurologÃa (English Edition), 2018, 33, 112-120.	0.2	30
771	Evaluation of optical coherence tomography angiographic findings in Alzheimerâ€™s type dementia. British Journal of Ophthalmology, 2018, 102, 233-237.	2.1	204
772	Innate immunity in Alzheimerâ€™s disease: the relevance of animal models?. Journal of Neural Transmission, 2018, 125, 827-846.	1.4	16
773	Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. Cell Calcium, 2018, 70, 87-94.	1.1	248
774	Dementia risk and prevention by targeting modifiable vascular risk factors. Journal of Neurochemistry, 2018, 144, 565-581.	2.1	82
775	Biomarkers for Alzheimer Disease: Classical and Novel Candidatesâ€™ Review. Neuroscience, 2018, 370, 181-190.	1.1	74
776	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery, 2018, 17, 19-33.	21.5	106
777	Oxidative stress and the amyloid beta peptide in Alzheimerâ€™s disease. Redox Biology, 2018, 14, 450-464.	3.9	1,411
778	Computer-Aided Drug Design Approaches to Study Key Therapeutic Targets in Alzheimerâ€™s Disease. Neuromethods, 2018, , 61-106.	0.2	2
779	Cu^{II} Binding to Various Forms of Amyloidâ€Î² Peptides: Are They Friends or Foes?. European Journal of Inorganic Chemistry, 2018, 2018, 7-15.	1.0	33
780	Obstructive sleep apnoea and Alzheimerâ€™s disease: In search of shared pathomechanisms. Neuroscience and Biobehavioral Reviews, 2018, 86, 142-149.	2.9	78
781	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 609-618.	1.7	109
782	Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Progress in Neurobiology, 2018, 162, 17-36.	2.8	34
783	NABi, a novel Î²-sheet breaker, inhibits AÎ² aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 71-80.	1.1	3
784	Neurogenesis and morphological-neural alterations closely related to amyloid Î²-peptide (25â€“35)-induced memory impairment in male rats. Neuropeptides, 2018, 67, 9-19.	0.9	20
785	Modulation of Î³- and Î²-Secretases as Early Prevention Against Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 320-327.	0.7	54
786	Simulating the effect of formation of amyloid plaques on aggregation of tau protein. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2018, 474, 20180511.	1.0	18

#	Article	IF	Citations
787	Copper reduction and dioxygen activation in Cuâ€“amyloid beta peptide complexes: insight from molecular modelling. Metallomics, 2018, 10, 1618-1630.	1.0	31
788	Basified Human Lysozyme: A Potent Inhibitor against Amyloid Î²-Protein Fibrillogenesis. Langmuir, 2018, 34, 15569-15577.	1.6	14
789	Anthocyanins Extracted from Aronia melanocarpa Protect SH-SY5Y Cells against Amyloid-beta (1â€“42)-Induced Apoptosis by Regulating Ca²⁺ Homeostasis and Inhibiting Mitochondrial Dysfunction. Journal of Agricultural and Food Chemistry, 2018, 66, 12967-12977.	2.4	33
790	Label-free imaging of amyloid plaques in Alzheimerâ€™s disease with stimulated Raman scattering microscopy. Science Advances, 2018, 4, eaat7715.	4.7	122
791	Hypothermia as a risk factor for Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 157, 727-735.	1.0	3
792	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimerâ€™s Disease (AD) Pathology Than in Severe AD Pathology. Metabolites, 2018, 8, 69.	1.3	17
793	The Correlation Analysis Between DTI Network Parameters and AVLT Scale Scores of Alzheimerâ€™s Disease. , 2018, 2018, 1132-1135.		1
794	Pathological Increases in Neuronal Hyperactivity in Selective Cholinergic and Noradrenergic Pathways May Limit the Efficacy of Amyloid-Î²-Based Interventions in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2018, 2, 165-167.	1.2	3
795	Culling Less Fit Neurons Protects against Amyloid-Î²-Induced Brain Damage and Cognitive and Motor Decline. Cell Reports, 2018, 25, 3661-3673.e3.	2.9	38
796	Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism. BioMed Research International, 2018, 2018, 1-8.	0.9	78
797	<scp>l</scp>-Dopa and dopamine conjugated naphthalenediimides modulate amyloid Î² toxicity. Organic and Biomolecular Chemistry, 2018, 16, 7682-7692.	1.5	20
798	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâ€™s disease (BLAZE). Alzheimer's Research and Therapy, 2018, 10, 96.	3.0	109
799	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
800	Neuromodulatory Effects of Guanine-Based Purines in Health and Disease. Frontiers in Cellular Neuroscience, 2018, 12, 376.	1.8	49
801	A Novel Peroxidase Mimics and Ameliorates Alzheimerâ€™s Disease-Related Pathology and Cognitive Decline in Mice. International Journal of Molecular Sciences, 2018, 19, 3304.	1.8	11
802	The effects of fluorescent labels on AÎ²₄₂ aggregation detected by fluorescence correlation spectroscopy. Biopolymers, 2018, 109, e23237.	1.2	9
803	Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. Free Radical Biology and Medicine, 2018, 129, 430-439.	1.3	20
804	Alzheimer Disease: Perspectives from Epidemiology and Genetics. Journal of Law, Medicine and Ethics, 2018, 46, 694-698.	0.4	33

#	Article	IF	Citations
805	Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2018, 22, 849-867.	1.5	11
806	Anti-amyloid Therapy of Alzheimerâ€™s Disease: Current State and Prospects. Biochemistry (Moscow), 2018, 83, 1057-1067.	0.7	29
807	cPLA2 and desaturases underlie the tau hyperphosphorylation offset induced by BACE knock-down in neuronal primary cultures. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3696-3707.	1.8	4
808	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2018, , 1-26.		0
809	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
810	Atomic Force Microscopy Analysis of EPPS-Driven Degradation and Reformation of Amyloid-Î² Aggregates. Journal of Alzheimer's Disease Reports, 2018, 2, 41-49.	1.2	10
811	Soluble TREM2 changes during the clinical course of Alzheimerâ€™s disease: A meta-analysis. Neuroscience Letters, 2018, 686, 10-16.	1.0	70
812	Optimization of 1,4-Oxazine Î²-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. Journal of Medicinal Chemistry, 2018, 61, 5292-5303.	2.9	15
813	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine Î²-Secretase (BACE1) Inhibitors via Active Conformation Stabilization. Journal of Medicinal Chemistry, 2018, 61, 5525-5546.	2.9	28
814	Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimerâ€™s disease by evaluating protein interactions through molecular docking and dynamic simulations. Neurological Sciences, 2018, 39, 1361-1374.	0.9	9
815	Induction ofÂnerve growth factor byÂphorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway. Heliyon, 2018, 4, e00617.	1.4	3
816	Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Î² Peptide Associated with Alzheimerâ€™s Disease. ACS Macro Letters, 2018, 7, 983-989.	2.3	17
817	In Vivo Near-Infrared Two-Photon Imaging of Amyloid Plaques in Deep Brain of Alzheimerâ€™s Disease Mouse Model. ACS Chemical Neuroscience, 2018, 9, 3128-3136.	1.7	50
818	Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. Nature Protocols, 2018, 13, 1850-1868.	5.5	70
819	Photoactive Bismuth Vanadate Structure for Lightâ€Triggered Dissociation of Alzheimer's Î²â€Amyloid Aggregates. Advanced Functional Materials, 2018, 28, 1802813.	7.8	34
820	Î²-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling. Frontiers in Pharmacology, 2018, 8, 969.	1.6	15
821	Targeting Reninâ€“Angiotensin System Against Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2018, 9, 440.	1.6	81
822	Gut microbiota influences Alzheimer's disease pathogenesis by regulating acetate in Drosophila model. Future Microbiology, 2018, 13, 1117-1128.	1.0	52

#	Article	IF	Citations
823	Morroniside prevents H2O2 or AÎ²1â€“42-induced apoptosis via attenuating JNK and p38 MAPK phosphorylation. European Journal of Pharmacology, 2018, 834, 295-304.	1.7	38
824	Genesis of Neuroprotective Peptoid from AÎ²30â€“34 Inhibits AÎ² Aggregation and AChE Activity. ACS Chemical Neuroscience, 2018, 9, 2929-2940.	1.7	13
825	Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact. International Journal of Molecular Sciences, 2018, 19, 2245.	1.8	102
826	Dihydropyridines Allosterically Modulate Hsp90 Providing a Novel Mechanism for Heat Shock Protein Co-induction and Neuroprotection. Frontiers in Molecular Biosciences, 2018, 5, 51.	1.6	27
827	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
828	Sleep Disorders Associated With Alzheimer's Disease: A Perspective. Frontiers in Neuroscience, 2018, 12, 330.	1.4	99
829	Circadian Rhythm and Alzheimerâ€™s Disease. Medical Sciences (Basel, Switzerland), 2018, 6, 52.	1.3	42
830	Peptides as Potential Therapeutics for Alzheimerâ€™s Disease. Molecules, 2018, 23, 283.	1.7	45
831	Î²-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. Journal of Neuropathology and Experimental Neurology, 2018, 77, 814-826.	0.9	46
832	Novel Dâ€“Aâ€“D based near-infrared probes for the detection of Î²-amyloid and Tau fibrils in Alzheimer's disease. Chemical Communications, 2018, 54, 8717-8720.	2.2	50
833	Antiinflammatory Properties of Dietary n-3 Polyunsaturated Fatty Acids Protect Against Cognitive Decline in Aging and Neurodegenerative Diseases. , 2018, , 367-384.		0
834	Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment. Frontiers in Chemistry, 2018, 6, 178.	1.8	126
835	Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. Journal of Neuroinflammation, 2018, 15, 1.	3.1	189
836	Molecular and functional signatures in a novel Alzheimerâ€™s disease mouse model assessed by quantitative proteomics. Molecular Neurodegeneration, 2018, 13, 2.	4.4	62
837	Alzheimerâ€™s disease hypothesis and related therapies. Translational Neurodegeneration, 2018, 7, 2.	3.6	385
838	Rational Design of Novel 1,3-Oxazine Based Î²-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust AÎ² Reduction in the Brain. Journal of Medicinal Chemistry, 2018, 61, 5122-5137.	2.9	29
839	Treatment of neurodegenerative disorders through the bloodâ€“brain barrier using nanocarriers. Nanoscale, 2018, 10, 16962-16983.	2.8	130
840	Changes in Glutathione Redox Potential Are Linked to AÎ²42-Induced Neurotoxicity. Cell Reports, 2018, 24, 1696-1703.	2.9	18

#	Article	IF	Citations
841	Postsynaptic Proteome of Non-Demented Individuals with Alzheimerâ€™s Disease Neuropathology. Journal of Alzheimer's Disease, 2018, 65, 659-682.	1.2	31
842	Systematic reviews of the literature: a better way of addressing basic science controversies. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L439-L442.	1.3	16
843	Psychosocial interventions for Alzheimerâ€™s disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatrics, 2018, 18, 175.	1.1	67
844	Importance of GPCR-Mediated Microglial Activation in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2018, 12, 258.	1.8	31
845	Brain targeting with lipidic nanocarriers. , 2018, , 255-324.		2
846	Sirtuins as Modifiers of Huntington's Disease (HD) Pathology. Progress in Molecular Biology and Translational Science, 2018, 154, 105-145.	0.9	17
847	Multi-functional neuroprotective activity of neohesperidin dihydrochalcone: a novel scaffold for Alzheimer's disease therapeutics identified via drug repurposing screening. New Journal of Chemistry, 2018, 42, 11755-11769.	1.4	12
848	Neural functions of bisecting GlcNAc. Glycoconjugate Journal, 2018, 35, 345-351.	1.4	33
849	Ganglioside-Mediated Assembly of Amyloid Î²-Protein: Roles in Alzheimer's Disease. Progress in Molecular Biology and Translational Science, 2018, 156, 413-434.	0.9	35
850	DAPK1: a Novel Pathology and Treatment Target for Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 2838-2844.	1.9	25
851	A Novel Method to Estimate Longâ€Term Chronological Changes From Fragmented Observations in Disease Progression. Clinical Pharmacology and Therapeutics, 2019, 105, 436-447.	2.3	12
852	Stability analysis of a steady state of a model describing Alzheimerâ€™s disease and interactions with prion proteins. Journal of Mathematical Biology, 2019, 78, 57-81.	0.8	8
853	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chemical Reviews, 2019, 119, 1221-1322.	23.0	360
854	Design and synthesis of thymine modified phthalocyanine for AÎ² protofibrils photodegradation and AÎ² peptide aggregation inhibition. Talanta, 2019, 191, 27-38.	2.9	11
855	AÎ² Oligomer Elimination Restores Cognition in Transgenic Alzheimerâ€™s Mice with Full-blown Pathology. Molecular Neurobiology, 2019, 56, 2211-2223.	1.9	29
856	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. Mitochondrion, 2019, 48, 67-77.	1.6	40
857	Dual-functional red-emitting fluorescent probes for imaging beta-amyloid plaques and viscosity. Sensors and Actuators B: Chemical, 2019, 298, 126903.	4.0	29
858	The interplay between microglial states and major risk factors in Alzheimerâ€™s disease through the eyes of single-cell RNA-sequencing: beyond black and white. Journal of Neurophysiology, 2019, 122, 1291-1296.	0.9	7

#	Article	IF	Citations
859	Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimerâ€™s Disease. ACS Omega, 2019, 4, 12833-12840.	1.6	100
860	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Journal of Neuroscience, 2019, 39, 7428-7437.	1.7	19
861	Gamma secretase modulators and BACE inhibitors reduce AÎ² production without altering gene expression in Alzheimer's disease iPSC-derived neurons and mice. Molecular and Cellular Neurosciences, 2019, 100, 103392.	1.0	8
862	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
863	Differential Interactome and Innate Immune Response Activation of Two Structurally Distinct Misfolded Protein Oligomers. ACS Chemical Neuroscience, 2019, 10, 3464-3478.	1.7	7
864	Vitamin E and Alzheimerâ€™s disease: what do we know so far? . Clinical Interventions in Aging, 2019, Volume 14, 1303-1317.	1.3	74
865	Structure and Function of Alzheimerâ€™s Amyloid Î²eta Proteins from Monomer to Fibrils: A Mini Review. Protein Journal, 2019, 38, 425-434.	0.7	21
866	Targeting the Interaction Between Apolipoprotein E and Amyloid Precursor Protein: A Novel Alzheimerâ€™s Disease Therapy. Biological Psychiatry, 2019, 86, 169-170.	0.7	2
867	Copper imbalance in Alzheimerâ€™s disease: Convergence of the chemistry and the clinic. Coordination Chemistry Reviews, 2019, 397, 168-187.	9.5	65
868	Tracing the GSAPâ€“APP C-99 Interaction Site in the Î²-Amyloid Pathway Leading to Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 3868-3879.	1.7	10
869	Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnestic Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 70, 477-486.	1.2	4
870	An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies. Methods in Molecular Biology, 2019, 2011, 393-412.	0.4	6
871	Molecular modeling of cardanol-derived AChE inhibitors. Chemical Physics Letters, 2019, 731, 136591.	1.2	5
872	Lysozyme encapsulated gold nanoclusters for probing the early stage of lysozyme aggregation under acidic conditions. Journal of Photochemistry and Photobiology B: Biology, 2019, 197, 111540.	1.7	9
873	Formation of compound I in heme bound AÎ²-peptides relevant to Alzheimer's disease. Chemical Science, 2019, 10, 8405-8410.	3.7	14
874	A Snapshot on the Current Status of Alzheimerâ€™s Disease, Treatment Perspectives, <i>in-Vitro</i> and <i>in-Vivo</i> Research Studies and Future Opportunities. Chemical and Pharmaceutical Bulletin, 2019, 67, 1030-1041.	0.6	8
875	Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases. Progress in Molecular Biology and Translational Science, 2019, 166, 145-223.	0.9	22
876	Small Molecule Inhibition of Protein Disulfide Isomerase in Neuroblastoma Cells Induces an Oxidative Stress Response and Apoptosis Pathways. ACS Chemical Neuroscience, 2019, 10, 4068-4075.	1.7	9

#	Article	IF	Citations
877	Amyloid-Î² induced neuropathological actions are suppressed by Padina gymnospora (Phaeophyceae) and its active constituent Î±-bisabolol in Neuro2a cells and transgenic Caenorhabditis elegans Alzheimer's model. Nitric Oxide - Biology and Chemistry, 2019, 91, 52-66.	1.2	34
878	Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update. Frontiers in Pharmacology, 2019, 10, 902.	1.6	173
879	Failure of in vitro-cultured schistosomes to produce eggs: how does the parasite meet its needs for host-derived cytokines such as TGF-Î²?. International Journal for Parasitology, 2019, 49, 747-757.	1.3	7
880	Hospital psychosocial interventions for patients with brain functional impairment: A retrospective cohort study. International Journal of Mental Health Nursing, 2019, 28, 1155-1164.	2.1	0
881	Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Molecular Medicine Reports, 2019, 20, 1479-1487.	1.1	293
882	Impact of Resilience on the Association Between Amyloid-Î² and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults. Journal of Alzheimer's Disease, 2019, 70, 361-370.	1.2	11
883	Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimerâ€™s disease spectrum. Alzheimer's Research and Therapy, 2019, 11, 60.	3.0	40
884	Cu 2+ Effects on Betaâ€Amyloid Oligomerisation Monitored by the Fluorescence of Intrinsic Tyrosine. ChemPhysChem, 2019, 20, 3181-3185.	1.0	7
885	Active-site environment of Cu bound amyloid Î² and amylin peptides. Journal of Biological Inorganic Chemistry, 2019, 24, 1245-1259.	1.1	9
886	The Role of Physical Fitness in Cognitive-Related Biomarkers in Persons at Genetic Risk of Familial Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2019, 8, 1639.	1.0	10
887	Effects of Cu(II) on the aggregation of amyloid-Î². Journal of Biological Inorganic Chemistry, 2019, 24, 1197-1215.	1.1	30
888	Nanomedicine Against AÎ² Aggregation by Î²â€“Sheet Breaker Peptide Delivery: In Vitro Evidence. Pharmaceutics, 2019, 11, 572.	2.0	18
889	Spirulina microalgae improves memory deficit induced by scopolamine in male pup rats: Role of oxidative stress. South African Journal of Botany, 2019, 127, 220-225.	1.2	9
890	Associations between Plasma Biomarkers and Cognition in Patients with Alzheimerâ€™s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. Journal of Clinical Medicine, 2019, 8, 1893.	1.0	31
891	Interrogating Amyloid Aggregates using Fluorescent Probes. Chemical Reviews, 2019, 119, 11819-11856.	23.0	184
892	Using mirror-image peptides to enhance robustness and reproducibility in studying the amyloid Î²-protein. Progress in Molecular Biology and Translational Science, 2019, 168, 57-67.	0.9	4
893	When Does Alzheimerâ€²s Disease Really Start? The Role of Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5536.	1.8	57
894	Trifluoromethyl Dihydrothiazineâ€Based Î²â€Secretase (BACE1) Inhibitors with Robust Central Î²â€Amyloid Reduction and Minimal Covalent Binding Burden. ChemMedChem, 2019, 14, 1894-1910.	1.6	8

#	Article	IF	Citations
895	Drugs for Targeted Therapies of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2019, 26, 335-359.	1.2	12
896	History and progress of hypotheses and clinical trials for Alzheimerâ€™s disease. Signal Transduction and Targeted Therapy, 2019, 4, 29.	7.1	370
897	AÎ²43 in human Alzheimerâ€™s disease: effects of active AÎ²42 immunization. Acta Neuropathologica Communications, 2019, 7, 141.	2.4	20
898	Traditional Oriental Medicines and Alzheimerâ€™s Disease. , 2019, 10, 307.		31
899	Targeting Autophagy for the Treatment of Alzheimerâ€™s Disease: Challenges and Opportunities. Frontiers in Molecular Neuroscience, 2019, 12, 203.	1.4	106
900	Monitoring the Formation of Amyloid Oligomers Using Photoluminescence Anisotropy. Journal of the American Chemical Society, 2019, 141, 15605-15610.	6.6	47
901	The mutational landscape of a prion-like domain. Nature Communications, 2019, 10, 4162.	5.8	116
902	Emerging Alternative Proteinases in APP Metabolism and Alzheimerâ€™s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. Frontiers in Aging Neuroscience, 2019, 11, 244.	1.7	46
903	Trends in Biomathematics: Mathematical Modeling for Health, Harvesting, and Population Dynamics. , 2019, , .		1
904	Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors. Biochemistry, 2019, 58, 4424-4435.	1.2	10
905	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
906	Catalytides derived from the Box A region in the ANA/BTG3 protein cleave amyloid-Î² fragment peptide. Heliyon, 2019, 5, e02454.	1.4	8
907	Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR. Bioorganic Chemistry, 2019, 92, 103253.	2.0	8
908	Steroid-Enriched Fraction of Achyranthes bidentata Protects Amyloid Î² Peptide 1â€“40-Induced Cognitive Dysfunction and Neuroinflammation in Rats. Molecular Neurobiology, 2019, 56, 5671-5688.	1.9	20
909	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
910	Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells, 2019, 8, 90.	1.8	144
911	Drug Development for Alzheimerâ€™s Disease: Microglia Induced Neuroinflammation as a Target?. International Journal of Molecular Sciences, 2019, 20, 558.	1.8	99
913	The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 13.	2.4	22

#	Article	IF	Citations
914	The Potential Role of Dysregulated miRNAs in Alzheimerâ€™s Disease Pathogenesis and Progression. Journal of Alzheimer's Disease, 2019, 67, 1123-1145.	1.2	13
915	Royal jelly peptides: potential inhibitors of Î²-secretase in N2a/APP695swe cells. Scientific Reports, 2019, 9, 168.	1.6	19
916	A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648.	2.7	17
917	Four new cembranoids from the Chinese soft coral Sinularia sp. and their anti-AÎ² aggregation activities. FÃ¬toterapÃ¬Ã¢, 2019, 136, 104176.	1.1	14
918	Amyloid-Î² Peptideâ€“Lipid Bilayer Interaction Investigated by Supercritical Angle Fluorescence. ACS Chemical Neuroscience, 2019, 10, 4776-4786.	1.7	7
919	Risk Factors and Clinical Treatments of Alzheimerâ€™s Disease. Journal of Physics: Conference Series, 2019, 1168, 032120.	0.3	0
920	Pharmacokinetic parameters and mechanism of action of an efficient anti-AÎ² single chain antibody fragment. PLoS ONE, 2019, 14, e0217793.	1.1	9
921	Assembly of Î±-synuclein aggregates on phospholipid bilayers. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 802-812.	1.1	34
922	BACE1 Translation: At the Crossroads Between Alzheimerâ€™s Disease Neurodegeneration and Memory Consolidation. Journal of Alzheimer's Disease Reports, 2019, 3, 113-148.	1.2	6
923	Assessing Neuroprotective Agents for AÎ²-Induced Neurotoxicity. Trends in Molecular Medicine, 2019, 25, 685-695.	3.5	18
924	Orientin Improves Cognition by Enhancing Autophagosome Clearance in an Alzheimerâ€™s Mouse Model. Journal of Molecular Neuroscience, 2019, 69, 246-253.	1.1	15
925	Intertwined Pathologies of Amyloid-Î² and Metal Ions in Alzheimerâ€™s Disease: Metalâ€“Amyloid-Î². Chemistry Letters, 2019, 48, 951-960.	0.7	14
926	Vanadyl acetylacetonate attenuates AÎ² pathogenesis in APP/PS1 transgenic mice depending on the intervention stage. New Journal of Chemistry, 2019, 43, 17588-17594.	1.4	5
927	Binary Structure of Amyloid Beta Oligomers Revealed by Dual Recognition Mapping. Analytical Chemistry, 2019, 91, 8422-8428.	3.2	9
928	Small Molecule Inhibits Metal-Dependent and -Independent Multifaceted Toxicity of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 3611-3621.	1.7	43
929	Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 22.	4.4	51
930	Anxiolytic impact of Apelin-13 in a rat model of Alzheimer's disease: Involvement of glucocorticoid receptor and FKBP5. Peptides, 2019, 118, 170102.	1.2	21
931	Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid Î²42 Anti-Aggregation Properties. Molecules, 2019, 24, 2125.	1.7	24

#	Article	IF	Citations
932	Synthesis and biological evaluation of 3â€“(4-aminophenyl)-coumarin derivatives as potential anti-Alzheimerâ€™s disease agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1083-1092.	2.5	23
933	CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice. Neurotherapeutics, 2019, 16, 710-724.	2.1	60
934	Affibody-Mediated Sequestration of Amyloid Î² Demonstrates Preventive Efficacy in a Transgenic Alzheimerâ€™s Disease Mouse Model. Frontiers in Aging Neuroscience, 2019, 11, 64.	1.7	16
935	The Major Risk Factors for Alzheimerâ€™s Disease: Age, Sex, and Genes Modulate the Microglia Response to AÎ² Plaques. Cell Reports, 2019, 27, 1293-1306.e6.	2.9	527
936	Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer×³s disease. Acta Pharmaceutica Sinica B, 2019, 9, 590-603.	5.7	28
937	Oleuropein aglycone and hydroxytyrosol interfere differently with toxic AÎ²1-42 aggregation. Food and Chemical Toxicology, 2019, 129, 1-12.	1.8	46
938	Secondary nucleation and elongation occur at different sites on Alzheimerâ€™s amyloid-Î² aggregates. Science Advances, 2019, 5, eaau3112.	4.7	127
939	Green Tea Seed Oil Suppressed AÎ²1â€“42-Induced Behavioral and Cognitive Deficit via the AÎ²-Related Akt Pathway. International Journal of Molecular Sciences, 2019, 20, 1865.	1.8	17
940	Herpesviral infections and antimicrobial protection for Alzheimer's disease: Implications for prevention and treatment. Journal of Medical Virology, 2019, 91, 1368-1377.	2.5	16
941	Neurochemical Aspects of Alzheimerâ€™s Type of Dementia. , 2019, , 73-112.		1
942	Non-conventional compounds with potential therapeutic effects against Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2019, 19, 375-395.	1.4	12
943	Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation. Journal of Computer-Aided Molecular Design, 2019, 33, 521-530.	1.3	20
944	Structure-Based Design of Selective Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. Journal of Medicinal Chemistry, 2019, 62, 5080-5095.	2.9	29
945	Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. International Journal of Molecular Sciences, 2019, 20, 1829.	1.8	43
946	BACE-1 and Î³-Secretase as Therapeutic Targets for Alzheimerâ€™s Disease. Pharmaceuticals, 2019, 12, 41.	1.7	78
947	Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 169, 200-223.	2.6	66
948	A review of the possible associations between ambient PM2.5 exposures and the development of Alzheimer's disease. Ecotoxicology and Environmental Safety, 2019, 174, 344-352.	2.9	188
949	A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss. Human Molecular Genetics, 2019, 28, 2174-2188.	1.4	40

#	Article	IF	Citations
950	Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease. Life Sciences, 2019, 224, 109-119.	2.0	190
951	Dual effect of chitosan-based nanoparticles on the inhibition of Î²-amyloid peptide aggregation and disintegration of the preformed fibrils. Journal of Materials Chemistry B, 2019, 7, 3362-3373.	2.9	30
952	Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloidâ€Î² in Alzheimer's Disease. Advanced Materials, 2019, 31, e1807965.	11.1	87
953	Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimerâ€™s disease. Inflammopharmacology, 2019, 27, 663-677.	1.9	276
954	Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy. Progress in Brain Research, 2019, 245, 57-88.	0.9	39
955	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage: Clinical, 2019, 22, 101771.	1.4	108
956	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
957	Systematically Characterize the Anti-Alzheimer's Disease Mechanism of Lignans from S. chinensis based on In-Vivo Ingredient Analysis and Target-Network Pharmacology Strategy by UHPLCâ€“Q-TOF-MS. Molecules, 2019, 24, 1203.	1.7	21
958	Polyphenols Modulate Alzheimerâ€™s Amyloid Beta Aggregation in a Structure-Dependent Manner. Nutrients, 2019, 11, 756.	1.7	61
959	Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-Î² oligomers. Scientific Reports, 2019, 9, 5715.	1.6	25
960	Inhibiting AÎ² toxicity in Alzheimer's disease by a pyridine amine derivative. European Journal of Medicinal Chemistry, 2019, 168, 330-339.	2.6	30
961	A Mathematical Model for Amyloid-? Aggregation in the Presence of Metal Ions: A Timescale Analysis for the Progress of Alzheimer Disease. Bulletin of Mathematical Biology, 2019, 81, 1943-1964.	0.9	6
962	A phase 1 clinical trial of the sigmaâ€2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 20-26.	1.8	73
963	Amyloid Î² perturbs elevated heme flux induced with neuronal development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 27-37.	1.8	8
964	The Role of Apolipoprotein E Isoforms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21
965	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
966	Alteration of the Wnt/GSK3Î²/Î²â€‘catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model. International Journal of Molecular Medicine, 2019, 44, 313-323.	1.8	20
967	Post-tetanic Potentiation and Depression in Hippocampal Neurons in a Rat Model of Alzheimerâ€™s Disease: Effects of Teucrium Polium Extract. Neurophysiology, 2019, 51, 332-343.	0.2	0

#	Article	IF	Citations
968	Alzheimerâ€™s disease: A clinical perspective and future nonhuman primate research opportunities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26224-26229.	3.3	61
969	Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis. Acta Neuropathologica Communications, 2019, 7, 180.	2.4	19
970	Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2019, 51, 1-17.	3.2	56
971	Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimerâ€™s Disease: From Animal Models to the Human Pathology. Cells, 2019, 8, 1430.	1.8	17
972	Exploring the Role of P2X Receptors in Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2019, 10, 1330.	1.6	23
973	Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. Frontiers in Pharmacology, 2019, 10, 1363.	1.6	57
974	The Convergence of Alzheimerâ€™s Disease Pathogenesis Concepts. Molecular Biology, 2019, 53, 896-903.	0.4	14
975	Exosomal Transport and Progression of Neurodegeneration in Amyotrophic Lateral Sclerosis. Neurochemical Journal, 2019, 13, 229-239.	0.2	2
976	Future Therapeutic Perspectives into the Alzheimerâ€™s Disease Targeting the Oxidative Stress Hypothesis. Molecules, 2019, 24, 4410.	1.7	67
977	Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 335.	1.7	28
978	Evidence for Decreased Nucleolar PARP-1 as an Early Marker of Cognitive Impairment. Neural Plasticity, 2019, 2019, 1-8.	1.0	12
979	Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoEâˆ’/âˆ’ Mice Experimental Model. Nutrients, 2019, 11, 11.	1.7	32
980	Metalâ€“Organic Frameworks Harness Cu Chelating and Photooxidation Against Amyloid Î² Aggregation in Vivo. Chemistry - A European Journal, 2019, 25, 3489-3495.	1.7	58
981	Calcium signalling: A common target in neurological disorders and neurogenesis. Seminars in Cell and Developmental Biology, 2019, 95, 25-33.	2.3	42
982	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
983	Getting to the Heart of Alzheimer Disease. Circulation Research, 2019, 124, 142-149.	2.0	136
984	New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 761-777.	1.0	57
985	Discovery of Neuroregenerative Peptoid from Amphibian Neuropeptide That Inhibits Amyloid-Î² Toxicity and Crosses Bloodâ€“Brain Barrier. ACS Chemical Neuroscience, 2019, 10, 1355-1368.	1.7	15

#	Article	IF	Citations
986	Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2019, 62, 4252-4264.	2.9	40
987	Nanocomposites Inhibit the Formation, Mitigate the Neurotoxicity, and Facilitate the Removal of Î²-Amyloid Aggregates in Alzheimerâ€™s Disease Mice. Nano Letters, 2019, 19, 674-683.	4.5	124
988	Amyloid-ÃŸ promotes neurotoxicity by Cdk5-induced p53 stabilization. Neuropharmacology, 2019, 146, 19-27.	2.0	40
989	Heteromultivalent peptide recognition by co-assembly of cyclodextrin and calixarene amphiphiles enables inhibition of amyloid fibrillation. Nature Chemistry, 2019, 11, 86-93.	6.6	148
990	Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2040-2047.	1.8	15
991	LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as anin vitromodel for Alzheimerâ€™s disease. Bioscience, Biotechnology and Biochemistry, 2019, 83, 609-621.	0.6	46
992	Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Metabolic Brain Disease, 2019, 34, 583-591.	1.4	41
993	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. Nature Genetics, 2019, 51, 404-413.	9.4	1,625
994	On the role of synthesized hydroxylated chalcones as dual functional amyloid-Î² aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 166, 11-21.	2.6	74
995	Sleepâ€“wake regulation and the hallmarks of the pathogenesis of Alzheimerâ€™s disease. Sleep, 2019, 42, .	0.6	42
996	Synthesis of Pyridopyrazine-1,6-dione Î³-Secretase Modulators via Selective 4-Methylimidazole N¹-Buchwald Arylation. Journal of Organic Chemistry, 2019, 84, 4921-4925.	1.7	3
997	Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy. Journal of Controlled Release, 2019, 296, 14-28.	4.8	37
998	Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimerâ€™s disease: Rational insights for the therapeutic approaches. Journal of Clinical Neuroscience, 2019, 59, 6-11.	0.8	113
999	A Numerical Study of Sensitivity Coefficients for a Model of Amyloid Precursor Protein and Tubulin-Associated Unit Protein Transport and Agglomeration in Neurons at the Onset of Alzheimer's Disease. Journal of Biomechanical Engineering, 2019, 141, .	0.6	5
1000	Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's disease pathways and genes. Neurobiology of Aging, 2019, 74, 225-233.	1.5	30
1001	Analysis of tauopathy research funding between 2006 and 2016 reveals critical gaps in research priorities. , 2019, 15, 42-54.		3
1002	Adsorption Mechanism of Amyloid Fibrils to Graphene Nanosheets and Their Structural Destruction. Journal of Physical Chemistry C, 2019, 123, 897-906.	1.5	22
1003	Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 852-862.	1.7	88

#	Article	IF	Citations
1004	Alzheimerâ€™s Disease and Dementia. , 2019, , 25-82.		2
1005	Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina. Neuroscience Bulletin, 2019, 35, 325-335.	1.5	22
1006	The relationship between cholesterol level and Alzheimerâ€™s disease-associated APP proteolysis/AÎ² metabolism. Nutritional Neuroscience, 2019, 22, 453-463.	1.5	32
1007	Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Statistical Methods in Medical Research, 2020, 29, 151-164.	0.7	30
1008	Omega-3 polyunsaturated fatty acids promote brain-to-blood clearance of Î²-Amyloid in a mouse model with Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2020, 85, 35-45.	2.0	35
1009	The Structure and Function of Î±, Î² and Î³-Secretase as Therapeutic Target Enzymes in the Development of Alzheimerâ€™s Disease: A Review. CNS and Neurological Disorders - Drug Targets, 2020, 18, 657-667.	0.8	11
1010	Hepcidin and its therapeutic potential in neurodegenerative disorders. Medicinal Research Reviews, 2020, 40, 633-653.	5.0	43
1011	Discovery of nitazoxanide-based derivatives asÂautophagy activators for the treatment ofÂAlzheimer's disease. Acta Pharmaceutica Sinica B, 2020, 10, 646-666.	5.7	18
1012	Biomarkers and brains: situating dementia in the laboratory and in the memory clinic. New Genetics and Society, 2020, 39, 80-100.	0.7	0
1013	Beta-Amyloid Increases the Expression Levels of Tid1 Responsible for Neuronal Cell Death and Amyloid Beta Production. Molecular Neurobiology, 2020, 57, 1099-1114.	1.9	12
1014	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimerâ€™s disease: A literature review. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 86-98.	2.7	40
1015	Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimerâ€™s Disease: Present and future applications. Brain Research, 2020, 1727, 146535.	1.1	21
1016	G protein-coupled receptors in neurodegenerative diseases. , 2020, , 335-365.		0
1017	A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimerâ€™s Disease. Journal of Immunology, 2020, 204, 243-250.	0.4	26
1018	Production of BBF2H7â€derived small peptide fragments via endoplasmic reticulum stressâ€dependent regulated intramembrane proteolysis. FASEB Journal, 2020, 34, 865-880.	0.2	2
1019	Novel therapeutic strategies for Alzheimer's disease: Implications from cell-based therapy and nanotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102149.	1.7	35
1020	Clinically accurate diagnosis of Alzheimerâ€™s disease via multiplexed sensing of core biomarkers in human plasma. Nature Communications, 2020, 11, 119.	5.8	130
1021	Extensive Structure Modification on Luteolin-Cinnamic Acid Conjugates Leading to BACE1 Inhibitors with Optimal Pharmacological Properties. Molecules, 2020, 25, 102.	1.7	5

#	Article	IF	Citations
1022	The dark side of Alzheimerâ€™s disease: unstructured biology of proteins from the amyloid cascade signaling pathway. Cellular and Molecular Life Sciences, 2020, 77, 4163-4208.	2.4	23
1023	Ultrasonic waves effect on S-shaped Î²-amyloids conformational dynamics by non-equilibrium molecular dynamics. Journal of Molecular Graphics and Modelling, 2020, 96, 107518.	1.3	8
1024	Melatonin attenuates streptozotocin-induced Alzheimer-like features in hyperglycemic rats. Neurochemistry International, 2020, 132, 104601.	1.9	25
1025	Interactions of a multifunctional di-triazole derivative with Alzheimer's AÎ²₄₂monomer and AÎ²₄₂protofibril: a systematic molecular dynamics study. Physical Chemistry Chemical Physics, 2020, 22, 1543-1556.	1.3	25
1026	Predicting Amyloid-Î² Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques. Journal of Alzheimer's Disease, 2020, 73, 1211-1219.	1.2	27
1027	Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. Biomaterials, 2020, 231, 119678.	5.7	37
1028	Pâ€glycoprotein: a role in the export of amyloidâ€Î² in Alzheimer's disease?. FEBS Journal, 2020, 287, 612-625.	2.2	62
1029	Amyloid-Î²-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience, 2020, 21, 21-35.	4.9	338
1030	Destabilization of Î²â€amyloid aggregates by thrombin derived peptide: plausible role of thrombin in neuroprotection. FEBS Journal, 2020, 287, 2386-2413.	2.2	1
1031	Facing the complexity of Alzheimer's disease. Future Medicinal Chemistry, 2020, 12, 175-177.	1.1	6
1032	Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model. Physiology and Behavior, 2020, 215, 112749.	1.0	19
1033	Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets. Theranostics, 2020, 10, 179-200.	4.6	37
1034	Design and evaluation of Nrf2 activators with 1,3,4-oxa/thiadiazole core as neuro-protective agents against oxidative stress in PC-12 cells. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126853.	1.0	4
1035	A novel fluorescent protein chromophore analogue to simultaneously probe lysosome viscosity and Î²-amyloid fibrils. Sensors and Actuators B: Chemical, 2020, 305, 127509.	4.0	32
1036	Involvement of the nitric oxide signaling in modulation of naringin against intranasal manganese and intracerbroventricular Î²-amyloid induced neurotoxicity in rats. Journal of Nutritional Biochemistry, 2020, 76, 108255.	1.9	22
1037	Developing Therapies for Neurodegenerative Disorders: Insights from Protein Aggregation and Cellular Stress Responses. Annual Review of Cell and Developmental Biology, 2020, 36, 165-189.	4.0	35
1038	Relationship Between Peripheral Transport Proteins and Plasma Amyloid-Î² in Patients with Alzheimerâ€™s Disease Were Different from Cognitively Normal Controls: A Propensity Score Matching Analysis. Journal of Alzheimer's Disease, 2020, 78, 699-709.	1.2	4
1039	The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles. Cells, 2020, 9, 2182.	1.8	31

#	Article	IF	Citations
1040	Lycopene - A pleiotropic neuroprotective nutraceutical: Deciphering its therapeutic potentials in broad spectrum neurological disorders. Neurochemistry International, 2020, 140, 104823.	1.9	25
1041	Bushen-Tiansui Formula Improves Cognitive Functions in an AÎ²1â€“42 Fibril-Infused Rat Model of Alzheimerâ€™s Disease. Neural Plasticity, 2020, 2020, 1-11.	1.0	4
1042	The amyloid cascade hypothesis and Alzheimerâ€™s disease: A mathematical model. European Journal of Applied Mathematics, 2021, 32, 749-768.	1.4	10
1043	Novel Dâ€“Ï€-A type near-infrared fluorescent probes for the detection of AÎ²₄₀ aggregates. Analyst, The, 2020, 145, 6579-6585.	1.7	9
1044	Spatial Transcriptomics and In Situ Sequencing to Study Alzheimerâ€™s Disease. Cell, 2020, 182, 976-991.e19.	13.5	491
1045	Rhodamine-Based Metal Chelator: A Potent Inhibitor of Metal-Catalyzed Amyloid Toxicity. ACS Omega, 2020, 5, 18958-18967.	1.6	14
1046	Metal-chelating benzothiazole multifunctional compounds for the modulation and ⁶⁴Cu PET imaging of AÎ² aggregation. Chemical Science, 2020, 11, 7789-7799.	3.7	40
1047	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101126.	5.0	31
1048	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
1049	Protective Effect and Mechanism of Fruit Extract of Aegle marmelos Against Amyloid-Î² Toxicity in a Transgenic Caenorhabditis elegans. Natural Product Communications, 2020, 15, 1934578X2093351.	0.2	0
1050	Molecular and Imaging Biomarkers in Alzheimerâ€™s Disease: A Focus on Recent Insights. Journal of Personalized Medicine, 2020, 10, 61.	1.1	35
1051	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. Medicinal Research Reviews, 2020, 40, 2386-2426.	5.0	61
1052	c-Jun N-Terminal Kinases in Alzheimerâ€™s Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's Disease, 2021, 82, S127-S139.	1.2	7
1053	The Interplay Between Beta-Amyloid 1â€“42 (AÎ²1â€“42)-Induced Hippocampal Inflammatory Response, p-tau, Vascular Pathology, and Their Synergistic Contributions to Neuronal Death and Behavioral Deficits. Frontiers in Molecular Neuroscience, 2020, 13, 522073.	1.4	26
1054	Sigma-2 Receptorâ€”A Potential Target for Cancer/Alzheimerâ€™s Disease Treatment via Its Regulation of Cholesterol Homeostasis. Molecules, 2020, 25, 5439.	1.7	21
1055	Biophysical, Biochemical, and Behavioral Implications of ApoE3 Conjugated Donepezil Nanomedicine in a AÎ²_{1â€“42} Induced Alzheimerâ€™s Disease Rat Model. ACS Chemical Neuroscience, 2020, 11, 4139-4151.	1.7	22
1056	Design of a multivalent bifunctional chelator for diagnostic ⁶⁴ Cu PET imaging in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30928-30933.	3.3	25
1057	Unfolding the Role of a Flavone-Based Fluorescent Antioxidant towards the Misfolding of Amyloid Proteins: An Endeavour to Probe Amyloid Aggregation. Journal of Physical Chemistry B, 2020, 124, 11133-11144.	1.2	9

#	Article	IF	Citations
1058	A meta-analysis of the effect of binge drinking on the oral microbiome and its relation to Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 19872.	1.6	19
1059	Integrating musicâ€based interventions with Gammaâ€frequency stimulation: Implications for healthy ageing. European Journal of Neuroscience, 2022, 55, 3303-3323.	1.2	10
1060	Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease. Heliyon, 2020, 6, e04716.	1.4	4
1061	Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimerâ€™s disease-like pathologies in APP/PS1 mouse model. Chinese Herbal Medicines, 2020, 12, 421-429.	1.2	9
1062	An Î±-helix mimetic oligopyridylamide, ADH-31, modulates AÎ²₄₂ monomer aggregation and destabilizes protofibril structures: insights from molecular dynamics simulations. Physical Chemistry Chemical Physics, 2020, 22, 28055-28073.	1.3	12
1063	Mathematical Model Shows How Sleep May Affect Amyloid-Î² Fibrillization. Biophysical Journal, 2020, 119, 862-872.	0.2	10
1064	Stepwise Design of Î³-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere. Journal of Medicinal Chemistry, 2020, 63, 8534-8553.	2.9	11
1065	Ginkgo biloba Alleviates Cisplatin-Mediated Neurotoxicity in Rats via Modulating APP/AÎ²/P2X7R/P2Y12R and XIAP/BDNF-Dependent Caspase-3 Apoptotic Pathway. Applied Sciences (Switzerland), 2020, 10, 4786.	1.3	8
1066	Molecular basis for the inhibitory effects of 5-hydroxycyclopenicillone on the conformational transition of AÎ²40 monomer. Journal of Biomolecular Structure and Dynamics, 2020, 39, 1-12.	2.0	2
1067	Repetitive Head Trauma Induces Chronic Traumatic Encephalopathy by Multiple Mechanisms. Seminars in Neurology, 2020, 40, 430-438.	0.5	10
1068	Astragaloside IV prevents AÎ²1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARÎ³/BDNF signaling pathway. Brain Research, 2020, 1747, 147041.	1.1	33
1069	Insights into the Effect of Curcumin and (â€“)-Epigallocatechin-3-Gallate on the Aggregation of AÎ²(1â€“40) Monomers by Means of Molecular Dynamics. International Journal of Molecular Sciences, 2020, 21, 5462.	1.8	18
1070	Nanoscale rearrangement of APP organization as a therapeutic target for Alzheimerâ€™s disease. Medical Hypotheses, 2020, 143, 110143.	0.8	4
1071	Dual-functional AIE fluorescent probes for imaging Î²-amyloid plaques and lipid droplets. Analytica Chimica Acta, 2020, 1133, 109-118.	2.6	40
1072	A â€œketo-enolâ€•plaque buster mechanism to diminish Alzheimerâ€™s Î²-Amyloid burden. Biochemical and Biophysical Research Communications, 2020, 532, 82-87.	1.0	2
1073	Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?. Neuropsychologia, 2020, 147, 107593.	0.7	17
1074	Effect of Moxibustion on Behavioral Changes and Expression of APP and BACE1 in Hippocampus of SAMP8 Mice. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	2
1075	Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2020, 52, 1275-1287.	3.2	17

#	Article	IF	Citations
1076	Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 4790.	5.8	188
1077	Limiting RyR2 Open Time Prevents Alzheimerâ€™s Disease-Related Neuronal Hyperactivity and Memory Loss but Not Î²-Amyloid Accumulation. Cell Reports, 2020, 32, 108169.	2.9	41
1078	Development of a brain-permeable peptide nanofiber that prevents aggregation of Alzheimer pathogenic proteins. PLoS ONE, 2020, 15, e0235979.	1.1	3
1079	5-N-ethyl Carboxamidoadenosine Stimulates Adenosine-2b Receptor-Mediated Mitogen-Activated Protein Kinase Pathway to Improve Brain Mitochondrial Function in Amyloid Beta-Induced Cognitive Deficit Mice. NeuroMolecular Medicine, 2020, 22, 542-556.	1.8	6
1080	Amyloid Targeting â€œArtificial Chaperoneâ€•Impairs Oligomer Mediated Neuronal Damage and Mitochondrial Dysfunction Associated with Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 3277-3287.	1.7	14
1081	Amyloid Beta Peptide (AÎ²1-42) Reverses the Cholinergic Control of Monocytic IL-1Î² Release. Journal of Clinical Medicine, 2020, 9, 2887.	1.0	9
1082	Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. Journal of Alzheimer's Disease, 2020, 77, 1397-1416.	1.2	12
1083	Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. Journal of Neuroinflammation, 2020, 17, 238.	3.1	60
1084	Ferroptosis Is Regulated by Mitochondria in Neurodegenerative Diseases. Neurodegenerative Diseases, 2020, 20, 20-34.	0.8	30
1085	Revisiting the Amyloid Cascade Hypothesis: From Anti-AÎ² Therapeutics to Auspicious New Ways for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	1.8	79
1086	Delta-secretase triggers Alzheimerâ€™s disease pathologies in wild-type hAPP/hMAPT double transgenic mice. Cell Death and Disease, 2020, 11, 1058.	2.7	10
1087	Casuarictin: A new herbal drug molecule for Alzheimer's disease as inhibitor of presenilin stabilization factor like protein. Heliyon, 2020, 6, e05546.	1.4	5
1088	The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29133-29143.	3.3	24
1089	A novel phytochemical from Dipteris wallichii inhibits human Î²-secretase 1: Implications for the treatment of Alzheimerâ€™s disease. Medical Hypotheses, 2020, 143, 109839.	0.8	8
1090	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimerâ€™s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer's Research and Therapy, 2020, 12, 58.	3.0	56
1091	Utility of Animal Models to Understand Human Alzheimerâ€™s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. International Journal of Molecular Sciences, 2020, 21, 3158.	1.8	12
1092	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Advanced Drug Delivery Reviews, 2020, 159, 54-93.	6.6	18
1093	Collagen hydrogel confinement of Amyloid-Î² (AÎ²) accelerates aggregation and reduces cytotoxic effects. Acta Biomaterialia, 2020, 112, 164-173.	4.1	11

#	Article	IF	Citations
1094	New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3765.	1.8	6
1095	Tacrine accelerates spatial long-term memory via improving impaired neural oscillations and modulating GAD isomers including neuro-receptors in the hippocampus of APP/PS1 AD mice. Brain Research Bulletin, 2020, 161, 166-176.	1.4	11
1096	The effects of melatonin, serotonin, tryptophan and NAS on the biophysical properties of DPPC monolayers. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183363.	1.4	16
1097	The L1 cell adhesion molecule affects protein kinase D1 activity in the cerebral cortex in a mouse model of Alzheimerâ€™s disease. Brain Research Bulletin, 2020, 162, 141-150.	1.4	13
1098	Icariin improves cognitive deficits by reducing the deposition of Î²-amyloid peptide and inhibition of neurons apoptosis in SAMP8 mice. NeuroReport, 2020, 31, 663-671.	0.6	16
1099	Fibrillization of 40-residue Î²-Amyloid Peptides in Membrane-Like Environments Leads to Different Fibril Structures and Reduced Molecular Polymorphisms. Biomolecules, 2020, 10, 881.	1.8	11
1100	Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimerâ€™s Disease. Neurotoxicity Research, 2020, 38, 833-849.	1.3	30
1101	Effects of Physical Activity on Brain Energy Biomarkers in Alzheimerâ€™s Diseases. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Over	1.0	3
1102	Targeting Microglial Population Dynamics in Alzheimerâ€™s Disease: Are We Ready for a Potential Impact on Immune Function?. Frontiers in Cellular Neuroscience, 2020, 14, 149.	1.8	19
1103	Self- assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer's disease. International Journal of Biological Macromolecules, 2020, 162, 246-261.	3.6	36
1104	Impact of APOE-Îµ4 carriage on the onset and rates of neocortical AÎ²-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	1.5	32
1105	Structure Analysis of Amyloid Aggregates at Lipid Bilayers by Supercritical Angle Raman Microscopy. Analytical Chemistry, 2020, 92, 4963-4970.	3.2	2
1106	Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimerâ€™s disease. Annals of Nuclear Medicine, 2020, 34, 337-348.	1.2	13
1107	Discovery of small molecules for the treatment of Alzheimerâ€™s disease. , 2020, , 289-322.		1
1108	CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques. Molecules, 2020, 25, 863.	1.7	10
1109	Pathological Continuum From the Rise in Pulse Pressure to Impaired Neurovascular Coupling and Cognitive Decline. American Journal of Hypertension, 2020, 33, 375-390.	1.0	12
1110	Wnt signalling pathway and tau phosphorylation: A comprehensive study on known connections. Cell Biochemistry and Function, 2020, 38, 686-694.	1.4	12
1111	Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits. PLoS ONE, 2020, 15, e0230277.	1.1	8

#	Article	IF	Citations
1112	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	3.9	40
1113	Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. Peptides, 2020, 132, 170352.	1.2	10
1114	Poor oral health conditions and cognitive decline: Studies in humans and rats. PLoS ONE, 2020, 15, e0234659.	1.1	13
1115	Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin. Journal of Neuroimmunology, 2020, 346, 577315.	1.1	7
1116	Iron stored in ferritin is chemically reduced in the presence of aggregating AÎ²(1-42). Scientific Reports, 2020, 10, 10332.	1.6	34
1117	Astrocyte- and Neuron-Derived Extracellular Vesicles from Alzheimerâ€™s Disease Patients Effect Complement-Mediated Neurotoxicity. Cells, 2020, 9, 1618.	1.8	52
1118	Brain Microvascular Endothelial Cell Derived Exosomes Potently Ameliorate Cognitive Dysfunction by Enhancing the Clearance of AÎ² Through Up-Regulation of P-gp in Mouse Model of AD. Neurochemical Research, 2020, 45, 2161-2172.	1.6	21
1119	Pharmacological Treatment of Alzheimerâ€™s Disease: Insights from Drosophila melanogaster. International Journal of Molecular Sciences, 2020, 21, 4621.	1.8	15
1120	LVFFARK-PEG-Stabilized Black Phosphorus Nanosheets Potently Inhibit Amyloid-Î² Fibrillogenesis. Langmuir, 2020, 36, 1804-1812.	1.6	37
1121	Evaluation of Toxic Amyloid Î²42 Oligomers in Rat Primary Cerebral Cortex Cells and Human iPS-derived Neurons Treated with 10-Me-Aplog-1, a New PKC Activator. International Journal of Molecular Sciences, 2020, 21, 1179.	1.8	6
1122	Activation of Inflammation is Associated with Amyloid-Î² Accumulation Induced by Chronic Sleep Restriction in Rats. Journal of Alzheimer's Disease, 2020, 74, 759-773.	1.2	17
1123	Auditory evoked potentials might have the potential to serve as early indicators related to amyloid beta peptide toxicity. Advances in Medical Sciences, 2020, 65, 223-232.	0.9	4
1124	miRNA-31 Improves Cognition and Abolishes Amyloid-Î² Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimerâ€™s Disease. Molecular Therapy - Nucleic Acids, 2020, 19, 1219-1236.	2.3	56
1125	Aggregation Mechanism of Alzheimerâ€™s Amyloid Î²-Peptide Mediated by Î±-Strand/Î±-Sheet Structure. International Journal of Molecular Sciences, 2020, 21, 1094.	1.8	12
1126	New Insights Into the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1312.	1.1	194
1127	â€œOlfactory Three-Needleâ€•Enhances Spatial Learning and Memory Ability in SAMP8 Mice. Behavioural Neurology, 2020, 2020, 1-11.	1.1	11
1128	Renin-Angiotensin System and Alzheimerâ€™s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. Protein and Peptide Letters, 2020, 27, 484-511.	0.4	25
1129	Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. Journal of Biomedical Science, 2020, 27, 49.	2.6	143

#	Article	IF	Citations
1130	Fish oil protects the bloodâ€“brain barrier integrity in a mouse model of Alzheimerâ€™s disease. Chinese Medicine, 2020, 15, 29.	1.6	14
1131	Association ofKlotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who CarryAPOE4. JAMA Neurology, 2020, 77, 849.	4.5	69
1132	A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery. European Journal of Medicinal Chemistry, 2020, 195, 112275.	2.6	72
1133	A facile biosensor for AÎ²40O based on fluorescence quenching of prussian blue nanoparticles. Talanta, 2020, 216, 120930.	2.9	29
1134	Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimerâ€™s Disease. Nutrients, 2020, 12, 1090.	1.7	38
1135	Liquidâ€Like Phases Preorder Peptides for Supramolecular Assembly. ChemSystemsChem, 2020, 2, e2000007.	1.1	5
1136	Circadian and sleep dysfunction in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 60, 101046.	5.0	99
1137	Aberrant interactions between amyloid-beta and alpha5 laminins as possible driver of neuronal disfunction in Alzheimerâ€™s disease. Biochimie, 2020, 174, 44-48.	1.3	2
1138	A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 1471-1481.	1.7	25
1139	Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the P2rx3/P2rx7 axis in mouse hippocampal neuronal cells. American Journal of Physiology - Cell Physiology, 2020, 318, C1123-C1135.	2.1	9
1140	Gold Nanoparticles Mediate Improved Detection of Î²-amyloid Aggregates by Fluorescence. Nanomaterials, 2020, 10, 690.	1.9	28
1141	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081.	2.0	27
1142	Anti-aging Klotho Protects SH-SY5Y Cells Against Amyloid Î²1â€“42 Neurotoxicity: Involvement of Wnt1/pCREB/Nrf2/HO-1 Signaling. Journal of Molecular Neuroscience, 2021, 71, 19-27.	1.1	15
1143	A new dilignan from the twigs and leaves of Archidendron clypearia. Journal of Asian Natural Products Research, 2021, 23, 609-614.	0.7	2
1144	The Î²-Secretase BACE1 in Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 745-756.	0.7	336
1145	Î´-Secretase-cleaved Tau stimulates AÎ² production via upregulating STAT1-BACE1 signaling in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 586-603.	4.1	54
1146	L-3-n-Butylphthalide improves synaptic and dendritic spine plasticity and ameliorates neurite pathology in Alzheimerâ€™s disease mouse model and cultured hippocampal neurons. Molecular Neurobiology, 2021, 58, 1260-1274.	1.9	10
1147	Maintained memory and longâ€term potentiation in a mouse model of Alzheimer's disease with both amyloid pathology and human tau. European Journal of Neuroscience, 2021, 53, 637-648.	1.2	4

#	Article	IF	Citations
1148	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews, 2021, 41, 2689-2745.	5.0	26
1149	Mapping the multicausality of Alzheimerâ€™s disease through group model building. GeroScience, 2021, 43, 829-843.	2.1	26
1150	Î²-amyloid pathology is not associated with depression in a large community sample autopsy study. Journal of Affective Disorders, 2021, 278, 372-381.	2.0	12
1151	Bile Acids: A Communication Channel in the Gut-Brain Axis. NeuroMolecular Medicine, 2021, 23, 99-117.	1.8	76
1152	Oral absorption enhancement of the amyloid-Î² oligomer eliminating compound RD2 by conjugation with folic acid. European Journal of Pharmaceutical Sciences, 2021, 156, 105581.	1.9	2
1153	A network thermodynamic analysis of amyloid aggregation along competing pathways. Applied Mathematics and Computation, 2021, 393, 125778.	1.4	3
1154	Inhibition of human amylin aggregation by Flavonoid Chrysin: An in-silico and in-vitro approach. International Journal of Medical Sciences, 2021, 18, 199-206.	1.1	9
1155	Role of Ten eleven translocationâ€2 (Tet2) in modulating neuronal morphology and cognition in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 2021, 157, 993-1012.	2.1	17
1156	Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects. Bioorganic Chemistry, 2021, 108, 104564.	2.0	6
1157	Combined Structure and Ligand-Based Design of Selective Acetylcholinesterase Inhibitors. Journal of Chemical Information and Modeling, 2021, 61, 467-480.	2.5	4
1158	Identification of truncated Câ€terminal fragments of the Alzheimerâ€™s disease amyloid protein precursor derived from sequential proteolytic pathways. Journal of Neurochemistry, 2021, 156, 943-956.	2.1	1
1159	Does hearing loss lead to dementia? A review of the literature. Hearing Research, 2021, 402, 108038.	0.9	37
1160	Multi-Target Drug Candidates for Multifactorial Alzheimerâ€™s Disease: AChE and NMDAR as Molecular Targets. Molecular Neurobiology, 2021, 58, 281-303.	1.9	53
1161	Glycoengineering artificial receptors for microglia to phagocytose AÎ² aggregates. Chemical Science, 2021, 12, 4963-4969.	3.7	16
1162	Donanemab (LY3002813) Phase 1b Study in Alzheimerâ€™s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-11.	1.5	24
1163	Probing Mechanisms and Therapeutic Potential of Î³-Secretase in Alzheimerâ€™s Disease. Molecules, 2021, 26, 388.	1.7	15
1164	Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. Progress in Brain Research, 2021, 265, 139-230.	0.9	9
1165	3D Alzheimer's disease in a dish: Implications for drug discovery. , 2021, , 311-331.		1

#	Article	IF	Citations
1166	Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia. Current Alzheimer Research, 2021, 17, 893-903.	0.7	4
1167	Whether cognitive behavioral therapy is effective for Alzheimer's disease. Medicine (United States), 2021, 100, e23945.	0.4	2
1168	Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimerâ€™s disease. Clinical Science, 2021, 135, 109-126.	1.8	32
1169	The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 1273.	1.8	59
1170	Experimental Approach to Alzheimerâ€™s Disease with Emphasis on Insulin Resistance in the Brain. , 2021, , 1-52.		4
1171	Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy. Sensors, 2021, 21, 788.	2.1	8
1172	The Involvement of Cellular Glycans in Alzheimer's Disease. , 2021, , 287-293.		0
1173	Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies. International Journal of Molecular Sciences, 2021, 22, 1051.	1.8	12
1174	Advances in fluorescent probes for detection and imaging of amyloid-Î² peptides in Alzheimer's disease. Advances in Clinical Chemistry, 2021, 103, 135-190.	1.8	13
1175	Development of molecular tools for diagnosis of Alzheimerâ€™s disease that are based on detection of amyloidogenic proteins. Prion, 2021, 15, 56-69.	0.9	12
1176	Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 285-300.	1.0	7
1177	Melatonin ameliorates diabetes-induced brain injury in rats. Acta Histochemica, 2021, 123, 151677.	0.9	13
1178	Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ, The, 2021, 372, n156.	3.0	113
1179	Fast green FCF inhibits AÎ² fibrillogenesis, disintegrates mature fibrils, reduces the cytotoxicity, and attenuates AÎ²-induced cognitive impairment in mice. International Journal of Biological Macromolecules, 2021, 170, 33-41.	3.6	9
1181	Insights Into the Mechanism of Tyrosine Nitration in Preventing Î²-Amyloid Aggregation in Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2021, 14, 619836.	1.4	4
1182	Structural Network Efficiency Predicts Resilience to Cognitive Decline in Elderly at Risk for Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 637002.	1.7	10
1183	Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review. Current Neuropharmacology, 2021, 19, 1884-1895.	1.4	7
1185	A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance. Physiology and Behavior, 2021, 230, 113268.	1.0	6

#	Article	IF	Citations
1186	Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimerâ€™s Disease. Sensors, 2021, 21, 2067.	2.1	19
1187	Enhancing calmodulin binding to ryanodine receptor is crucial to limit neuronal cell loss in Alzheimer disease. Scientific Reports, 2021, 11, 7289.	1.6	14
1188	The role of microRNAs regulatory network in Alzheimerâ€™s disease: a bioinformatics analysis. Archives of Medical Science, 2021, 18, 206-222.	0.4	10
1189	Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-Î² Disaggregation. International Journal of Molecular Sciences, 2021, 22, 2888.	1.8	22
1190	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimerâ€™s Disease. Cells, 2021, 10, 546.	1.8	11
1191	Effect of high-frequency low-intensity pulsed electric field on protecting SH-SY5Y cells against hydrogen peroxide and Î²-amyloid-induced cell injury via ERK pathway. PLoS ONE, 2021, 16, e0250491.	1.1	2
1192	Neuroprotective effects of dexpanthenol on streptozotocin-induced neuronal damage in rats. Drug and Chemical Toxicology, 2022, 45, 2160-2168.	1.2	5
1193	Ang (1â€“7)/Mas receptor-axis activation promotes amyloid beta-induced altered mitochondrial bioenergetics in discrete brain regions of Alzheimer's disease-like rats. Neuropeptides, 2021, 86, 102122.	0.9	13
1194	Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. Metabolites, 2021, 11, 233.	1.3	10
1196	Synthesis, characterization and pharmacological evaluation of quinoline derivatives and their complexes with copper(Î™Î™) in in vitro cell models of Alzheimer's disease. Journal of Inorganic Biochemistry, 2021, 217, 111393.	1.5	13
1197	Alternative Targets to Fight Alzheimerâ€™s Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	1.8	16
1198	Alzheimerâ€™s disease and its treatment by different approaches: A review. European Journal of Medicinal Chemistry, 2021, 216, 113320.	2.6	199
1199	Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 283-294.	1.2	19
1200	In Vivo/Ex Vivo EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 25-34.	0.7	3
1201	Protein Footprinting via Covalent Protein Painting Reveals Structural Changes of the Proteome in Alzheimerâ€™s Disease. Journal of Proteome Research, 2021, 20, 2762-2771.	1.8	34
1202	The role of Bcl-2 proteins in modulating neuronal Ca2+ signaling in health and in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118997.	1.9	31
1203	Nanomedicine against Alzheimerâ€™s and Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2021, 27, 1507-1545.	0.9	7
1204	Alzheimerâ€™s Disease Associated Presenilin 1 and 2 Genes Dysregulation in Neonatal Lymphocytes Following Perinatal Asphyxia. International Journal of Molecular Sciences, 2021, 22, 5140.	1.8	7

#	Article	IF	Citations
1206	Amyloids: The History of Toxicity and Functionality. Biology, 2021, 10, 394.	1.3	12
1207	Insights into Î²-amyloid transition prevention by cucurbit[7]uril from molecular modeling. Journal of Biomolecular Structure and Dynamics, 2022, 40, 9602-9612.	2.0	3
1208	RRY Inhibits Amyloid-Î²1â€“42 Peptide Aggregation and Neurotoxicity. Journal of Alzheimer's Disease Reports, 2021, 5, 479-495.	1.2	4
1209	Multifaceted Therapy of Nanocatalysts in Neurological Diseases. Journal of Biomedical Nanotechnology, 2021, 17, 711-743.	0.5	4
1210	Recent Progress in the Drug Development for the Treatment of Alzheimerâ€™s Disease Especially on Inhibition of Amyloid-peptide Aggregation. Mini-Reviews in Medicinal Chemistry, 2021, 21, 969-990.	1.1	6
1211	Advances in Brain Amyloid Imaging. Seminars in Nuclear Medicine, 2021, 51, 241-252.	2.5	30
1212	Hydrogen Bond Surrogateâ€Constrained Dynamic Antiparallel Î²â€Sheets. ChemBioChem, 2021, 22, 2111-2115.	1.3	2
1213	Genetically and pharmacologically limiting RyR2 open time prevents neuronal hyperactivity of hippocampal CA1 neurons in brain slices of 5xFAD mice. Neuroscience Letters, 2021, 758, 136011.	1.0	6
1215	Identification and coregulation pattern analysis of long noncoding RNAs following subacute spinal cord injury. Journal of Orthopaedic Research, 2022, 40, 661-673.	1.2	3
1216	Nanomaterials toward the treatment of Alzheimerâ€™s disease: Recent advances and future trends. Chinese Chemical Letters, 2021, 32, 1857-1868.	4.8	39
1217	EEG coherence and power spectra during REM sleep related to melatonin intake in mild-to-moderate Alzheimerâ€™s disease: a pilot study. International Journal of Neuroscience, 2023, 133, 441-449.	0.8	3
1218	Repurposing Licensed Drugs for Use Against Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 81, 921-932.	1.2	4
1219	Biomarkers for neurodegenerative diseases. Nature Medicine, 2021, 27, 954-963.	15.2	399
1220	Synaptic Plasticity and Oscillations in Alzheimerâ€™s Disease: A Complex Picture of a Multifaceted Disease. Frontiers in Molecular Neuroscience, 2021, 14, 696476.	1.4	16
1221	Is Cerebral Amyloid-Î² Deposition Related to Post-stroke Cognitive Impairment?. Translational Stroke Research, 2021, 12, 946-957.	2.3	12
1222	Blood Pressure Level Is Associated With Changes in Plasma AÎ²1 â€“40 and AÎ²1â€“42 Levels: A Cross-sectional Study Conducted in the Suburbs of Xiâ€™an, China. Frontiers in Aging Neuroscience, 2021, 13, 650679.	1.7	6
1223	Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications. International Journal of Molecular Sciences, 2021, 22, 6016.	1.8	28
1224	A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated AÎ² Aggregation. International Journal of Molecular Sciences, 2021, 22, 6842.	1.8	14

#	Article	IF	Citations
1225	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
1227	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
1228	The Impact of Assay Design on Medicinal Chemistry: Case Studies. SLAS Discovery, 2021, 26, 1243-1255.	1.4	2
1229	Knock-in models related to Alzheimerâ€™s disease: synaptic transmission, plaques and the role of microglia. Molecular Neurodegeneration, 2021, 16, 47.	4.4	27
1230	Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders. Biochemical Journal, 2021, 478, 2733-2758.	1.7	28
1231	When Does Alzheimerâ€™s Disease Really Start? The Role of Biomarkers. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	1
1232	Heart failure and dementia: a comparative analysis with different types of cancer. European Heart Journal Open, 2021, 1, .	0.9	3
1233	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 541-560.	1.2	18
1234	Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid Î² Aggregates in Alzheimerâ€™s Disease. Journal of the American Chemical Society, 2021, 143, 10462-10476.	6.6	51
1235	Nanotechnologyâ€Based Strategies for Early Diagnosis of Central Nervous System Disorders. Advanced NanoBiomed Research, 2021, 1, 2100008.	1.7	16
1236	Failure of the Brain Glucagon-Like Peptide-1-Mediated Control of Intestinal Redox Homeostasis in a Rat Model of Sporadic Alzheimerâ€™s Disease. Antioxidants, 2021, 10, 1118.	2.2	20
1237	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	0.9	11
1238	The PI3K/Akt signaling axis in Alzheimerâ€™s disease: a valuable target to stimulate or suppress?. Cell Stress and Chaperones, 2021, 26, 871-887.	1.2	71
1239	Probing Amyloid Nanostructures Using Photoluminescent Metal Complexes. European Journal of Inorganic Chemistry, 2021, 2021, 4408-4424.	1.0	4
1240	Electroacupuncture Improves Clearance of Amyloid-Î² through the Glymphatic System in the SAMP8 Mouse Model of Alzheimerâ€™s Disease. Neural Plasticity, 2021, 2021, 1-11.	1.0	13
1241	Strategic approaches to target the enzymes using natural compounds for the management of Alzheimerâ€™s disease: A review. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	1
1242	N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimerâ€™s disease. Bioorganic Chemistry, 2021, 113, 105013.	2.0	9
1244	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimerâ€™s disease. Cell Death and Disease, 2021, 12, 769.	2.7	8

#	Article	IF	Citations
1245	Enterovirus 71 infection induced Aquaporin-4 depolarization by increasing matrix metalloproteinase-9 activity. Neuroscience Letters, 2021, 759, 136049.	1.0	8
1247	Differences in Multimodal Electroencephalogram and Clinical Correlations Between Early-Onset Alzheimerâ€™s Disease and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 687053.	1.4	8
1248	Aducanumab: a new phase in therapeutic development for Alzheimerâ€™s disease?. EMBO Molecular Medicine, 2021, 13, e14781.	3.3	47
1249	Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review. Nanomedicine, 2021, 16, 1595-1611.	1.7	23
1251	Limiting RyR2 open time prevents Alzheimer's diseaseâ€related deficits in the 3xTGâ€AD mouse model. Journal of Neuroscience Research, 2021, 99, 2906-2921.	1.3	18
1252	A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1537-1552.	1.2	38
1254	Assessment and Validation of Globodera pallida as a Novel In Vivo Model for Studying Alzheimerâ€™s Disease. Cells, 2021, 10, 2481.	1.8	3
1255	The curvature of gold nanoparticles influences the exposure of amyloid-Î² and modulates its aggregation process. Materials Science and Engineering C, 2021, 128, 112269.	3.8	8
1256	Improved automated synthesis of [18F]FINH-Me via direct radio-fluorination and quality control for Aβ-amyloid imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 276-281.	0.4	1
1257	Molecular Insights into the Inhibitory Effect of GV971 Components Derived from Marine Acidic Oligosaccharides against the Conformational Transition of Aβ42 Monomers. ACS Chemical Neuroscience, 2021, 12, 3772-3784.	1.7	4
1258	Lipid Profiling of Alzheimerâ€™s Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. Cells, 2021, 10, 2591.	1.8	38
1259	Fine or Gross Motor Index as a Simple Tool for Predicting Cognitive Impairment in Elderly People: Findings from The Irish Longitudinal Study on Ageing (TILDA). Journal of Alzheimer's Disease, 2021, 83, 889-896.	1.2	6
1260	1H-1,2,3-triazole grafted tacrine-chalcone conjugates as potential cholinesterase inhibitors with the evaluation of their behavioral tests and oxidative stress in mice brain cells. Bioorganic Chemistry, 2021, 114, 105053.	2.0	16
1261	Inflammatory Cascade in Alzheimerâ€™s Disease Pathogenesis: A Review of Experimental Findings. Cells, 2021, 10, 2581.	1.8	42
1262	Stem cells from human exfoliated deciduous teeth affect mitochondria and reverse cognitive decline in a senescence-accelerated mouse prone 8 model. Cytotherapy, 2022, 24, 59-71.	0.3	6
1263	Fusiform gyrus phosphoâ€tau is associated with failure of proper name retrieval in aging. Annals of Neurology, 2021, 90, 988-993.	2.8	4
1264	Structural significance of Neprylysin from Streptococcus suis GZ1 in the degradation of Aβ peptides, a causative agent in Alzheimer's disease. Computers in Biology and Medicine, 2021, 136, 104691.	3.9	7
1265	Peptides for disrupting and degrading amyloids. Current Opinion in Chemical Biology, 2021, 64, 124-130.	2.8	14

#	Article	IF	Citations
1266	A green fluorescent protein chromophore analogue to promote self-assembly of diphenylalanine into fluorescent microtubes. Journal of Luminescence, 2021, 238, 118320.	1.5	4
1267	An update on Alzheimer's disease: Immunotherapeutic agents, stem cell therapy and gene editing. Life Sciences, 2021, 282, 119790.	2.0	9
1268	Synthesis and approbation of new neuroprotective chemicals of pyrrolyl- and indolylazine classes in a cell model of Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 222, 113577.	2.6	10
1269	Functional bioprobe for responsive imaging and inhibition of amyloid-Î² oligomer based on curcuminoid scaffold. Journal of Luminescence, 2021, 238, 118218.	1.5	8
1270	Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's Disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119116.	1.9	3
1271	Amyloid beta cleavage by ANAâ€TA9, a synthetic peptide from the ANA/BTG3 Box A region. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12146.	1.8	2
1272	In vivo micro computed tomography detection and decrease in amyloid load by using multifunctionalized gold nanorods: a neurotheranostic platform for Alzheimer's disease. Biomaterials Science, 2021, 9, 4178-4190.	2.6	14
1273	Exercise as Potential Therapeutic Target to Modulate Alzheimerâ€™s Disease Pathology in APOE Îµ4 Carriers: A Systematic Review. Cardiology and Therapy, 2021, 10, 67-88.	1.1	16
1274	Interdisciplinary Research in Alzheimerâ€™s Disease and the Roles International Societies Can Play. , 2021, 12, 36.		10
1275	Modeling protein-protein interactions in axon initial segment to understand their potential impact on action potential initiation. Neural Regeneration Research, 2021, 16, 700.	1.6	2
1276	Extracellular GAPDH Promotes Alzheimer Disease Progression by Enhancing Amyloid-Î² Aggregation and Cytotoxicity. , 2021, 12, 1223.		16
1277	Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimerâ€™s Disease. Neuromethods, 2018, , 533-571.	0.2	6
1278	Oxidative Stress and Alzheimerâ€™s Disease. , 2014, , 2147-2174.		3
1279	Astroglia in Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 273-324.	0.8	59
1280	Amyloid-Î² and Tau at theÂCrossroads of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 187-203.	0.8	115
1281	Stress and the Etiopathogenesis of Alzheimerâ€™s Disease and Depression. Advances in Experimental Medicine and Biology, 2019, 1184, 241-257.	0.8	27
1282	Selected microRNAs Increase Synaptic Resilience to the Damaging Binding of the Alzheimerâ€™s Disease Amyloid Beta Oligomers. Molecular Neurobiology, 2020, 57, 2232-2243.	1.9	20
1283	A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?. International Review of Neurobiology, 2020, 155, 113-140.	0.9	27

#	Article	IF	Citations
1284	Discovery and development of ASK1 inhibitors. Progress in Medicinal Chemistry, 2020, 59, 101-179.	4.1	17
1285	Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators. Bioorganic and Medicinal Chemistry, 2020, 28, 115734.	1.4	8
1286	The in vivo effect of oil palm phenolics (OPP) in atherogenic diet induced rat model of Alzheimer's Disease (AD). FASEB Journal, 2015, 29, 271.8.	0.2	2
1293	Brain investigation and brain conceptualization. Functional Neurology, 2013, 28, 175-90.	1.3	30
1294	Deep brain two-photon NIR fluorescence imaging for study of Alzheimerâ€™s disease. , 2018, , .		1
1295	APOE4-mediated amyloid-Î² pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	3.9	96
1296	Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1. Journal of Clinical Investigation, 2019, 129, 969-971.	3.9	6
1297	Alzheimerâ€™s disease: the new promise. Journal of Clinical Investigation, 2012, 122, 1191-1191.	3.9	8
1298	Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of AlzheimerÂ¿s disease. Acta Neuropathologica Communications, 2014, 2, 76.	2.4	70
1299	Haplotype-based association analysis of general cognitive ability in Generation Scotland, the English Longitudinal Study of Ageing, and UK Biobank. Wellcome Open Research, 2017, 2, 61.	0.9	4
1300	Distribution of Aquaporins 1 and 4 in the Central Nervous System. Current Health Sciences Journal, 2019, 45, 218-226.	0.2	5
1301	Biofunctional Characteristics of Dendritic Glycocluster Modified Surfaces. Kobunshi Ronbunshu, 2017, 74, 1-9.	0.2	1
1302	New treatment modalities in Alzheimer's disease. World Journal of Clinical Cases, 2019, 7, 1764-1774.	0.3	12
1303	Model Hirano Bodies Protect against Tau-Independent and Tau-Dependent Cell Death Initiated by the Amyloid Precursor Protein Intracellular Domain. PLoS ONE, 2012, 7, e44996.	1.1	18
1304	Stabilizing ER Ca2+ Channel Function as an Early Preventative Strategy for Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e52056.	1.1	114
1305	Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease. PLoS ONE, 2013, 8, e56870.	1.1	66
1306	Modeling Alzheimerâ€™s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of AÎ² and Tau. PLoS ONE, 2013, 8, e80706.	1.1	28
1307	The Anti-Tumor Histone Deacetylase Inhibitor SAHA and the Natural Flavonoid Curcumin Exhibit Synergistic Neuroprotection against Amyloid-Beta Toxicity. PLoS ONE, 2014, 9, e85570.	1.1	35

#	Article	IF	Citations
1308	Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e89454.	1.1	101
1309	Aminostyrylbenzofuran Directly Reduces Oligomeric Amyloid-Î² and Reverses Cognitive Deficits in Alzheimer Transgenic Mice. PLoS ONE, 2014, 9, e95733.	1.1	12
1310	Oridonin Attenuates AÎ²1â€“42-Induced Neuroinflammation and Inhibits NF-ÎºB Pathway. PLoS ONE, 2014, 9, e104745.	1.1	74
1311	Involvement of Intracellular and Mitochondrial AÎ² in the Ameliorative Effects of Huperzine A against Oligomeric AÎ²42-Induced Injury in Primary Rat Neurons. PLoS ONE, 2015, 10, e0128366.	1.1	23
1312	Perinatal Asphyxia May Influence the Level of Beta-Amyloid (1-42) in Cerebrospinal Fluid: An Experimental Study on Newborn Pigs. PLoS ONE, 2015, 10, e0140966.	1.1	18
1313	An Anti-Î²-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. PLoS ONE, 2016, 11, e0152471.	1.1	33
1314	Identification of the primary peptide contaminant that inhibits fibrillation and toxicity in synthetic amyloid-Î²42. PLoS ONE, 2017, 12, e0182804.	1.1	8
1315	APP Overexpression Causes AÎ²-Independent Neuronal Death through Intrinsic Apoptosis Pathway. ENeuro, 2016, 3, ENEURO.0150-16.2016.	0.9	29
1316	Inactive variants of death receptor p75 ^{NTR} reduce Alzheimerâ€™s neuropathology by interfering with APP internalization. EMBO Journal, 2021, 40, e104450.	3.5	11
1317	Effect of mouse strain as a background for Alzheimerâ€™s disease models on the clearance of amyloid-Î². Journal of Systems and Integrative Neuroscience, 2016, 2, 135-140.	0.6	9
1319	Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body. EXCLI Journal, 2017, 16, 959-972.	0.5	20
1320	Recapitulating Amyloid ÃŸ and Tau Pathology in Human Neural Cell Culture Modelsâ€”Clinical Implications. US Neurology, 2015, 11, 102.	0.2	19
1321	Detection of mis-folded protein aggregates from a clinical perspective. Journal of Clinical and Translational Research, 2016, 2, .	0.3	2
1322	Current Trends in the Development of Drugs for the Treatment of Alzheimerâ€™s Disease and their Clinical Trials. Biomedical Chemistry Research and Methods, 2018, 1, e00015.	0.1	7
1323	Targeting therapy for homocysteic acid in the blood represents a potential recovery treatment for cognition in Alzheimerâ€™s disease patients. Aging, 2016, 8, 1838-1843.	1.4	3
1324	Activation of Î±7 nAChR by PNU-282987 improves synaptic and cognitive functions through restoring the expression of synaptic-associated proteins and the CaM-CaMKII-CREB signaling pathway. Aging, 2020, 12, 543-570.	1.4	27
1325	Synthetic AÎ² peptides acquire prion-like properties in the brain. Oncotarget, 2015, 6, 642-650.	0.8	2
1326	Tranexamic Acid Improves Memory and Learning Abilities in Aging Mice . Journal of Experimental Pharmacology, 2020, Volume 12, 653-663.	1.5	4

#	Article	IF	Citations
1327	Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2015, 22, 3169-3184.	1.2	61
1328	99mTc-labeled Small Molecules for Diagnosis of Alzheimerâ€™s Disease: Past, Recent and Future Perspectives. Current Medicinal Chemistry, 2019, 26, 2166-2189.	1.2	4
1329	Recent Advances in the Rational Drug Design Based on Multi-target Ligands. Current Medicinal Chemistry, 2020, 27, 4720-4740.	1.2	23
1330	The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 2506-2519.	0.9	30
1331	Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer';s Disease. Current Pharmaceutical Design, 2016, 22, 688-700.	0.9	17
1332	Dietary Patterns and Cognitive Decline: key features for prevention. Current Pharmaceutical Design, 2019, 25, 2428-2442.	0.9	29
1333	Therapeutic Study of Phytochemicals Against Cancer and Alzheimerâ€™s Disease Management. Current Drug Metabolism, 2020, 20, 1006-1013.	0.7	11
1334	Key Peptides and Proteins in Alzheimerâ€™s Disease. Current Protein and Peptide Science, 2019, 20, 577-599.	0.7	30
1335	Prion-like Mechanisms in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 755-764.	0.7	27
1336	A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimerâ€™s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice. Current Alzheimer Research, 2015, 12, 870-885.	0.7	13
1337	Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 359-369.	0.7	44
1338	Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies. Current Alzheimer Research, 2016, 13, 450-464.	0.7	19
1339	From the Multifactorial Nature of Alzheimer`s Disease to Multitarget Therapy: The Contribution of the Translational Approach. Current Topics in Medicinal Chemistry, 2013, 13, 1843-1852.	1.0	13
1340	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	1.4	12
1341	Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design. Current Neuropharmacology, 2018, 16, 726-739.	1.4	40
1342	The Ambiguous Role of Microglia in Aî² Toxicity: Chances for Therapeutic Intervention. Current Neuropharmacology, 2020, 18, 446-455.	1.4	16
1343	Multiple Targets for the Management of Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1279-1289.	0.8	29
1344	Oxidative Stress in the Pathogenesis of Alzheimerâ€™s Disease and Cerebrovascular Disease with Therapeutic Implications. CNS and Neurological Disorders - Drug Targets, 2020, 19, 94-108.	0.8	20

#	Article	IF	Citations
1345	Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer's Disease. Iranian Journal of Pharmaceutical Research, 2020, 19, 45-60.	0.3	19
1346	Nutritional prevention of cognitive decline and dementia. Acta Biomedica, 2018, 89, 276-290.	0.2	54
1347	Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?. Journal of Neurology and Neuromedicine, 2016, 1, 53-57.	0.9	43
1348	The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?. Dialogues in Clinical Neuroscience, 2014, 16, 373-393.	1.8	55
1349	Outline of Therapeutic Interventions With Muscarinic Receptor-Mediated Transmission. Physiological Research, 2014, 63, S177-S189.	0.4	5
1350	Alzheimerâ€™s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. Nanomaterials, 2021, 11, 59.	1.9	14
1351	PNU282987 inhibits amyloidâ€Î² aggregation by upregulating astrocytic endogenous Î±Bâ€crystallin and HSPâ€70 via regulation of the Î±7AChR, PI3K/Akt/HSFâ€1 signaling axis. Molecular Medicine Reports, 2020, 22, 201-208.	1.1	13
1352	Towards defining the Mechanisms of Alzheimer's disease based on a contextual analysis of molecular pathways. AIMS Genetics, 2016, 03, 025-048.	1.9	3
1353	Oxidative stress, cellular senescence and ageing. AIMS Molecular Science, 2016, 3, 300-324.	0.3	82
1354	Where do we stand on the relationship between tau biomarkers and mild cognitive impairment?. Quantitative Imaging in Medicine and Surgery, 2013, 3, 189-91.	1.1	2
1355	Protective Effect of Arabinoxylan against Scopolamine-Induced Learning and Memory Impairment. Biomolecules and Therapeutics, 2014, 22, 467-473.	1.1	12
1356	Review of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds. Pharmacognosy Research (discontinued), 2015, 7, 225.	0.3	85
1357	SIRT1 facilitates amyloid beta peptide degradation by upregulating lysosome number in primary astrocytes. Neural Regeneration Research, 2018, 13, 2005.	1.6	49
1358	Multitarget therapeutic strategies for Alzheimerâ€™s disease. Neural Regeneration Research, 2019, 14, 437.	1.6	120
1359	Newly Designed Magnetic and Non-Magnetic Nanoparticles for Potential Diagnostics and Therapy of Alzheimer?s Disease. Journal of Biotechnology & Biomaterials, 2013, 03, .	0.3	6
1360	The Potential Role of Epigenetics in Alzheimer?s Disease Etiology. Biological Systems, Open Access, 2012, 02, .	0.1	3
1361	Strategizing the Development of Alzheimerâ€™s Therapeutics. Advances in Alzheimer's Disease, 2014, 03, 107-127.	0.3	7
1362	Pharmacological Assessment of <i>Î³</i>-Secretase Activity from Rodent and Human Brain. Neuroscience and Medicine, 2012, 03, 149-161.	0.2	3

#	Article	IF	Citations
1363	Platelets and Alzheimerâ€™s disease: Potential of APP as a biomarker. World Journal of Psychiatry, 2012, 2, 102.	1.3	54
1364	Destabilization of Alzheimer's AÎ²₄₂ protofibrils with acyclovir, carmustine, curcumin, and tetracycline: insights from molecular dynamics simulations. New Journal of Chemistry, 2021, 45, 21031-21048.	1.4	6
1365	Amyloid Î² structural polymorphism, associated toxicity and therapeutic strategies. Cellular and Molecular Life Sciences, 2021, 78, 7185-7198.	2.4	7
1366	Direct Delivery of ANA-TA9, a Peptide Capable of AÎ² Hydrolysis, to the Brain by Intranasal Administration. Pharmaceutics, 2021, 13, 1673.	2.0	2
1367	Alzheimer's disease therapeutics - Are we winning or losing? Highlights from the Society for Medicines Research Symposium, held on March 16, 2012, Brussels, Belgium. Drugs of the Future, 2012, 37, 375.	0.0	0
1368	Towards Effective Treatment Strategies for Alzheimers disease (AD). Journal of Developing Drugs, 2012, 01, .	0.9	0
1369	Role of Neprilysin in The Pathogenesis of Alzheimerâ€²s Disease*. Progress in Biochemistry and Biophysics, 2012, 39, 721-725.	0.3	1
1372	Stem Cell Therapies for Age Associated Neurodegeneration. , 2014, , 2299-2314.		0
1373	Linking Molecular Neurobiology to Therapeutic Approaches for Alzheimerâ€™s Disease with PET. , 2014, , 451-478.		0
1374	AÎ² Imaging in Aging, Alzheimerâ€™s Disease and Other Neurodegenerative Conditions. , 2014, , 213-254.		2
1376	Alzheimer-Associated Pathology in the Extracellular Space. Advances in Anatomy, Embryology and Cell Biology, 2015, , 75-93.	1.0	1
1377	Pharmacotherapy in Alzheimerâ€™s disease and other dementias in practical settings: which drug, when and for whom?. Aktualnosci Neurologiczne, 2014, 14, 218-227.	0.1	1
1380	Frontiers in Clinical Drug Research - Alzheimer Disorders. , 2015, , .		0
1381	A New Public Health Paradigm for Alzheimer's Disease Research. SOJ Neurology, 2015, 2, 01-07.	0.1	4
1382	Aristotelische Ursache-Wirkungsprinzipien in der Medizin â€“ Versuch eines Beitrags zur "konzeptuellen Integration". Der Merkurstab, 2016, 69, 110-116.	0.0	0
1383	Pathological Consequences of AÎ² From Extracellular to Intraneuronal. , 2016, , 69-113.		0
1385	Imaging in Neurology Research III: Neurodegenerative Diseases. , 2017, , 761-772.		0
1386	Alzheimerâ€™s and perspectives from medicinalÂPlants as therapeutics: a review. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0

#	Article	IF	Citations
1387	Expression of Neural Glycans and Their Role in Disease. Trends in Glycoscience and Glycotechnology, 2017, 29, E11-E18.	0.0	0
1388	Expression of Neural Glycans and Their Role in Disease. Trends in Glycoscience and Glycotechnology, 2017, 29, J13-J20.	0.0	0
1390	Synthesis and the activity assessment of adamantylcontaining thiazolium inhibitors of butyrylcholinesterase. Journal of Organic and Pharmaceutical Chemistry, 2017, 15, 48-55.	0.0	0
1391	Effect and Disease Indicative Role of Inflammation in Neurodegenerative Pathology: A Mechanistic Crosstalk of Promise and Dilemma. Neuropsychiatry, 2018, 08, .	0.4	0
1392	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
1393	In vitro Anti-cholinesterase and Anti-oxidant Activity of Three Standardised Polyherbal Products Used for Memory Enhancing in Ethnomedicine of South-East Nigeria. The Malaysian Journal of Medical Sciences, 2018, 25, 27-39.	0.3	1
1394	What can computational modeling offer for studying the Ca2+ dysregulation in Alzheimerâ€™s disease: current research and future directions. Neural Regeneration Research, 2018, 13, 1156.	1.6	0
1397	Addressing BACE1 flexibility to identify inhibitors for Alzheimerâ€™s Disease therapeutics. , 0, , .		0
1399	Therapeutic Vaccines Targeting Alzheimerâ€™s Disease. , 2019, , 9-20.		1
1400	Alzheimer Disease: Convergence Result from a Discrete Model Towards a Continuous One. , 2019, , 397-431.		0
1401	Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimerâ€™s Disease. , 2019, , 307-341.		0
1402	New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. Medical Alphabet, 2019, 1, 35-42.	0.0	4
1404	Notch Signaling: From Neurogenesis to Neurodegeneration. , 2019, , 185-221.		0
1411	The Effects of Treadmill Exercise on Iron Accumulation and Microglia Activation in the Brain of APP-C105 Transgenic Mice of Alzheimerâ€™s Disease. Exercise Science, 2019, 28, 409-418.	0.1	0
1414	The Î²-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 184-194.	0.8	5
1415	Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11677.	1.8	54
1416	Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases. , 2020, , 241-268.		0
1417	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.4	5

#	Article	IF	Citations
1419	A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice. Current Alzheimer Research, 2020, 17, 753-765.	0.7	3
1421	The Role of AÎ² in the Development of Alzheimerâ€™s Disease and its Mechanisms. E3S Web of Conferences, 2020, 218, 03041.	0.2	0
1423	Revisiting Alzheimerâ€™s Disease. , 2020, , 137-155.		0
1424	Neuromodulation for Cognitive Disorders: In Search of Lazarus?. Neurology India, 2020, 68, 288.	0.2	0
1425	Natural products as anti-Alzheimer's drugs. Studies in Natural Products Chemistry, 2020, 66, 157-174.	0.8	0
1427	Common herbal treatments for senile dementia in ancient civilizations: Greco-Roman, Chinese, Indian, and Iranian. Journal of Medicinal Plants, 2020, 1, 37-62.	0.3	1
1430	BDMC protects AD in vitro via AMPK and SIRT1. Translational Neuroscience, 2020, 11, 319-327.	0.7	8
1431	AÎ² Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
1432	Potential non-oncological applications of histone deacetylase inhibitors. American Journal of Translational Research (discontinued), 2011, 3, 454-67.	0.0	18
1433	Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. American Journal of Neurodegenerative Disease, 2013, 2, 145-75.	0.1	116
1435	Evaluation of the effect of Cyperus rotundus L. in scopolamine-induced learning deficit in mice. Advanced Biomedical Research, 2014, 3, 217.	0.2	8
1436	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. American Journal of Translational Research (discontinued), 2016, 8, 154-65.	0.0	24
1438	PATHOBIOLOGY OF NEURODEGENERATION: THE ROLE FOR ASTROGLIA. Opera Medica Et Physiologica, 2016, 1, 13-22.	1.0	14
1441	Taming Alzheimer's disease: New perspectives, newer horizons. Iranian Journal of Neurology, 2017, 16, 146-155.	0.5	4
1442	Lipopolysaccharide endotoxemia induces amyloid-Î² and p-tau formation in the rat brain. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 86-99.	1.0	27
1443	The Role of Î±-sheet in Amyloid Oligomer Aggregation and Toxicity. Yale Journal of Biology and Medicine, 2018, 91, 247-255.	0.2	9
1444	SQYZ granules, a traditional Chinese herbal, attenuate cognitive deficits in AD transgenic mice by modulating on multiple pathogenesis processes. American Journal of Translational Research (discontinued), 2018, 10, 3857-3875.	0.0	5
1445	Detection of misfolded protein aggregates from a clinical perspective. Journal of Clinical and Translational Research, 2016, 2, 11-26.	0.3	3

#	Article	IF	Citations
1446	The expression of the nicotinic acetylcholine receptor Î±3 subunit in the brains of patients with Alzheimer's disease and its effects on Î±- and Î³-secretases and Notch signal transduction in SH-SY5Y cells. International Journal of Clinical and Experimental Pathology, 2019, 12, 3644-3652.	0.5	0
1447	Differential gene expression in the cortical sulcus compared to the gyral crest within the early stages of chronic traumatic encephalopathy. Free Neuropathology, 2021, 2, .	2.4	1
1448	Prions and Neurodegenerative Diseases: A Focus on Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 503-518.	1.2	17
1449	Novel Synthetic Coumarin-Chalcone Derivative (E)-3-(3-(4-(Dimethylamino)Phenyl)Acryloyl)-4-Hydroxy-2H-Chromen-2-One Activates CREB-Mediated Neuroprotection in AÎ² and Tau Cell Models of Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-19.	1.9	11
1450	The Protective Effect of Ubiquinone against the Amyloid Peptide in Endothelial Cells Is Isoprenoid Chain Length-Dependent. Antioxidants, 2021, 10, 1806.	2.2	7
1451	Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2021, 18, 273.	3.1	2
1452	Nutrition, Physical Activity, and Other Lifestyle Factors in the Prevention of Cognitive Decline and Dementia. Nutrients, 2021, 13, 4080.	1.7	114
1453	Role of Receptors in Relation to Plaques and Tangles in Alzheimerâ€™s Disease Pathology. International Journal of Molecular Sciences, 2021, 22, 12987.	1.8	12
1454	O-Glycosylation Induces Amyloid-Î² To Form New Fibril Polymorphs Vulnerable for Degradation. Journal of the American Chemical Society, 2021, 143, 20216-20223.	6.6	22
1455	Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study. European Journal of Medicinal Chemistry, 2022, 228, 114028.	2.6	0
1456	Redox Homeostasis in Alzheimerâ€™s Disease. Healthy Ageing and Longevity, 2022, , 323-348.	0.2	11
1458	A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid Î² In Vivo. ACS Medicinal Chemistry Letters, 2022, 13, 76-83.	1.3	3
1459	Chronic Exposure to Environmentally Relevant Concentrations of Guanylurea Impairs the Behavior, Redox Status, Acetylcholinesterase Homeostasis,ÂÂAnd Expression of Antioxidant Defense-, Apoptosis-, and Neuronal Communication-Related Genes OfÂDanio RerioÂAdults. SSRN Electronic Journal, 0, , .	0.4	0
1460	Psychedelics as Novel Therapeutics in Alzheimerâ€™s Disease: Rationale and Potential Mechanisms. Current Topics in Behavioral Neurosciences, 2021, , 287-317.	0.8	11
1461	Electrophysiological resting state brain network and episodic memory in healthy aging adults. NeuroImage, 2022, 253, 118926.	2.1	4
1462	Promising bioactive compounds from the marine environment and their potential effects on various diseases. Journal of Genetic Engineering and Biotechnology, 2022, 20, 14.	1.5	71
1463	Frailty Syndrome and Oxidative Stress as Possible Links Between Age-Related Hearing Loss and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 816300.	1.4	5
1464	Impairment of the autophagyâ€“lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B, 2022, 12, 1019-1040.	5.7	56

#	Article	IF	Citations
1465	Neurodegenerative disease by SRS microscopy. , 2022, , 501-514.		0
1466	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases. Journal of Biological Chemistry, 2022, 298, 101478.	1.6	12
1467	Occlusal disharmony transiently decrease cognition via cognitive suppressor molecules and partially restores cognitive ability via clearance molecules. Biochemical and Biophysical Research Communications, 2022, 594, 74-80.	1.0	2
1468	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2022, 85, 1143-1151.	1.2	7
1469	G-protein coupled purinergic P2Y12 receptor interacts and internalizes TauRD-mediated by membrane-associated actin cytoskeleton remodeling in microglia. European Journal of Cell Biology, 2022, 101, 151201.	1.6	8
1470	Chronic exposure to environmentally relevant concentrations of guanylurea induces neurotoxicity of Danio rerio adults. Science of the Total Environment, 2022, 819, 153095.	3.9	16
1471	Phage display derived peptides for Alzheimer's disease therapy and diagnosis. Theranostics, 2022, 12, 2041-2062.	4.6	31
1472	New Perspectives for Treatment in Alzheimerâ€™s Disease. , 2022, , 199-225.		0
1473	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. International Journal of Molecular Sciences, 2022, 23, 2011.	1.8	22
1474	Astrocytic Î±2-Na ⁺ /K ⁺ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Science Translational Medicine, 2022, 14, eabm4107.	5.8	40
1475	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.4	13
1476	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimerâ€™s Disease. Life, 2022, 12, 275.	1.1	9
1477	Spatial Training Attenuates Long-Term Alzheimerâ€™s Disease-Related Pathogenic Processes in APP/PS1 Mice. Journal of Alzheimer's Disease, 2022, 85, 1453-1466.	1.2	3
1478	Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimerâ€™s Disease. International Journal of Nanomedicine, 0, Volume 17, 927-936.	3.3	2
1479	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	21.5	273
1481	Roles of Long Non-coding RNAs in the Development of Aging-Related Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2022, 15, 844193.	1.4	18
1482	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
1484	Novel Psychoactive Substances: The Razorâ€™s Edge between Therapeutical Potential and Psychoactive Recreational Misuse. Medicines (Basel, Switzerland), 2022, 9, 19.	0.7	6

#	Article	IF	Citations
1485	Metal-Organic Framework Based Drug Delivery for Alzheimer Therapy and Clinical Progress. Mini-Reviews in Organic Chemistry, 2022, 19, .	0.6	0
1486	Addressing Bloodâ€“Brain Barrier Impairment in Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 742.	1.4	25
1487	Protective Effect of Human-Neural-Crest-Derived Nasal Turbinate Stem Cells against Amyloid-Î² Neurotoxicity through Inhibition of Osteopontin in a Human Cerebral Organoid Model of Alzheimerâ€™s Disease. Cells, 2022, 11, 1029.	1.8	5
1488	A Pyridyl Zn (II) Chelate for the Sensitive Detection of AÎ² Fibrils. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 0, , .	0.6	2
1489	The bidirectional lung brain-axis of amyloid-Î² pathology: ozone dysregulates the peri-plaque microenvironment. Brain, 2023, 146, 991-1005.	3.7	17
1490	Composite of gold nanoclusters and basified human serum albumin significantly boosts the inhibition of Alzheimer's Î²-amyloid by photo-oxygenation. Acta Biomaterialia, 2022, 144, 157-167.	4.1	16
1491	Wolframin is a novel regulator of tau pathology and neurodegeneration. Acta Neuropathologica, 2022, 143, 547-569.	3.9	22
1493	Current Drug Targets in Alzheimerâ€™s Associated Memory Impairment: A Comprehensive Review. CNS and Neurological Disorders - Drug Targets, 2023, 22, 255-275.	0.8	4
1494	Drug repositioning: Progress and challenges in drug discovery for various diseases. European Journal of Medicinal Chemistry, 2022, 234, 114239.	2.6	42
1495	Microglial Endocannabinoid Signalling in AD. Cells, 2022, 11, 1237.	1.8	8
1496	Design of Gallic Acidâ€“Glutamine Conjugate and Chemical Implications for Its Potency Against Alzheimerâ€™s Amyloid-Î² Fibrillogenesis. Bioconjugate Chemistry, 2022, 33, 677-690.	1.8	4
1497	Advancements in the development of multi-target directed ligands for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2022, 61, 116742.	1.4	37
1498	Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer's disease. Bioorganic Chemistry, 2022, 122, 105662.	2.0	6
1499	The positive impact of 12Âweeks of dance and balance training on the circulating amyloid precursor protein and serotonin concentration as well as physical and cognitive abilities in elderly women. Experimental Gerontology, 2022, 162, 111746.	1.2	6
1500	The effect of lipocalin-2 (LCN2) on apoptosis: a proteomics analysis study in an LCN2 deficient mouse model. BMC Genomics, 2021, 22, 892.	1.2	8
1501	Small Angle X-ray Scattering Sensing Membrane Composition: The Role of Sphingolipids in Membrane-Amyloid Î²-Peptide Interaction. Biology, 2022, 11, 26.	1.3	3
1502	Association of CSF AÎ² ₃₈ Levels With Risk of Alzheimer Diseaseâ€“Related Decline. Neurology, 2022, 98, .	1.5	16
1503	TM2D genes regulate Notch signaling and neuronal function in Drosophila. PLoS Genetics, 2021, 17, e1009962.	1.5	5

#	Article	IF	Citations
1504	Evaluating effect of metallic ions on aggregation behavior of Î²-amyloid peptides by atomic force microscope and surface-enhanced Raman Scattering. BioMedical Engineering OnLine, 2021, 20, 132.	1.3	6
1505	Secretases Related to Amyloid Precursor Protein Processing. Membranes, 2021, 11, 983.	1.4	13
1506	Rational Design of a Cu Chelator That Mitigates Cuâ€Induced ROS Production by Amyloid Beta. ChemBioChem, 2022, 23, .	1.3	2
1507	High-Phytate Diets Increase Amyloid Î² Deposition and Apoptotic Neuronal Cell Death in a Rat Model. Nutrients, 2021, 13, 4370.	1.7	3
1508	Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of AÎ² Fibrillation. Nano Letters, 2021, 21, 10494-10500.	4.5	8
1509	Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100100.	1.7	10
1510	Amyloid-Î² Induces Cdh1-Mediated Rock2 Stabilization Causing Neurodegeneration. Frontiers in Pharmacology, 2022, 13, 884470.	1.6	9
1511	Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimerâ€™s Disease. Cells, 2022, 11, 1284.	1.8	9
1519	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Network Open, 2022, 5, e228392.	2.8	44
1520	Galantamine nanoparticles outperform oral galantamine in an Alzheimerâ€™s rat model: pharmacokinetics and pharmacodynamics. Nanomedicine, 2021, 16, 1281-1296.	1.7	11
1521	Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.. European Review for Medical and Pharmacological Sciences, 2022, 26, 2201-2214.	0.5	2
1522	Evaluation of the effect of Cyperus rotundus L. in scopolamine-induced learning deficit in mice. Advanced Biomedical Research, 2014, 3, 217.	0.2	9
1523	Cyclodextrins as promising therapeutics against cholesterol overload. , 2022, , 927-967.		1
1524	Copper chelating cyclic peptidomimetic inhibits AÎ² fibrillogenesis. RSC Medicinal Chemistry, 2022, 13, 761-774.	1.7	3
1525	Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS. Biophysical Journal, 2022, 121, 2084-2095.	0.2	7
1526	Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2022, 65, 7088-7105.	2.9	21
1527	History in Perspective: The prime pathological players and role of phytochemicals in Alzheimerâ€™s disease. IBRO Neuroscience Reports, 2022, 12, 377-389.	0.7	10
1528	Superoxide Reduction by Cuâ€Amyloid Beta Peptide Complexes: A Density Functional Theory Study. European Journal of Inorganic Chemistry, 2022, 2022, .	1.0	4

#	Article	IF	Citations
1529	The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics, 2022, 19, 228-247.	2.1	10
1530	Near-infrared irradiation controlled thermo-switchable polymeric photosensitizer against Î²-amyloid fibrillation. Journal of Materials Chemistry B, 2022, 10, 4832-4839.	2.9	1
1532	Molecular details of aluminium-amyloid Î² peptide interaction by nuclear magnetic resonance. BioMetals, 2022, 35, 759-769.	1.8	1
1533	Anti-Amyloid-Î² Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
1534	Phloroglucinol, a clinical-used antispasmodic, inhibits amyloid aggregation and degrades the pre-formed amyloid proteins. International Journal of Biological Macromolecules, 2022, 213, 675-689.	3.6	2
1537	Potential targeting sites in brain and brain tumors. , 2022, , 69-120.		0
1538	Amyloids on Membrane Interfaces: Implications for Neurodegeneration. Journal of Membrane Biology, 2022, 255, 705-722.	1.0	2
1539	Monosialotetrahexosylganglioside Promotes Early AÎ²42 Oligomer Formation and Maintenance. ACS Chemical Neuroscience, 2022, 13, 1979-1991.	1.7	6
1540	Deep tissue multi-photon imaging using adaptive optics with direct focus sensing and shaping. Nature Biotechnology, 2022, 40, 1663-1671.	9.4	32
1541	Neuroprotective Effect of Caffeine in Alzheimerâ€™s Disease. Molecules, 2022, 27, 3737.	1.7	12
1542	The Periodontal Pathogen Fusobacterium nucleatum Exacerbates Alzheimerâ€™s Pathogenesis via Specific Pathways. Frontiers in Aging Neuroscience, 0, 14, .	1.7	14
1543	Hypothermia after Perinatal Asphyxia Does Not Affect Genes Responsible for Amyloid Production in Neonatal Peripheral Lymphocytes. Journal of Clinical Medicine, 2022, 11, 3263.	1.0	2
1544	Overview of therapeutic targets in management of dementia. Biomedicine and Pharmacotherapy, 2022, 152, 113168.	2.5	15
1545	Emerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology. International Journal of Biological Sciences, 2022, 18, 4260-4274.	2.6	30
1546	Phytochemical based Modulation of Endoplasmic Reticulum Stress in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2022, 22, 1880-1896.	1.0	2
1547	Astragalus mongholicus Bunge (Fabaceae): Bioactive Compounds and Potential Therapeutic Mechanisms Against Alzheimerâ€™s Disease. Frontiers in Pharmacology, 0, 13, .	1.6	6
1548	Amylin and Secretases in the Pathology and Treatment of Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 996.	1.8	5
1549	Aptamer-Functionalized Carbon Nanotube Field-Effect Transistor Biosensors for Alzheimerâ€™s Disease Serum Biomarker Detection. ACS Sensors, 2022, 7, 2075-2083.	4.0	38

#	Article	IF	Citations
1550	Acidic pH Promotes Refolding and Macroscopic Assembly of Amyloid Î² (16â€“22) Peptides at the Airâ€“Water Interface. Journal of Physical Chemistry Letters, 2022, 13, 6674-6679.	2.1	3
1551	Î±-bisabolol Î²-D-fucopyranoside inhibits Î²-amyloid (AÎ²)25â€“35 induced oxidative stress in Neuro-2a cells via antioxidant approaches. Process Biochemistry, 2022, 121, 493-503.	1.8	3
1552	The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 2669-2686.	0.4	169
1554	The Potential of Small Molecules to Modulate the Mitochondriaâ€“Endoplasmic Reticulum Interplay in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	6
1555	Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. American Journal of Neuroradiology, 2022, 43, E19-E35.	1.2	31
1556	Mild Behavioral Impairment: An Early Sign and Predictor of Alzheimer's Disease Dementia. Current Alzheimer Research, 2022, 19, 407-419.	0.7	4
1557	Exploring the binding kinetics and behaviors of self-aggregated beta-amyloid oligomers to phase-separated lipid rafts with or without ganglioside-clusters. Biophysical Chemistry, 2022, 290, 106874.	1.5	15
1558	An in vitro workflow of neuron-laden agarose-laminin hydrogel for studying small molecule-induced amyloidogenic condition. PLoS ONE, 2022, 17, e0273458.	1.1	1
1559	A novel H2O2-activated NIR fluorescent probe for imaging Î²-amyloid fibrils and mitochondrial viscosity. Dyes and Pigments, 2022, 206, 110665.	2.0	6
1560	Chronic exposure to realistic concentrations of metformin prompts a neurotoxic response in Danio rerio adults. Science of the Total Environment, 2022, 849, 157888.	3.9	11
1561	Recent advances of small molecule JNK3 inhibitors for Alzheimerâ€™s disease. Bioorganic Chemistry, 2022, 128, 106090.	2.0	8
1562	Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
1563	Influence of genetic and cardiometabolic risk factors in Alzheimerâ€™s disease. Ageing Research Reviews, 2022, 81, 101723.	5.0	11
1564	Mechanistic regulation of Î³-secretase by their substrates. Physical Chemistry Chemical Physics, 2022, 24, 19223-19232.	1.3	1
1565	The role of AÎ² in Alzheimerâ€™s Disease as an Evolutionary Outcome of Optimized Innate Immune Defense. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	0
1566	Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome. International Review of Research in Developmental Disabilities, 2022, , 227-263.	0.6	1
1567	Natural Therapeutics in Aid of Treating Alzheimerâ€™s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders. Frontiers in Neuroscience, 0, 16, .	1.4	19
1569	Alzheimerâ€™s Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History. , 2022, , 260-275.		0

#	Article	IF	Citations
1570	Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable metaâ€analysis. Alzheimer's and Dementia, 2023, 19, 1292-1299.	0.4	5
1571	Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity. Molecular Neurodegeneration, 2022, 17, .	4.4	5
1572	Alzheimerâ€™s Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History. , 2022, , 260-275.		2
1573	Genome-wide meta-analysis for Alzheimerâ€™s disease cerebrospinal fluid biomarkers. Acta Neuropathologica, 2022, 144, 821-842.	3.9	38
1574	Investigating a Genetic Link Between Alzheimerâ€™s Disease and CADASIL-Related Cerebral Small Vessel Disease. Molecular Neurobiology, 2022, 59, 7293-7302.	1.9	1
1575	3, 14, <scp>19â€Triacetyl</scp> Andrographolide alleviates the cognitive dysfunction of 3â€‰Ã—â€‰<scp>Tgâ€AD</scp> mice by inducing initiation and promoting degradation process of autophagy. Phytotherapy Research, 2023, 37, 410-423.	2.8	4
1578	The Mitochondrial Enzyme 17Î²HSD10 Modulates Ischemic and Amyloid-Î²-Induced Stress in Primary Mouse Astrocytes. ENeuro, 2022, 9, ENEURO.0040-22.2022.	0.9	3
1581	Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease. European Journal of Medicinal Chemistry, 2022, 244, 114806.	2.6	8
1582	Amphiphilic stilbene derivatives attenuate the neurotoxicity of soluble AÎ²₄₂ oligomers by controlling their interactions with cell membranes. Chemical Science, 2022, 13, 12818-12830.	3.7	5
1583	Animal models of Alzheimerâ€™s disease: Applications, evaluation, and perspectives. Zoological Research, 2022, 43, 1026-1040.	0.9	29
1584	Sticker-and-spacer model for amyloid beta condensation and fibrillation. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2
1585	Itâ€™s Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimerâ€™s Disease Research?. Journal of Alzheimer's Disease, 2022, 90, 1401-1415.	1.2	2
1586	Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. Journal of Experimental Pharmacology, 0, Volume 14, 331-352.	1.5	8
1587	Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimerâ€™s Disease. Current Neuropharmacology, 2023, 21, 787-807.	1.4	1
1588	Amyloid-Related Imaging Abnormalities: An Update. American Journal of Roentgenology, 2023, 220, 562-574.	1.0	16
1589	Moderating effect of cognitive reserve on brain integrity and cognitive performance. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
1590	In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease. European Journal of Medicinal Chemistry, 2022, 244, 114825.	2.6	4
1592	PET molecular imaging for pathophysiological visualization in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 765-783.	3.3	18

#	Article	IF	Citations
1593	Multiple Actions of H₂S-Releasing Peptides in Human Î²-Amyloid Expressing C. elegans. ACS Chemical Neuroscience, 2022, 13, 3378-3388.	1.7	6
1594	Ependymal cells and neurodegenerative disease: outcomes of compromised ependymal barrier function. Brain Communications, 2022, 4, .	1.5	9
1595	Infectious origin of Alzheimerâ€™s disease: Amyloid beta as a component of brain antimicrobial immunity. PLoS Pathogens, 2022, 18, e1010929.	2.1	22
1596	The link between periodontitis and Alzheimer's disease â€“ emerging clinical evidence. , 2023, 3, 100062.		3
1597	Spin state dependent peroxidase activity of heme bound amyloid Î² peptides relevant to Alzheimer's disease. Chemical Science, 2022, 13, 14305-14319.	3.7	3
1598	Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-Î² Peptide Toxicity. Journal of Alzheimer's Disease, 2022, , 1-12.	1.2	2
1599	DSCR1 deficiency ameliorates the AÎ² pathology of Alzheimerâ€™s disease by enhancing microglial activity. Life Science Alliance, 2023, 6, e202201556.	1.3	1
1600	Experimental evidence for temporal uncoupling of brain AÎ² deposition and neurodegenerative sequelae. Nature Communications, 2022, 13, .	5.8	6
1602	Impact of Amyloid Pathology in Mild Cognitive Impairment Subjects: The Longitudinal Cognition and Surface Morphometry Data. International Journal of Molecular Sciences, 2022, 23, 14635.	1.8	2
1603	Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?. Pharmaceutics, 2022, 14, 2559.	2.0	11
1604	New Insights into lncRNAs in AÎ² Cascade Hypothesis of Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 1802.	1.8	4
1605	Amyloid-Î² (25â€“35) induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus. Neuroscience Letters, 2023, 795, 137030.	1.0	0
1607	Network organization of resting-state cerebral hemodynamics and their aliasing contributions measured by functional near-infrared spectroscopy. Journal of Neural Engineering, 0, , .	1.8	0
1609	Indolylazine Derivative Induces Chaperone Expression in Aged Neural Cells and Prevents the Progression of Alzheimerâ€™s Disease. Molecules, 2022, 27, 8950.	1.7	2
1610	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11
1611	Experimental Approach to Alzheimerâ€™s Disease with Emphasis on Insulin Resistance in the Brain. , 2022, , 1657-1708.		0
1612	Contribution of Extracellular Vesicles and Molecular Chaperones in Age-Related Neurodegenerative Disorders of the CNS. International Journal of Molecular Sciences, 2023, 24, 927.	1.8	5
1613	Highly Efficient Singlet Oxygen Generation by BODIPYâ€“Ruthenium(II) Complexes for Promoting Neurite Outgrowth and Suppressing Tau Protein Aggregation. Inorganic Chemistry, 2023, 62, 1102-1112.	1.9	4

#	Article	IF	Citations
1614	Wholeâ€brain DTI parameters associated with tau protein and hippocampal volume in Alzheimer's disease. Brain and Behavior, 2023, 13, .	1.0	4
1615	<scp>sTREM2</scp> is associated with amyloidâ€related pâ€tau increases and glucose hypermetabolism in Alzheimer's disease. EMBO Molecular Medicine, 2023, 15, .	3.3	13
1616	Application of a novel coumarin-derivative near-infrared fluorescence probe to amyloid-Î² imaging and inhibition in Alzheimer's disease. Journal of Luminescence, 2023, 256, 119661.	1.5	7
1617	Atrial Natriuretic Peptide Associated with Cardiovascular Diseases Inhibits Amyloid-Î² Aggregation via Cross-Seeding. ACS Chemical Neuroscience, 2023, 14, 312-322.	1.7	3
1618	Analysis of Cerebral Small Vessel Changes in AD Model Mice. Biomedicines, 2023, 11, 50.	1.4	6
1619	Pharmacotherapy Evolution in Alzheimerâ€™s Disease: Current Framework and Relevant Directions. Cells, 2023, 12, 131.	1.8	19
1620	Insights into the remarkable attenuation of hen egg white lysozyme amyloid fibril formation mediated by biogenic gold nanoparticles stabilized by quercetin-functionalized tara gum. International Journal of Biological Macromolecules, 2023, 232, 123044.	3.6	2
1621	Isoniazid improves cognitive performance, clears AÎ² plaques, and protects dendritic synapses in APP/PS1 transgenic mice. Frontiers in Aging Neuroscience, 0, 15, .	1.7	0
1622	A Review on the Natural Components Applied as Lead Compounds for Potential Multi-target Anti-AD Theranostic Agents. Current Medicinal Chemistry, 2023, 30, 4586-4604.	1.2	3
1623	Deconvoluting binding sites in amyloid nanofibrils using time-resolved spectroscopy. Chemical Science, 2023, 14, 1072-1081.	3.7	2
1624	Uncovering the Oxidative Stress Mechanisms and Targets in Alzheimerâ€™s Disease by Integrating Phenotypic Screening Data and Polypharmacology Networks. Journal of Alzheimer's Disease, 2023, , 1-18.	1.2	3
1625	NQO1 regulates expression and alternative splicing of apoptotic genes associated with Alzheimer's disease in PC12 cells. Brain and Behavior, 2023, 13, .	1.0	2
1626	Sex Differences between Neuronal Loss and the Early Onset of Amyloid Deposits and Behavioral Consequences in 5xFAD Transgenic Mouse as a Model for Alzheimerâ€™s Disease. Cells, 2023, 12, 780.	1.8	8
1627	Partial Destabilization of Amyloid-Î² Protofibril by Methionine Photo-Oxidation: A Molecular Dynamic Simulation Study. ACS Omega, 2023, 8, 10148-10159.	1.6	1
1628	Genetically identical twin-pair difference models support the amyloid cascade hypothesis. Brain, 0, , .	3.7	1
1629	Depletion of gut microbiota resistance in 5Ã—FAD mice enhances the therapeutic effect of mesenchymal stem cell-derived exosomes. Biomedicine and Pharmacotherapy, 2023, 161, 114455.	2.5	4
1630	Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Disease-a-Month, 2023, 69, 101547.	0.4	4
1631	Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease. Biosensors and Bioelectronics, 2023, 230, 115269.	5.3	2

#	Article	IF	Citations
1632	Elevated plasma sulfides are associated with cognitive dysfunction and brain atrophy in human Alzheimer's disease and related dementias. Redox Biology, 2023, 62, 102633.	3.9	8
1633	Mitochondrial cholesterol: Metabolism and impact on redox biology and disease. Redox Biology, 2023, 61, 102643.	3.9	14
1634	Melatonin: A Potential Candidate for the Treatment of Experimental and Clinical Perinatal Asphyxia. Molecules, 2023, 28, 1105.	1.7	3
1635	How Can Static and Oscillating Electric Fields Serve in Decomposing Alzheimerâ€™s and Other Senile Plaques?. Journal of the American Chemical Society, 2023, 145, 3543-3553.	6.6	9
1636	C/EBPÎ²/AEP Signaling Drives Alzheimerâ€™s Disease Pathogenesis. Neuroscience Bulletin, 0, , .	1.5	0
1637	Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-218.	1.0	1
1638	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.0	6
1639	Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimerâ€™s Disease. Biochemistry (Moscow), 2023, 88, S75-S87.	0.7	1
1640	Acridine: A Scaffold for the development of drugs for Alzheimer's disease. Current Topics in Medicinal Chemistry, 2023, 23, .	1.0	1
1641	Masitinib for mild-to-moderate Alzheimerâ€™s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimer's Research and Therapy, 2023, 15, .	3.0	12
1642	RyR2â€dependent modulation of neuronal hyperactivity: A potential therapeutic target for treating Alzheimer's disease. Journal of Physiology, 0, , .	1.3	1
1643	Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimerâ€™s disease model in rats. International Journal of Immunopathology and Pharmacology, 2023, 37, 039463202311614.	1.0	3
1644	Management of Alzheimerâ€™s disease in the next ten years. Medical Journal of the University of Toronto, 2023, 100, .	0.0	0
1645	Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. Nature Metabolism, 2023, 5, 445-465.	5.1	33
1646	Clinical Management in Alzheimerâ€™s Disease in the Era of Disease-Modifying Therapies. Current Treatment Options in Neurology, 2023, 25, 121-133.	0.7	1
1647	BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimerâ€™s disease. Journal of Nanobiotechnology, 2023, 21, .	4.2	23
1648	Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cellular and Molecular Neurobiology, 2023, 43, 2627-2642.	1.7	4
1649	Padlock Probeâ€“Based Targeted In Situ Sequencing: Overview of Methods and Applications. Annual Review of Genomics and Human Genetics, 2023, 24, 133-150.	2.5	1

#	Article	IF	Citations
1650	A glycan epitope correlates with tau in serum and predicts progression to Alzheimer's disease in combination with APOE4 allele status. Alzheimer's and Dementia, 2023, 19, 3244-3249.	0.4	4
1652	Five-mer peptides prevent short-term spatial memory deficits in AÎ²25-35-induced Alzheimerâ€™s model mouse by suppressing AÎ²25-35 aggregation and resolving its aggregate form. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
1653	Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nature Communications, 2023, 14, .	5.8	17
1672	Microtechnologies for single-cell and spatial multi-omics. , 2023, 1, 769-784.		2
1692	Traversing Through the Trajectory of Pathogenic Astrocytes in Alzheimerâ€™s Disease. , 2023, , 151-180.		0
1695	Recent progress of small-molecule-based theranostic agents in Alzheimer's disease. RSC Medicinal Chemistry, 0, , .	1.7	0
1723	The supersaturation perspective on the amyloid hypothesis. Chemical Science, 2023, 15, 46-54.	3.7	2
1731	Laboratory Findings of NPH. , 2023, , 243-275.		0
1755	Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD. , 2024, , 73-92.		0
1757	Targeting angiogenesis, inflammation, and oxidative stress in Alzheimer's diseases. , 2024, , 215-249.		0